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ABSTRACT 
Factors that impact the development of neuroAIDS include monocyte expansion and 
activation, viral neuroinvasion and replication, and accumulation of activated and 
infected macrophages in the CNS. To better understand changes in 
monocyte/macrophage biology associated with the development of SIV encephalitis 
(SIVE) and neuroAIDS, we: 1) performed gene expression analyses using high density 
microarrays to characterize the response of monocyte subsets to SIV infection, 2) 
serially labeled CNS macrophages with fluorescent dextrans by intracranial injection 
and labeled myeloid progenitors in the bone marrow with BrdU to determine the timing 
of SIV neuroinvasion and macrophage recruitment/turnover in the CNS, and 3) 
performed in vitro studies to determine the role of PCNA expression in macrophages 
with SIV infection. We found the majority of macrophages in SIVE lesions were present 
in the CNS early in infection and productively infected macrophages were recruited to 
the CNS terminally with AIDS. We observed differences in the timing of recruitment, rate 
of turnover, PCNA expression, and productive infection between CD163+ and 
MAC387+ macrophages in the CNS. SIV infection was associated with induction of 
interferon stimulated genes in all monocytes, maturation of the intermediate monocyte 
subset, and increased rate of monocyte/macrophage recruitment to the CNS. Greater 
ratios of CD163+ to MAC387+ macrophages in the CNS were associated with SIVE. 
We also found that PCNA expression decreased macrophage apoptosis with SIV 
infection. Together, these studies suggest that the development of SIVE is a dynamic 
process and that continuous recruitment of activated monocyte/macrophage and 
reintroduction of virus from the periphery is required to drive CNS disease. 
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Chapter 1. Introduction 
I. Thesis overview 
This thesis investigates changes in the biology of monocytes and macrophages with 
simian immunodeficiency virus (SIV) infection and the role of monocytes/macrophages 
in the development of SIV encephalitis (SIVE). Human immunodeficiency virus (HIV) 
and SIV infection are characterized by monocyte dysregulation including an expansion 
of monocytes from the bone marrow and increased monocyte activation. Increased 
numbers of activated monocytes are associated with increased traffic of 
monocytes/macrophages to the CNS, some of which may be infected. Viral 
neuroinvasion and accumulation of activated macrophages in the CNS contribute to 
CNS inflammation and neuropathogenesis. In these studies we investigate: 1) 
differences in gene expression between monocyte subsets and changes in gene 
expression with SIV infection, 2) recruitment and turnover of CNS macrophages and the 
development of SIVE, and 3) proliferating cell nuclear antigen (PCNA) expression in 
CNS macrophages (Figure 1.1).   
 
Monocytes are heterogeneous with regard to phenotype and three populations that 
differ in absolute number, biological function, and activation state are currently defined 
in rhesus macaques: classical, intermediate, and nonclassical monocytes. The specific 
role of each monocyte subset in SIV pathogenesis is not known at present. In the first 
set of studies (Chapter 3), we characterize the gene expression profile of classical, 
intermediate, and nonclassical monocytes in healthy animals and changes in gene 
expression that occur with SIV infection. These studies are unique in the specificity and 
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scope, as longitudinal studies of gene expression in monocytes with HIV or SIV 
infection that differentiate the monocyte subsets have not been done.  
 
 
Figure 1.1. Interplay of monocytes, macrophages, and SIV in  
the development of AIDS and SIV encephalitis. 
 
Due to the limitations of in vivo studies of CNS inflammation with HIV or SIV infection 
(e.g. unknown timing of HIV infection, inability to sample CNS tissue in live subjects), 
the dynamics of macrophage recruitment to the CNS, the timing of viral neuroinvasion, 
and the role of macrophage subpopulations in the development of HIV encephalitis 
(HIVE) and SIVE are understudied. In the second set of studies (Chapter 4), we use 
BrdU labeling and state of the art serial, intracisternal administration of fluorescent 
PCNA expression and 
macrophage retention 
in SIVE lesions (Ch. 5). 
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dextrans in vivo to quantitate macrophage recruitment and turnover in the CNS with SIV 
infection. Additionally, we characterize the infection status of CNS macrophages with 
regard to time of CNS entry to investigate the timing of SIV neuroinvasion.  
 
Proliferating cell nuclear antigen (PCNA) expression in CNS macrophages is associated 
with productive HIV and SIV infection in the absence of cell division. PCNA plays a role 
in multiple cell functions including DNA replication, apoptosis, and DNA damage repair. 
The specific function of PCNA in CNS macrophages with SIV infection is not known. In 
the third set of studies (Chapter 5), we characterize PCNA expression in monocytes and 
subpopulations of CNS macrophages in SIV-infected macaques. We also conduct in 
vitro studies to knockdown PCNA in macrophages to characterize the effect of PCNA 
expression on viral replication and apoptosis.  
 
Together, these studies provide new insight regarding the role of specific 
monocyte/macrophage subsets in SIV pathogenesis, macrophage recruitment to the 
CNS and SIVE lesion formation, timing of SIV neuroinvasion, and the function of PCNA 
in CNS macrophages. 
 
II. HIV, AIDS, and simian models of neuroAIDS 
Presently more than 30 million people worldwide are infected with HIV (UNAIDS 2012), 
the etiological agent of acquired immune deficiency syndrome (AIDS). Although the 
advent of highly active antiretroviral therapy (HAART), which uses a combination of 
protease inhibitors and reverse transcriptase inhibitors, has mitigated the morbidity and 
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mortality of HIV infection, HIV-associated neurocognitive disorders (HAND) remain 
clinically relevant and are associated with a worse clinical prognosis1-4. Though studies 
in humans are limited by ethical considerations, SIV infection of rhesus macaques 
results in a disease that is similar to HIV infection in humans pre-HAART. In this thesis 
we utilize an established model of SIV infection in rhesus macaques with CD8+ T-
lymphocyte depletion that results in rapid AIDS with a high incidence of SIVE. 
 
A. Clinical progression of HIV-1 infection 
HIV type 1 (HIV-1) is transmitted by exposure of mucosal surfaces or 
intravenous/percutaneous exposure5,6. In mucosal exposure DC’s, CD4+ T lymphocytes, 
and macrophages have been implicated in mediating primary infection5,7-10. Founder 
virus replicates in the mucosa and is subsequently disseminated systemically (Figure 
1.2)6,7,10,11. Within days to weeks of primary infection, HIV-1 replicates exponentially 
leading to acute viremia, which may present as acute retroviral syndrome (Figure 1.2)6. 
It is thought that during this stage latent viral reservoirs are established where virus is 
seeded in the brain and other tissues12-16. The initial host response to viral replication 
includes production of acute-phase proteins and inflammatory cytokines and induction 
of CD8+ cytotoxic T-lymphocyte (CTL) responses17-20. Subsequently, humoral 
responses to HIV-1 are induced. HIV-specific antibodies are detectable several weeks 
after primary infection, and antibodies that are capable of neutralizing the virus are 
found approximately three months post infection21,22. During the asymptomatic period, 
viral replication is controlled by the host immune responses. Ongoing viral replication 
leads to a progressive reduction in the number of CD4+ T-lymphocytes and sustained 
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Figure 1.2. Clinical progression of HIV-1 infection 
(adapted from Simon and Ho, Nat. Rev. Microbiol. 2003) 
 
immune activation that culminates in the development of AIDS (Figure 1.2)23. With AIDS, 
the host’s ability to mediate normal immune responses is impaired leading to increased 
HIV-1 in plasma (viremia), opportunistic infections (OIs), increased incidence of cancer, 
organ failure, and possibly death (Figure 1.2)24. End stage disease without HAART is 
frequently associated with organ specific pathologies such as HIV-associated 
respiratory diseases and HAND3,24-26. 
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B. Simian models of neuroAIDS 
Shortly after the identification of HIV and AIDS in humans, Desrosiers and colleagues 
identified a virus from immune compromised rhesus macaques (now know as SIV) with  
antigenic similarity to HIV that induced a disease in macaques similar to AIDS, 
including: wasting syndrome, primary viral encephalitis (SIVE), opportunistic infections, 
and destruction of CD4+ T lymphocytes27-29. SIV in rhesus macaques (SIVmac) was  
 
 
Figure 1.3. Schematic representation of lentiviral genomes 
(adapted from Peeters and Courgnaud 2002) 
 
found to be the result of exposure to SIV from infected sooty mangabees (SIVsm) in 
regional primate centers in the United States (Figure 1.3)30. In humans, HIV-1 is derived 
from chimpanzee SIV (SIVcpz) and represents the primary HIV burden in the world 
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(Figure 1.3)31. HIV-2 is derived from SIVsm and is restricted primarily to individuals in 
West Africa (Figure 1.3)31. Interestingly, SIVs are generally only found to be pathogenic 
in a non-native host primate, as a result of zoonotic infection32. This idea is recapitulated 
in pathogenic HIV infection in humans, who are a non-native host to lentivirus from 
chimpanzee or sooty mangabees.   
 
A simian model of rapid AIDS using SIVmac251 infection and  
CD8+ T-lymphocyte depletion  
Studies of SIV neuropathogenesis in rhesus macaques frequently use the molecular 
clone SIVmac239 or the viral swarm SIVmac251 that are R5 tropic (see below) and 
neurovirulent33-37. SIVmac251 infection in macaques recapitulates the major features of 
HIV infection in humans (dynamic viremia, CD4+ T cell depletion, biphasic monocyte 
expansion, AIDS) and results in similar neuropathology (early neuroinvasion, meningitis, 
perivascular cuffing, infected perivascular macrophages and microglia, decreased 
neuronal integrity, MNGCs, SIVE lesions)7,11,38,39. Faster disease progression and 
increased incidence of SIVE can be achieved by the administration of a chimeric 
humanized mouse anti-CD8 antibody, which results in depletion of CD8 expressing 
lymphocytes and NK cells18,39-43. CD8+ lymphocyte depletion results in loss of viremic 
control through impaired ability to mount cellular and humoral immune responses and 
increased destruction of CD4+ T cells17,18,40,44-46. SIVmac251 infected macaques 
develop AIDS within 1-3 years of infection with a 25% incidence of SIVE. In contrast, 
CD8+ T-lymphocyte depleted animals develop AIDS in 3-4 months with SIVE in more 
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than 75% of animals39. The SIVmac251, CD8+ depletion rapid AIDS model is well 
established, reproducible, and results in uniform pathogenesis18,39-43. 
 
III. Monocyte Biology 
In HIV and SIV infection, the progression to AIDS is associated with changes in 
monocyte biology including increased egress from the bone marrow, accelerated 
turnover in the blood, and increased activation42,47-52. Importantly, monocytes are 
phenotypically and functionally heterogeneous, and subpopulations likely differ with 
regard to putative immune functions, activation status, migratory properties, and 
susceptibility to HIV or SIV infection49,53-56. Due to functional differences between the 
classical, intermediate, and nonclassical monocyte subsets, perturbations to normal 
monocyte homeostasis and the relative proportion of each subset may influence 
disease progression. The gene expression profiles of classical, intermediate and 
nonclassical monocytes and the specific immune response of each subset to SIV 
infection are characterized in Chapter 3.   
 
A. Monocyte Subsets 
Monocytes are mononuclear phagocytes that comprise 5-10% of circulating leukocytes 
in humans57. Antigens commonly used as pan-monocyte markers include CD14 (LPS 
coreceptor) and CD11b (macrophage receptor 1, integrin αMβ2) in humans and CD11b, 
CSFR1 (macrophage colony-stimulating factor 1 receptor, CD115), and F4/80 (EMR1 
hormone receptor) in mice58,59. Monocytes are heterogeneous, and multiple 
subpopulations can be defined by differences in surface antigens, morphology (size, 
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granularity), and function (antigen presentation, phagocytosis, cytokine secretion) 
49,56,57,60,61. Human monocytes have been historically defined as CD14+ (LPS 
coreceptor) mononuclear phagocytes. In 1989, Zeigler-Heitbrock and colleagues 
defined a second population of monocytes that expressed CD16 (FcγRIII) and were 
morphologically and functionally distinct from classical monocytes60. For two decades 
monocytes were phenotypically defined as CD14+CD16- or CD14+CD16+ monocytes 
(often referred to as CD16- and CD16+ monocytes respectively)54. Recent research  
 
 
Figure 1.4. Phenotypic and transcriptional relationship of human monocytes 
(adapted from Wong et al. Blood 2011) 
 
has revealed heterogeneity within CD16+ monocytes that lead to a new nomenclature 
for three monocyte subsets defined by expression of CD14 and CD16: CD14++CD16- 
classical monocytes, CD14++CD16+ intermediate monocytes, and CD14+CD16++ 
nonclassical monocytes (Figure 1.4)61,62. It is not known whether these subpopulations 
are unique monocyte subsets or whether they represent progressive stages of 
activation/maturation of a single monocyte lineage. 
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Current understanding of the biology of monocyte subpopulations comes from studies in 
human and macaques as well as homologous monocyte populations in mice. Mouse 
Ly6C+, Ly6Cint, and Ly6C- monocytes correspond to classical, intermediate, and 
nonclassical monocytes respectively57-59,63,64. In humans, circulating monocytes are 
comprised of approximately 80% classical monocytes, 5% intermediate monocytes, and 
10% nonclassical monocytes (Figure 1.4)49,61,65. Classical monocytes exhibit high 
phagocytic ability and produce reactive oxygen species and interleukin (IL)-10 in 
response to LPS54,60,65. Additionally, classical monocytes express CCR2 and CD62L, 
migrate in response to inflammation, and may differentiate into classically activated, M1 
polarized macrophages or dendritic cells (DC) in inflamed tissue (Figure 1.5) 
58,59,61,63,64,66. Intermediate monocytes express proteins associated with MHC class II  
 
Figure 1.5. Development and function of monocyte subsets 
(adapted from Gordon and Taylor, Nat. Rev. Immunol. 2005) 
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presentation, are capable of T-cell activation, and may be a transitional population 
between classical and nonclassical monocytes (Figure 1.5)49,61. In response to LPS, 
intermediate monocytes produce TNFα and IL-1β65. Nonclassical monocytes migrate 
along the luminal face of the vasculature, express CX3CR1 (fractalkine receptor), and 
may extravasate into tissue to replenish resident macrophage populations (Figure 1.5) 
49,58,59,61,62,65. In response to TLR7/TLR8 agonists (viruses, nucleic acids) nonclassical 
monocytes produce proinflammatory cytokines TNFα, IL-1β, and CCL3/MIP-1α65. Thus 
monocyte subsets differ in abundance, phenotype, migratory ability, and response to 
immune stimuli.  
 
The developmental relationship of monocyte subsets.  
If classical monocytes mature into intermediate then nonclassical monocytes, expansion 
of CD16+ monocyte populations with SIV infection may represent increased 
activation/maturation of classical monocytes. A developmental relationship between 
classical, intermediate, and nonclassical monocytes is suggested by several lines of 
evidence. In mice, classical monocytes exit the bone marrow and mature into 
nonclasssical monocytes (Figure 1.5).  In humans treated with a two-week regimen of 
macrophage colony-stimulating factor (M-CSF) there was an increase in the number of 
intermediate monocytes at day 8 followed by an increase in the number of nonclassical 
monocytes at day 1567. Similarly, studies in SIV infected rhesus macaques found that 
after labeling promonocytes with BrdU (5-bromo-2’-deoxyuridine), BrdU+ monocytes 
were present in the classical subset at 24-48 hours post treatment, followed by the 
intermediate subset at 72-96 hours post treatment, and the nonclassical subset at 96- 
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Figure 1.6. BrdU is detected first in classical then intermediate and nonclassical 
monocytes following BrdU administration in SIV-infected rhesus macaques 
(T.H. Burdo, unpublished data) 
 
144 hours post treatment (Figure 1.6)42,52. These dynamics mirror kinetic studies in 
human monocytes that indicate monocytes leave the bone marrow 13- 26 hours after 
the promonocyte division and circulate in the blood with a half life of 71 hours68,69. When 
cultured in vitro, classical monocytes acquire expression of CD16 suggesting a 
transition to the intermediate phenotype70. Consistent with the notion that intermediate 
monocytes are a transitional population, analysis of cell surface markers and gene 
expression profiles of the three monocyte subsets indicates that intermediate 
monocytes express a majority of transcripts and surface proteins at levels between 
	   13	  
classical and nonclassical monocytes in humans and rhesus macaques49,61. In humans, 
transcripts associated with withdrawal from cell cycle, maturation, and macrophage 
phenotype are associated with nonclassical or both intermediate and nonclassical 
monocytes suggesting these cells are more terminally differentiated compared to 
classical monocytes56,61. Together such evidence suggests that there is a progression 
from classical to intermediate to nonclassical monocytes. An alternative hypothesis is 
that the three monocyte subsets are independent monocyte lineages with unique 
turnover characteristics.  
 
B. Monocytopoiesis 
Increased egress of monocytes from the bone marrow suggests that monocytopoiesis is 
altered with HIV and SIV infection. Also, anemia is a comorbidity of HIV infection and 
increased bone marrow diffusivity is shown to correlate with HAD71. The monononuclear 
phagocyte system is composed of monocytes and macrophages as well as their 
developmental precursors. During early development monocytes and macrophages are 
produced from primitive precursors in the yolk sac and later by hematopoiesis in the 
fetal liver57,72,73. In the adult, monocytes are produced from hematopoietic stem cells 
(HSC) in the bone marrow57,58. Monocytes are derived from a common myeloid 
progenitor that commits to a granulocyte/macrophage lineage (granulocyte/macrophage 
colony forming unit, GM-CFU) then a macrophage lineage (macrophage colony forming 
unit, M-CFU)57. In subsequent divisions, the M-CFU becomes a monoblast then a 
promonocyte, which is the immediate precursor of monocytes57,58,74. Human monocytes 
	   14	  
and macrophages are not thought to divide after the promonocyte stage, although 
macrophage proliferation has been reported in mice57,74,75. 
 
Newly formed monocytes exit the bone marrow and enter the circulation. In mice traffic 
of classical Ly6C+ monocytes out of the bone marrow is dependent on CCR2 and its 
ligands CCL2 (Macrophage Chemoattractant Protein 1, MCP-1) and CCL7 
(Macrophage Chemoattractant Protein 3, MCP-3)76-78. Additionally, a reduced number 
of nonclassical Ly6C- monocytes was reported in CX3CR1-/- knockout mice78. This 
suggests that the specific receptor-ligand interactions controlling bone marrow egress 
vary between monocyte subsets. It is not know if a retention mechanism exists to keep 
monocytes in the bone marrow.  
 
C. Monocytes and inflammation 
Monocyte emigration from the bone marrow is increased with inflammation42,52,76,77,79. In 
inflammatory states, there is an increased production of monocyte mobilization ligands 
that may contribute to monocyte expansion and recruitment50,80,81. Recent research has 
identified a splenic reservoir of monocytes in mice that is also mobilized in response to 
inflammation66,82-84. In mice, both classical Ly6C+ and nonclassical Ly6C- monocytes 
are deployed from the spleen in response to atherosclerosis and myocardial infarction. 
Splenic Ly6C+ monocytes are recruited to the site of inflammation in a CCR2 
dependent manner and differentiate into classically activated, M1-polarized 
macrophages83,84. 
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The progression of CNS disease is directly influenced by monocyte dysregulation in HIV 
and SIV infection39,51,68,85. Importantly, traffic of infected monocytes/macrophages is a 
potential mechanism of dissemination of virus across the blood brain barrier (BBB)86-90. 
With HIV and SIV infection, increased numbers of circulating monocytes and increased 
monocyte activation correlate with the development of encephalitis and 
dementia41,42,91,92. Given the low rate of monocyte infection in vivo, the changes 
observed in monocyte biology are most likely the result of systemic immune activation, 
altered cytokine signaling, and other indirect mechanisms resulting from chronic 
infection. Historically in HIV research, particular attention has been paid to activated 
CD16+CD69+ monocytes (intermediate monocytes), which expand with inflammation, 
are precursors of tissue macrophages, and targets of HIV infection42,50,52,88,91-93. 
Classical and nonclassical monocytes in contrast have received little attention. In 
Chapter 3 of this thesis, we perform microarray analyses to investigate the shared and 
unique biology of the three monocyte subsets and the response of each to SIV infection.   
 
IV. Biology of HIV and SIV 
HIV and SIV are related lentiviruses with similar biology and disease progression in their 
respective hosts. Primary infection is mediated by a small population of founder viruses 
that expands and evolves over the course of infection. Evolution of viral quasispecies 
results in changes in tropism that allow virus to infect different cell types and anatomical 
compartments and establish viral reservoirs. In particular, the ability of virus to replicate 
in macrophages in the CNS is an important factor in the development of HIV dementia 
and SIVE. The studies in this thesis were conducted in SIV-infected rhesus macaques, 
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but we will take advantage of the abundance of information regarding HIV in addressing 
the general biology of lentiviruses by discussing both HIV and SIV and noting relevant 
differences where applicable.  
 
A. Viral genome and proteins 
HIV and SIV are enveloped retroviruses composed of 15 unique proteins and two 
copies of an RNA genome (Figure 1.7)31,94,95. The viral genome consists of 9 open 
reading frames (ORF’s) (Figure 1.7). Three of these encode the Gag, Pol, and Env 
polyproteins found in all retroviruses (Figure 1.7). Polyproteins are protelytically cleaved  
 
 
Figure 1.7. HIV-1 genome and virion structure 
(Scarlata and Carter Biochim. et Biophys. Acta 2003) 
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into individual proteins by viral protease. Gag is processed into the structural proteins 
matrix (MA), capsid (CA), nucleocapsid (NC) and p6 (Figure 1.7). Pol encodes the viral 
enzymes protease (PR), reverse transcriptase (RT), and integrase (IN) (Figure 1.7). Env 
is processed into the two envelope proteins gp120/surface (SU) and 
gp41/transmembrane (TM) (Figure 1.7). The remaining ORFs  encode regulatory (Rev, 
Tat, Nef) and accessory proteins (Vif, Vpr, and Vpu in HIV-1 or Vpx in SIV/HIV-2) that 
function in regulating viral infectivity, transcription of the viral genome, and production of 
progeny virions31,95,96. Noncoding, long terminal repeats (LTRs) are present at the 5’ 
and 3’ ends of the viral genome that regulate transcription of viral genes (Figure 1.7)97.  
 
B. Viral life cycle  
The individual steps that comprise the life cycle of HIV have been described extensively 
and will be briefly summarized here23,86,94,95,97,98. Beginning with a mature virion, 
gp120/SU binds CD4, the primary HIV and SIV receptor, and relevant coreceptors 
(discussed below) on the target cell which leads to conformational changes in gp41/TM 
that promote fusion of the viral envelope with the cell membrane (Figure 1.8)99,100. Once 
in the cell, the viral core particle is uncapsidated, and RT transcribes the RNA genome 
into dsDNA (Figure 1.8). A preintegration complex (PIC) consisting of the HIV genome 
and viral and host derived factors is translocated to the nucleus (Figure 1.8). Viral 
integrase catalyzes the insertion of the HIV provirus into the host genome, and the DNA 
is repaired by the host DNA damage repair machinery (Figure 1.8). Once the cell is 
infected, viral transcripts and full-length genomic RNA are transcribed and exported to 
the cell cytoplasm (Figure 1.8). The env transcripts are translated at the endoplasmic 
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reticulum while the other viral mRNAs are translated in the cytoplasm.  Envelope 
proteins, now in the lipid bilayer, traffic to the cell membrane where the viral  
 
 
Figure 1.8. Life cycle of HIV-1 
(Verani et al. Molec. Immunol. 2005) 
 
core particle is assembled from the Gag polyprotein (Figure 1.8). The immature virion 
buds from the cell membrane and is released into the extracellular space (Figure 1.8). 
In macrophages, HIV may also bud into late endosomes/multi-vesicular bodies 
(LE/MVB) that release virus into the extracellular space through exocytosis (Figure 
1.8)98. Proteolytic cleavage of Gag into the individual structural proteins leads to 
	   19	  
rearrangement of the immature virion into an infectious virus particle94. Although the life 
cycle of SIV differs from HIV with regard to coreceptor usage, the interaction between 
viral accessory proteins and host restriction factors, and transcriptional regulation of 
viral genes, the general features of HIV and SIV replication are the same. 
 
C. HIV and SIV Tropism 
Viral tropism can be described in terms of viral entry by coreceptor usage, the preferred 
target cell for viral replication, and tissue specificity. The identification of chemokine 
receptors CCR5 and CXCR4 as the primary coreceptors for HIV lead to classification of 
the virus as R5, X4, or R5X4 based on the ability of HIV to use one or both 
coreceptors86,101-107. CD4+ cells, monocytes/macrophages and CD4+ T lymphocytes, 
express varying levels of both CCR5 and CXCR486,95. Although CCR5 usage is 
associated with macrophage tropism and CXCR4 usage is associated with T cell 
tropism in vitro, HIV target cell preference in vivo cannot be explained solely by 
differences in coreceptor usage. The majority of SIVs use CCR5 as the primary 
coreceptor and additional coreceptors include GPR15 and STRL33108-111. Both 
macrophage and T-cell tropic SIV use CCR5 and not CXCR4109. Coreceptor usage, 
target cell preference, and tissue specificity influence the progression of HIV and SIV 
infection. HIV infection in humans is associated with a switch from R5 tropic strains 
during primary/early infection to R5X4 or X4 tropic strains during end stage 
disease25,102,105,112-114. Changes in receptor tropism are also associated with infection of 
specific tissues, which is likely dependent on the major cell type infected in each tissue. 
Distinct subtypes of HIV and different strains of SIV show different patterns of tissue 
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distribution and neuropathogenesis suggesting that differences in the viral genome are 
associated with altered tissue tropism and pathogenesis9,38,80,90,115. Analyses of HIV and 
SIV envelope sequences indicate that infection of the CNS is associated with expansion 
of sequence variants with neurotropic/macrophage-tropic motifs in the plasma as well 
as in the lung and the bone marrow37,116,117. This may indicate that during end stage 
disease novel sequence variants that are able to replicate in CNS macrophages are 
introduced into the CNS and contribute to the development of HIVE/SIVE and 
neuroAIDS. That the development of CNS disease is associated with the ability of virus 
to replicate in macrophages in the CNS is particularly relevant to this thesis.  
 
D. Intrahost viral evolution 
Primary infection at the mucosa is mediated by transmission of a small number (1 to 5) 
of R5 tropic virions6,10,118. In chronically HIV-infected individuals or SIV-infected 
macaques, numerous sequence variants can be isolated indicating an evolution and 
expansion of the transmitted/founder sequence37,118-120. This diversity contributes to the 
ability of HIV to evade immune responses and generate resistance to antiretroviral 
therapy. Multiple mechanisms contribute to increased genetic diversity121. Viral reverse 
transcriptase is error prone and may generate de novo mutations122,123. Additionally, two 
copies of the RNA genome are packaged into each virion with both being used to 
generate a single provirus in a process facilitated by recombination124. Moreover, 
superinfection of a target cell may result in recombination of two genetically distinct viral 
variants121,125. Host factors also contribute to viral diversity. For example, members of 
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the APOBEC family of cytidine deaminases are packaged into newly synthesized virions 
and lead to G to A hypermutation of the viral genome126-128.  
 
Innate, cellular, and humoral immunity each apply a selective pressure that promotes 
survival of viral variants that are able to evade the host immune response. Beginning in 
early infection CTL responses select for escape mutants6,10,20,129,130. Humoral immune 
responses result in production of HIV specific antibodies that drives variation in the viral 
envelope proteins. In particular, changes to the hypervariable regions of Env allow the 
virus access to additional target cell types or anatomical compartments. An important 
factor in HIV pathogenesis is the evolution of virus that is able to infect long-lived cell 
types (e.g. macrophages, resting memory CD4+ T cells) or anatomical locations (e.g. 
CNS, bone marrow) that promote the establishment of viral reservoirs.         
 
E. Viral reservoirs 
At present, combination antiretroviral therapy (cART) is able to suppress plasma viral 
loads below the current limit of clinical detection (<50 copies/mL). However, 
ultrasensitive assays indicate persistent low-level viremia that is not sensitive to drug 
intensification and is able to rebound to pre-treatment levels when ART is interrupted131-
133. These observations indicate the presence of viral reservoirs capable of supporting 
productive infection in spite of host immune responses and effective ART.  
 
Macrophages and latently infected resting memory CD4+ T-lymphocytes are the two 
major cellular reservoirs of HIV-168,86,89,131,134-136. These cellular reservoirs are thought to 
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be established during acute viremia and prior to the initiation of ART. Analysis of decay 
kinetics of the latent CD4+ reservoir in HIV+ patients on ART determined the half-life to 
be 44 months and the latently infected population to be more than a million cells137. In 
rhesus macaques infected with a highly pathogenic chimeric SIV/HIV (SHIV), 
macrophages comprised the major cellular reservoir of virus after depletion of the CD4+ 
T cell population135. Macrophages are resistant to the cytopathic effects of HIV infection 
and have low turnover rates that may contribute to persistent viremia particularly during 
end stage disease89,134,135,138. Antiretroviral drugs that target reverse transcription or 
integration have no effect on macrophages that are already infected139. In addition, 
protease inhibitors, the only class of drug that acts on post-integration stages of the viral 
life cycle, are only effective in macrophages at high concentrations that are at the upper 
limit of what is physiologically achievable89. The ability of macrophages to support viral 
replication without cytopathic effects, increased macrophage longevity with HIV infection, 
and the decreased sensitivity to ART make macrophages an important mediator of 
persistent viremia in chronic HIV infection.     
 
Tissue reservoirs of virus may be formed in anatomical sites where drug penetrance is 
low or immune responses are lacking, such as the CNS, genital tract, or bone marrow, 
which may lead to compartmentalized replication of virus131. In this thesis, we address 
the CNS as a site of ongoing inflammation and a viral reservoir. Several factors make 
the CNS a particularly well-suited anatomical reservoir of HIV: 1) low drug penetrance 
into the CNS termed CNS penetration-effectiveness (CPE), 2) the absence or restriction 
of normal immune responses, and 3) the presence of multiple target cells (perivascular 
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macrophages and microglia) that support productive infection. With ART, HIV decay is 
slower in the cerebrospinal fluid than in plasma in agreement with compartmentalized 
virus replicating in a long-lived cell type25,140. This is pathologically important as 
increased compartmentalization of virus in the CNS has been associated with HIV-
associated dementia (HAD)141. HIV is also able to infect bone marrow macrophages 
and multipotent hematopoietic precursor cells (HPC) and establish latent reservoirs in 
the bone marrow136,142. HPC are able to differentiate into multiple hematopoietic 
lineages, and differentiation results in increased susceptibility to infection and increased 
viral replication136,142. HIV-infected HPC may give rise to infected daughter cells, 
including monocytes/macrophages, that subsequently traffic through the periphery and 
infect tissues including the CNS39,42,48,51,52,56,88,142. Sequestration of virus in anatomical 
reservoirs and dissemination of virus from these sites into the periphery is a potential 
mechanism of sustained viremia and a barrier to treatment in HIV infection.  
 
V. Infection of monocytes and macrophages 
In addition to CD4+ T-cells, monocytes and macrophages are targets of HIV and SIV 
infection and may be infected in the bone marrow, in the periphery, or in tissues (Figure 
1.9)143. Infection of the bone marrow, may contribute to changes in monocyte 
homeostasis including increased activation and accelerated turnover, which results in 
increased traffic of monocytes/macrophages to the CNS. In addition infection of 
monocytes or their progenitors may lead to dissemination of virus into the CNS (Figure 
1.9)143. Viral replication and accumulation of activated macrophages in the CNS 
contribute to the development of CNS disease. 
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A. Infection of the bone marrow 
The primary targets of HIV and SIV infection in the bone marrow are macrophages and 
multipotent hematopoietic progenitor cells136,144,145. Bone marrow macrophages are 
susceptible to infection by a broader range of HIV strains, including T cell tropic virus, 
than blood macrophages145. Reports of infection of HPCs indicate that susceptibility to  
HIV is dependent on the level of maturation or lineage commitment of the HPCs142. 
Importantly, primitive hematopoietic stem cells are refractory to HIV-1 infection via a p21 
dependent block prior to integration and inhibition of coreceptor binding by production of  
 
 
Figure 1.9. HIV-1 infection of monocytes and macrophages and systemic 
dissemination of virus  
(adapted from Bergamaschi and Pancino Retrovirol. 2010) 
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CCR5 ligands136,146-148. The clinical significance of HPC infection has been contested 
because HIV-infected CD34+ cells in the bone marrow are not universally observed in 
vivo149-151. However, HIV infection of the bone marrow is associated with hematological 
abnormalities such as leukopenias, dysplasia, and anemia71,142. These effects are 
thought to be directly mediated by both infectious virus and viral proteins interacting with 
hematopoietic progenitors and stromal cells in the bone marrow152-155. Changes to bone 
marrow homeostasis are also implicated in neuropathogenesis. Decreased bone 
marrow diffusivity and increased monocyte egress from the bone marrow are 
associated with the development of HIV dementia and SIV encephalitis42,71. Also, 
sequence similarity between HIV isolated from the CNS and from bone marrow in a 
patient with HIV dementia suggests traffic of infected monocytes/macrophages from 
bone marrow may influence CNS disease156. HIV infection of the bone marrow leads to 
altered hematopoiesis and potential dissemination of virus by infected daughter cells, 
which may negatively impact immune regulation of monocytes/macrophages and CNS 
pathology (Figure 1.9).  
  
B. Infection of circulating monocytes 
HIV can replicate in monocytes although the frequency of productively infected 
monocytes in vivo is low55,143,157,158. HIV-1 replication in monocytes is restricted at or 
prior to reverse transcription; however, the block to infection is not absolute68,143,158.  
Monocytes are refractory to HIV and SIV infection compared to macrophages, and 
susceptibility to infection has been shown to increase with maturation/differentiation158-
160. Compared to macrophages, monocytes express higher levels of the restriction 
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factors APOBEC3A and 3G and lower levels of HIV coreceptor CCR5159,161. CD16+ 
monocytes are more permissive to HIV and SIV infection compared to CD16- 
monocytes and are preferentially infected in vivo49,55. This is due, in part, to higher 
expression of CCR5 and lower levels of the active form of the restriction factor 
APOBEC3G in CD16+ monocytes55. In patients on ART, the mean half-life of HIV-1 
DNA in monocytes was found to be greater than 40 months indicating persistent 
monocyte infection in spite of effective therapy162. 
 
C. Infection of tissue macrophages 
Macrophages from different donors are highly variable in the ability to replicate virus 
indicating that intrinsic genetic differences affect susceptibility to HIV-1 infection143. 
Lentiviral infection of monocytes and macrophages occurs independently of cell division 
and requires the ability of the viral preintegration complex to cross the nuclear envelope, 
which is achieved through utilization of host factors such as transportin-SR2 and the 
nuclear envelope protein emerin86,163,164. Infected macrophages appear to be resistant 
to both the cytopathic effects of lentiviral infection and immune detection and 
consequently may be long lived in vivo.  Proposed mechanisms of the ability of infected 
monocytes and macrophages to avoid the immune response and cytopathic effects of 
viral replication include inhibition of apoptotic signaling, limited viral replication, and viral 
assembly at sites other than the cell surface86,98,165,166. Infected macrophages contribute 
to HIV pathogenesis through production of toxic viral proteins and elaboration of 
inflammatory cytokines that increase local inflammation, recruit additional target cells, 
and increase viral replication39,87,97,98,167. Infected macrophages are also able to transfer 
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virus directly to T cells168-170. Because HIV-infected macrophages are long lived they 
also contribute to the formation of a viral reservoir in the CNS. In Chapter 4 of this thesis, 
we characterize productive SIV infection in resident CNS macrophages present in the 
CNS prior to infection and in macrophages recruited to the CNS from the blood 
terminally with AIDS in animals with SIVE.     
 
VI. Infection of the CNS 
HIV and SIV are thought to enter the CNS through traffic of infected 
monocytes/macrophages. In the CNS perivascular macrophages and parenchymal 
microglia are the primary cell types that are productively infected. CNS inflammation is 
mediated in part by activated macrophages that replicate virus and produce 
proinflammatory and neurotoxic substances. Multiple populations of macrophages exist 
in the CNS and the ratio of macrophage subsets may influence disease progression. 
Importantly, multiple rounds of neuroinvasion and continued traffic of activated 
macrophages to the CNS terminally with AIDS may be required for the development of 
HIVE and SIVE. CNS macrophage recruitment, SIV neuroinvasion, and the role of 
macrophage subsets in the development of SIVE are investigated in Chapter 4.  
 
A. Populations of CNS macrophages 
CNS macrophages are comprised of parenchymal microglia and macrophages of the 
perivascular space, meninges, and choroid plexus57,88,171-173. Microglia are 
embryonically derived and have negligible turnover in humans and nonhuman 
primates174,175. Perivascular, meningeal, and choroid plexus macrophages are derived 
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from the bone marrow and turnover on the order of months to years88,171,176-180. In the 
healthy CNS, both microglia and perivascular macrophages are immune reactive to the 
pan-macrophage marker CD68 (Figure 1.10). Recruited macrophages (CD163+CD68+) 
can be differentiated from microglia (CD68+CD163-) by expression of CD163, a type B 
scavenger receptor that is only expressed by perivascular macrophages (Figure 
1.10)88,181,182. CD14+CD16+CD163+ monocytes are thought to be the immediate 
precursors of CD163+ perivascular macrophages in the CNS88,183. Importantly, 
hematogenous macrophages recruited to the CNS remain distinct from parenchymal  
 
 
Figure 1.10. CD163+CD68+ perivascular macrophages, CD68+CD163- microglia 
and MAC387+ inflammatory macrophages are distinct populations present in the 
CNS with HIV and SIV infection 
(adapted from Soulas et al. Am. J Pathol. 2011) 
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microglia in phenotype and CNS location88,173,181. Microglia help maintain homeostasis 
in the CNS parenchyma and are necessary for normal glial function174,175. Perivascular 
macrophages function in immune surveillance at the blood brain barrier and express 
proteins that suggest the ability to function as antigen presenting cells88,177,178. A third 
population of inflammatory macrophages (MAC387+CD163-CD68-) that is immune 
reactive to the antibody MAC387, which recognizes MRP14 or the MRP8/MRP14 
heterodimer, is not present in the healthy CNS but is recruited to the CNS with 
inflammation (Figure 1.10)181,184. CD163+ perivascular macrophages and microglia are 
targets of HIV and SIV infection, but MAC387+ inflammatory macrophages are not  
(Figure 1.11)88,181,183,185. 
 
B. Viral neuroinvasion 
HIV and SIV can be detected in the CNS within days to weeks of primary infection12-16. 
Seeding of the CNS with virus is thought to be mediated by the traffic of infected 
monocytes/macrophages into the CNS; although, the contribution of cell free virus to 
CNS infection cannot be excluded. CD163+ perivascular macrophages represent the 
primary cell type infected in the CNS88,183,185,186. Also, parenchymal microglia extend 
foot processes that comprise part of the glia limitans and are therefore in direct contact 
with infected cells or virus in the perivascular space. Infected microglia are primarily 
observed only during end stage disease186,187. During acute infection HIV DNA, RNA, 
and proteins are present in the CNS indicating productive infection. Inflammation of the 
choroid plexus and meninges can present with acute viremia, but is not thought to 
contribute to long-term viral pathogenesis in the CNS12,15,188-191. Productive infection is  
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Figure 1.11. CD163+CD68+ perivascular macrophages and CD68+CD163- 
microglia, but not MAC387+ macrophages are targets of SIV infection 
(adapted from Kim et al. Am J Pathol. 2006 and Soulas et al. Am. J Pathol. 2011) 
 
not observed in the CNS during clinical latency. HIV-1 DNA has been detected in the 
CNS macrophages during the asymptomatic period, though it is not known if such 
provirus is replication competent or pathologically important186,189,192,193. Extensive 
productive infection of the CNS is observed terminally with AIDS in ART naïve patients. 
It is not known whether productive CNS infection with AIDS is due to reemergence of 
virus seeded in the CNS during acute infection or reintroduction of virus via traffic of 
activated and infected monocytes/macrophages to the CNS during end stage disease. 
 
C. AIDS neuropathogenesis and viral encephalitis 
Mechanisms of neuropathogenesis 
Infection of the CNS compromises normal function leading to a range of neurological 
disorders categorized as HIV-associated neurocognitive disorders (HAND): 
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asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND, 
formerly MCMD), and HIV-associated dementia (HAD)194. Anti-retroviral therapy initially 
decreased the apparent incidence of the most severe neurological complications2,195. 
However, with increased longevity of HIV infected individuals on durable ART, the 
continued presence of HAD and the less fulminant MND indicate that CNS disorders are 
still clinically relevant2,195. Neuroinflammation with AIDS is characterized by microglial 
activation, increased macrophage infiltration, focal accumulation of macrophages and 
multinucleated giant cells (MNGCs), atrophy of the cerebral cortex, myelin pallor, and 
loss of BBB integrity87,196-198. The observation that neurological complications are 
associated with aging of the HIV-infected population suggests that neurodegeneration 
may be progressive.  
 
 
Figure 1.12. Mechanisms of neurodegeneration and neuroprotection in AIDS 
(Gonzalez-Scarano and Martin-Garcia Nat. Rev. Immunol. 2005) 
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Neuronal damage in HIV infection of the CNS is not likely due to direct cytopathic 
effects of HIV infection as neurons are not productively infected in vivo. Traffic of 
activated monocytes from the periphery and infection of CNS macrophages result in the 
production of inflammatory cytokines, infectious virus, and viral proteins in the CNS 
(Figure 1.12)87. Inflammatory mediators and viral proteins may exert direct effects on 
astrocytes, neurons, the vascular endothelium, and microglia (Figure 1.12)199. Neuronal 
apoptosis can be induced by exposure to tumor necrosis factor (TNF) and the viral 
proteins gp120, Tat, and Vpr (Figure 1.12)87,200-203. Additionally, activation of astrocytes 
alters calcium and glutatmate homeostasis potentially leading to increased neuronal 
excitotoxicity and apoptosis (Figure 1.12). Macrophage-mediated inflammation in the 
CNS can be elaborated through bystander macrophages (Figure 1.12). Additionally, 
loss of BBB integrity, endothelial activation, and production of chemoattractant 
cytokines provide a mechanism of continued recruitment and accumulation of activated 
monocytes and macrophages. Microglia are also targets of HIV infection and may 
contribute to neuropathogenesis, but also maintain homeostasis in the normal CNS. As 
such, microglia (and recruited macrophages?) may also be able to produce chemokines 
and growth factors that inhibit cellular activation and apoptosis and contribute to 
neuronal survival (Figure 1.12)204,205.   
 
HIV and SIV encephalitis 
HIV encephalitis is the histopathological correlate of HIV-associated dementia (HAD), 
the most severe form of HAND194,206. Necropsy tissues from HIVE cases have evidence 
of viral replication in the CNS, focal accumulation of activated macrophages (HIVE 
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lesions), and multinucleated giant cells12,195-198,206,207. In macaques SIV encephalitis 
(SIVE) is associated with rapid disease progression and death80. The number of 
activated macrophages in the CNS is a better correlate of HAD than the number of 
productively infected macrophages198. This suggests that chronic immune activation in 
the CNS may contribute to the development of HIVE and SIVE. HIV-1 neuroinvasion 
during acute viremia coincides with intrathecal immune activation that persists 
throughout HIV-1 infection12,15. Ongoing inflammation may be the result of low-level viral 
replication and persistent immune activation in the CNS, although productive infection of 
the CNS is not detected during clinical latency or in virally suppressed individuals. In the 
blood, greater numbers of circulating monocytes, increased monocyte activation, and 
expansion of monocytes from the bone marrow correlate with the development of HIVE 
(pre-ART) or SIVE42,71,93,198,206,208. Thus, increased traffic of activated macrophages to 
the CNS, some of which may be infected, is likely another mechanism by which ongoing 
inflammation is maintained in the CNS. Additionally, increased compartmentalization of 
virus in the CNS during end stage disease is also associated with the development of 
HAD141. Thus, reintroduction of virus into the CNS terminally with AIDS may be 
necessary to drive HIVE.  
 
We have previously shown animals with severe SIVE had higher ratios of CD68+ to 
MAC387+ macrophages in SIVE lesions and more extensive viral replication compared 
to animals with mild SIVE181.  MAC387+ macrophages may be considered to be 
classically activated, M1-polarized macrophages that mediate proinflammatory 
responses favoring an anti-microbial microenvironment. In contrast, CD68+ 
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macrophages may be considered to be alternatively activated, M2-polarized 
macrophages that favor resolution of inflammation and are able to support viral 
replication181-183,209. The existence of multiple macrophage subsets with contrasting 
function have been widely reported in sterile inflammation, infection, and wound 
repair83,181,184,210-214. Importantly, proper coordination of M1 and M2 responses may be 
necessary to remove the inflammatory insult and remediate injured tissue213,215. Thus 
SIV inflammation in the CNS may share general features with the normal immune 
response to infection or injury. The development of HIVE may reflect a lack of proper 
resolution of the inflammatory response in the CNS, likely due to chronic infection and 
increased macrophage activation as the immune system compensates for the loss of 
CD4+ T-lymphocyte mediated immunity.  
 
D. PCNA expression in CNS macrophages 
Studies investigating local macrophage proliferation as a source of macrophage 
accumulation with HIV and SIV infection found that CNS macrophages lack standard 
markers of proliferation (Ki67, Topoisomerase IIa, BrdU uptake) but do express 
proliferating cell nuclear antigen (PCNA)216-218. PCNA expression is detected in CD68+ 
macrophages in the perivascular space and in HIVE and SIVE lesions (Figure 
1.13)216,217. PCNA expression is also associated with productive HIV and SIV infection 
in the same cell (Figure 1.13)216,217. PCNA is a processivity factor for DNA polymerase 
delta during cellular division, but is also involved in DNA damage repair (DDR) and p53 
dependent cell survival pathways in non-dividing cells219-222. It is not known whether 
PCNA is expressed by CNS macrophages prior to or as a result of HIV and SIV 
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infection. Studies investigating the specific role of PCNA in HIV and SIV infection of 
macrophages have not been done. 
 
 
Figure 1.13. PCNA expression by macrophages in HIVE and SIVE lesions is 
associated with productive infection  
(adapted from Williams et al. Am. J Pathol. 2002 and 
Fisher-Smith et al. Am. J Pathol. 2004) 
 
PCNA expression in productively infected macrophages may indicate a mechanism of 
preferential infection of CD68+ macrophages in the CNS. During proviral integration, 
viral integrase trims the 3’ ends of the viral DNA and creates double strand breaks in the 
host DNA where the provirus is inserted223-225. The resulting DNA lesion is repaired by 
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the host DDR machinery224,226. Induction of DDR in response to double-strand breaks 
has been shown to increase lentiviral transduction227,228. Thus, PCNA expression may 
be associated with induction of DDR pathways that facilitate viral integration into the 
host genome. Alternatively, DDR pathways may recognize the incoming provirus as a 
DNA lesion and inhibit integration224,229. Evidence for this includes previous reports that 
PCNA-associated proteins p21, Rad18, and Rad52 attenuate HIV infection147,230-232.  
 
It has also been proposed that induction of cell survival pathways may explain retention 
of HIV+PCNA+ macrophages in the CNS217. PCNA is induced downstream of p21 and 
p53 in response to genotoxic stress and is associated with inhibition of apoptosis233,234. 
HIV infection increases macrophage longevity in vitro and reduces the frequency of 
apoptotic CD68+ macrophages in the CNS165,235. Accumulation of macrophages in 
HIVE and SIVE lesions may therefore be mediated in part by inhibition of apoptosis in 
subpopulations of CNS macrophages. PCNA expression in monocytes and CNS 
macrophages and the role of PCNA induction in macrophage infection are investigated 
in Chapter 5.  
 
VII. Summary 
As innate immune cells and targets of HIV infection, monocytes and macrophages are 
important in HIV pathogenesis. Monocytes and macrophages are heterogeneous and 
are comprised of phenotypically distinct subpopulations that differ in immune function 
and susceptibility to infection. Increased monocyte egress from the bone marrow and 
expansion of activated monocyte subsets in the blood correlate with increased 
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monocyte traffic to the CNS and the development of HIVE and SIVE. Infection of the 
CNS is associated with persistent macrophage activation and inflammation that 
contribute to the development of CNS disease. In the CNS, CD163+ perivascular 
macrophages and CD68+ parenchymal microglia are productively infected, whereas 
MAC387+ inflammatory macrophages are not. Productive infection of CNS 
macrophages correlates with PCNA expression in the same cell. In end stage disease, 
HIVE (pre-ART) and SIVE are characterized by viral replication, increased numbers of 
activated macrophages, and focal accumulation of macrophages in HIVE lesions. Thus, 
HIV infection is associated with changes in the biology of monocytes and macrophages 
that contribute to the development of CNS disease and HIVE. 
 
This thesis investigates the biology of monocytes and macrophages in rhesus 
macaques using a rapid model of neuroAIDS. In these studies we characterize the gene 
expression profiles of classical, intermediate and nonclassical monocytes and 
investigate changes in gene expression that occur in each subset with SIV infection 
(Chapter 3). Additionally, we investigate the relationship between SIV infection, 
monocyte activation, CNS macrophage recruitment, viral neruroinvasion, and the 
development of SIVE (Chapter 4). Finally, we characterize PCNA expression within 
monocyte and macrophage subsets in vivo and investigate the role of PCNA in 
macrophages with regard to viability and the ability to promote or inhibit SIV infection 
(Chapter 5).   
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Chapter 2. Materials and methods 
Ethics Statement 
All animals were handled in accordance with good animal practice as defined by the 
Tulane National Primate Research Center’s Institutional Animal Care and Use 
Committee (IACUC). All animal work was approved by this committee and the IACUC of 
Boston College.  
 
Animals, viral infection, and CD8+ T-lymphocyte depletion 
Twelve adult male rhesus macaques were infected intravenously with 1ng of SIVp27 of 
SIVmac251, a generous gift from Dr. Ronald Desrosiers (New England Regional 
Primate Research Center). CD8+ lymphocytes were depleted in order to achieve rapid 
AIDS (3-4 months) with greater than 75% incidence of SIV encephalitis (SIVE)42,43,52,181.  
While there is an increase in the number of monocytes/macrophages and virus in the 
CNS of CD8+ Lymphocyte depleted animals compared to non-depleted animals, with 
AIDS and SIVE, the pathology is the same. The chimeric anti-CD8 antibody cM-T807 
(NIH Non-human Primate Reagent Resource) was administered s.c. (10mg/kg) at 6 
days post infection (dpi) and i.v. (5mg/kg) on 8 dpi and 12 dpi42,91. Complete blood 
counts and flow cytometry to monitor leukocyte populations and CD8+ lymphocyte 
depletion were performed prior to infection and weekly thereafter. Blood and 
cerebrospinal fluid were sampled weekly, and CNS and other tissues were collected at 
necropsy. Choroid plexus tissue was available from 7 of the 12 animals.  
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SIV-infected animals were sacrificed with any of the following criteria, indicative of AIDS 
when present: >15% decrease of body weight in 2 weeks or >30% decrease of body 
weight in 2 months; documented opportunistic infection; persistent anorexia >3 days 
without explicable cause; severe, intractable diarrhea; progressive neurological 
symptoms; significant cardiac or pulmonary symptoms. Prior to sacrifice, animals were 
anesthetized with ketamine-HCl and euthanized by an intravenous pentobarbital 
overdose and exsanguinated. A post mortem diagnosis of AIDS was confirmed by the 
presence of AIDS defining lesions including: Pneumocystis pneumonia, Mycobacterium 
avium infection, and intestinal adenovirus infection. SIVE was defined by the presence 
of multinucleated giant cells (MNGCs), accumulation of macrophages in the CNS, and 
productive viral infection42,80,207,236. 
 
BrdU administration to SIV infected animals 
A stock solution of 5-bromo-2’-deoxyuridine (BrdU, 30 mg/mL, Sigma-Aldrich) was 
prepared in calcium and magnesium free PBS (U.S.P. grade) as previously 
described52,237. BrdU was administered as an i.v. injection at a dose of 60 mg BrdU/kg 
body weight. BrdU was administered either at: 1) 6 dpi and 20 dpi (termed “Early”) or 2) 
49 dpi and 48 hours prior to necropsy (termed “Late”). The percentage of BrdU+ 
monocytes was determined by flow cytometry 24h post-administration. 
 
Tissue collection at necropsy 
Necropsy tissues were either: 1) collected in 10% neutral buffered formalin and 
embedded in paraffin, 2) fixed with 2% paraformaldehyde for 4h and embedded in 
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optimum cutting temperature compound (OCT, Miles Scientific), or 3) embedded in OCT 
without fixation and snap-frozen.  Formalin-fixed, paraffin-embedded tissues were cut 
into 5µm thick sections and frozen tissues were sectioned at 10µm. CNS tissues from 
three uninfected control animals which received autologous CD34+ bone marrow stem 
cells transduced with an EGFP-expressing lentiviral construct were used to determine 
basal turnover of CNS macrophages179. 
 
Viral load determination 
SIV RNA in the plasma was quantitated by real-time PCR as previously described.238 
SIV virions were pelleted from 0.5ml EDTA plasma by centrifugation at 20,000 g for 1 
hour. The fluorescently labeled, real-time PCR probe employed contained a non-
fluorescent quencher, BHQ-1, at its 3’ end. The threshold of sensitivity was 100 copy 
equivalents/mL, with an average interassay coefficient of variation of less than 25%. 
 
Isolation of monocyte subpopulations for microarray analysis 
Prior to infection, at 26 dpi, and at necropsy, mononuclear cells were isolated from 
10mL EDTA treated whole blood (n = 4 animals: CM07, DB79, FD05, FB92) by density 
gradient centrifugation over Ficoll-Hypaque (GE Healthcare).  Buffy coats were 
collected and washed in calcium and magnesium free PBS and stained for 15 minutes 
with anti-CD14-PacificBlue, anti-CD16-PE, anti-HLA-DR-PerCP-Cy-5.5, anti-CD3-FITC, 
and anti-CD20-APC (BD Biosciences) in PBS containing 2% FBS. Monocytes were 
isolated by forward and side scatter characteristics and CD14 antigen expression. HLA-
DR+CD3-CD20- cells were selected to exclude B-cells and T-cells. Non-overlapping 
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populations of classical, intermediate, and nonclassical monocytes were isolated based 
on expression of CD14 and CD16 on a BD FACS ARIA (BD Biosciences). FACS 
isolated monocytes were washed in PBS to remove residual FACS buffer and vacuum 
pelleted to preserve RNA integrity.   
 
Microarray  processing 
RNA extraction, labeling, and hybridization were performed by the Beth Israel 
Deaconess Medical Center Genomics Core Laboratory as previously described239,240. 
Briefly, total RNA was extracted with TRIzol (Life Technologies) according to the 
manufacturer’s instructions. RNA quality at all steps was assayed on an Agilent 2100 
Bioanlayzer (Agilent Technologies). RNA (>500pg) was amplified using the Ovation pico 
WTA system (NuGEN Technologies Inc.). 20 µg cRNA was fragmented as described 
and hybridized with a preequilibrated Affymetrix GeneChip Rhesus Macaque Genome 
Array (Affymetrix) at 45°C for 16 hours. After the hybridization cocktails were removed, 
the chips were washed, stained, and scanned according to the manufacturer’s protocols 
as previously described239. 
 
Microarray data analysis 
The gene expression data generated (>47,000 rhesus transcripts interrogated per array) 
were analyzed with Partek Express Genomics Suite software (Partek Inc.). The data 
were normalized by using a robust multi-chip average (RMA) algorithm241,242. Due to the 
low abundance of the nonclassical monocyte subset, insufficient RNA was isolated from 
this population at preinfection from animals FD05 and FB92, and at necropsy from 
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animal CM07. These samples did not meet quality control parameters and were 
excluded form further analysis.  
 
Probe sets with a significant p-value corrected with a 5% false discovery rate between 
monocyte subset or SIV infection timepoint were filtered based on a fold change ≥ |2|. 
Probe sets were annotated with the human official gene symbol based on information 
provided by the manufacturer and supplementary annotation data from the Norgren lab, 
which collaborated in the development of the Affymetrix rhesus macaque genome array 
(http://www.unmc.edu/rhesusgenechip/#RhesusGeneChip). Heatmaps were generated 
using dChip software243. Gene lists were subjected to functional annotation clustering 
with DAVID bioinformatics tools to identify enrichment clusters associated with specific 
biological processes according to gene ontology annotations244,245.  
 
Quantitative real time PCR for microarray validation 
RNA from each sample was extracted with TRIzol as indicated above. First strand 
cDNA was generated from >40ng total RNA with Superscript III first strand synthesis kit 
(Invitrogen). Quantitative real-time PCR was performed on 3ng of cDNA with the 
Platinum qPCR SuperMix-UDG kit (Invitrogen) using a Step One Plus system (Life 
Technologies). Samples were analyzed in duplicate and normalized to the GAPDH 
housekeeping gene. Relative gene expression was determined using the ΔΔCT method 
and converted to arbitrary units relative to a reference RNA sample from pooled CD14+ 
monocytes. qPCR expression data were correlated with normalized log2 expression 
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data from the microarray also normalized to GAPDH. Oligonucleotides (IDT Inc.) used 
are listed in Table 2.1. 
 
Dextran uptake by uninfected monocytes 
EDTA anti-coagulated whole blood from uninfected rhesus macaques (n = 6 animals) 
was incubated with fluorescein-conjugated dextran (1mg/mL) (Molecular Probes) for 15 
minutes at 37°C. Erythrocytes were lysed using the ImmunoPrep Reagent System 
(Beckman Coulter), washed twice with PBS containing 2% FBS and incubated for 15 
minutes at room temperature with fluorochrome-conjugated surface antibodies: anti-
HLA-DR-ECD (Immu-357, Beckman Coulter), anti-CD16-PE-Cy7 (3G8, Biolegend), 
anti-CD3-APC (SP34-2, BD Biosciences), anti-CD8-APC (RPA-T8, BD Biosciences), 
anti-CD20-APC (2H7, BD Biosciences) and anti-CD14-Pacific blue (M5E2, BD 
Biosciences). Data were acquired on a BD FACS Aria (BD Biosciences) and analyzed 
with Flow Jo version 8.7 (Tree Star Software). 
 
Intracisternal injection of dextran amines and detection in CNS tissues 
Animals were tranquilized with ketamine or telazol and anesthetized with sodium 
pentobarbital.  One milliliter of dextran amines (25mg/mL) dissolved in 0.9% saline was 
injected into the cerebellomedullary cistern using a stereotaxic apparatus. Following 
intracranial injection, the hydrophilic fluorescent dextran dyes diffuse along the 
perivascular space and are taken up by essentially all perivascular macrophages 
(>98%) via nonspecific micropinocytosis88,176,177. To establish a baseline for subsequent 
turnover, all animals (n=12) received fluorescein-conjugated dextran (abbreviated 
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“Dextran:FITC”, Molecular Probes) at 20 dpi (Table 4.1). Five animals received a 
second injection of Alexa Fluor647-conjugated dextran (abbreviated “Dextran:AF647”, 
Molecular Probes) 48h prior to necropsy to determine macrophage recruitment from 20 
dpi to necropsy. Four additional animals received a second injection of Alexa Fluor 647-
conjugated dextran at 49 dpi and a third injection of biotinylated dextran (Molecular 
Probes) 48h prior to necropsy to determine macrophage recruitment from 20 dpi to 49 
dpi and 49 dpi to necropsy, respectively (Table 4.1). 
 
Immunofluorescence microscopy 
Fixed tissue samples on slides were washed and permeabilized with PBS containing 
0.2% fish skin gelatin (Sigma-Aldrich), and 0.1% Triton X-100 (Sigma-Aldrich). 
Nonspecific binding was blocked with 10% normal goat serum (Invitrogen) and 2% 
normal human serum (Valley Biomedical Inc.) in wash buffer. Alexa Fluor 568- or Alexa 
Fluor 350-conjugated secondary antibodies were used to detect primary antibodies 
according to standard protocols88. Background endogenous autofluorescence was 
reduced by incubating sections with 50 mM CuSO4 as previously described prior to 
mounting in Prolong Gold Antifade reagent (Invitrogen) with DAPI (4',6-Diamidino-2-
Phenylindole, Dihydrochloride)246. Slides were viewed on a 4-color Zeiss Axio Imager 
M1 microscope (Carl Zeiss MicroImaging, Inc.).  
 
For the dextran dye studies, antibodies against macrophage markers anti-CD163 
(EDHu-1, AbD Serotec) and anti-myeloid histiocyte antigen (MAC387, DAKO), or 
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against viral capsid anti-SIVp28 (3F7, Fitzgerald Industries) were used. For PCNA in 
vitro studies anti-PCNA (PC10, DAKO) was used.   
 
Detection and enumeration of dextran labeled macrophages 
The fluorescent dextran conjugates are directly visualized by fluorescence microscopy 
in sections of paraformaldehyde-fixed, OCT-embedded frozen tissue after washing and 
mounting as above. Biotinylated dextran was detected with streptavidin conjugated to 
Alexa Fluor 568 or Alexa Fluor 647 (Invitrogen). Dextran dye labeled macrophages in 
CNS tissues were counted by sampling 3000-4000 cells from frontal, temporal, and 
parietal cortices; 1000 cells from meninges; and 2 sections of choroid plexus per animal. 
Additionally, 10 or more SIVE lesions were evaluated for animals with AIDS and SIVE 
(n=5). For one of the SIVE animals, only three SIVE lesions were found in the frozen 
tissue available; this animal was excluded from the analysis of macrophage turnover in 
SIVE lesions. 
 
Single and double label immunohistochemistry 
Immunohistochemistry was performed in formalin-fixed paraffin embedded tissues. For 
BrdU staining, tissue sections were treated with antigen unmasking solution (Vector 
Labs). A dual endogenous enzyme block (DAKO) and serum-free protein block (DAKO) 
was applied prior to immunostaining followed by visualization with EnVision+ 
horseradish peroxidase (HRP) system (DAKO) using DAB (3,3’-diaminobenzidine 
tetrahydrochloride) as the chromogen. For detection of two epitopes, the EnVision G2 
doublestain system (DAKO) was used with DAB as the HRP substrate and Vector Blue 
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(Vector Labs) or permanent red (DAKO) as the alkaline phosphatase substrate. Isotype-
matched immunoglobulin (DAKO) served as controls. Tissue sections were visualized 
using a Zeiss Axio Imager M1 microscope using Plan-Apochromat 620/0.8 and 640/0.95 
Korr objectives. 
 
For the dextran dye studies, anti-CD163 (EDHu-1, AbD Serotec), anti-myeloid histiocyte 
antigen (MAC387, DAKO), and anti-BrdU (Bu20a, DAKO) were used to determine 
macrophage accumulation and the phenotype of BrdU-labeled macrophages. More than 
twenty, 20x fields were examined from each of three cortical sections with associated 
meninges, and one section of choroid plexus per animal for each stain. For PCNA 
studies, CNS tissues were stained with anti-PCNA (PC10, DAKO) and either anti-BrdU 
(Bu20, DAKO), anti-myeloid histiocyte antigen (MAC387, DAKO), or anti-CD163 (EDHu-
1, AbD Serotec). For each of 4 SIVE animals, SIVE lesions from 3-5 cortical sections 
were counted for each stain. 
 
Isolation of primary monocytes for in vitro PCNA studies 
Blood from uninfected and SIV-infected animals was obtained by venipuncture, 
collected in EDTA, and processed within six hours. Whole blood was diluted with 
Ca/Mg-free PBS (Thermo Scientific) and PBMCs were obtained by centrifugation over 
Ficoll-Hypaque (GE Healthcare). CD14+ monocytes were isolated from total PBMCs 
with anti-CD14 immunomagentic beads according to the manufacturer’s instructions 
(Miltenyi Biotech). CD14+ purity was determined by labeling with anti-CD14-Pacific Blue 
antibody (M5E2, BD Biosciences). Samples were acquired on a BD FACS Aria (BD 
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Biosciences) and analyzed with Flow Jo version 8.7 (TreeStar Software). Samples with 
less than 90% purity were not used. Mean CD14+ purity was 94 ± 0.8% (Mean ± SEM). 
 
Western Blotting for PCNA studies 
All steps prior to SDS-PAGE were performed at 4°C. Cells were lysed in RIPA buffer 
(50mM Tris HCl, 150mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0,1% 
SDS) containing complete protease inhibitor cocktail (Roche). Lysates were sonicated 
to free nuclear proteins and incubated at 4°C for 30 minutes. Insoluble material was 
removed by centrifugation and total protein was quantified by Bradford assay. 
Approximately 20µg of total lysate was resolved on a 4-15% polyacrylamide gel 
(BioRad). Protein was transferred to Hybond-ECL membrane (GE Healthcare) blocked 
with 5% nonfat milk and probed for PCNA (PC10, Chemicon). HRP conjugated goat 
anti-mouse antibody (Jackson Labs) was used to detect the primary antibody, and the 
chemiluminescence reaction was performed with Supersignal West Pico kit (Thermo 
Scientific). Hybond autoradiography film (Denville Scientific) was exposed to the labeled 
blots and developed with an X-OMAT 2000A processor (KODAK). Blots were stripped in 
0.2M NaOH in PBS for 30 minutes, washed extensively, and re-blocked with 5% nonfat 
milk. Anti-actin (Thermo Scientific) was used as the loading control. Bands were 
quantitated using Image J software (NIH).  
 
Quantitative real time PCR for PCNA 
RNA was extracted with RNeasy micro kit (Qiagen) according to the manufacturer’s 
instructions. First strand cDNA was generated from approximately 100ng total RNA with 
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Superscript III first strand synthesis kit (Invitrogen). Quantitative real-time PCR was 
performed on approximately 25ng cDNA with the Platinum qPCR SuperMix-UDG kit 
(Invitrogen) using a Step One Plus system (Applied Biosciences). Samples were 
analyzed in duplicate and normalized to the GAPDH housekeeping gene. Relative gene 
expression was determined using the ΔΔCT method. Oligonucleotides (IDT Inc.) used 
are listed in Table 2.1.  
 
Cell culture for in vitro PCNA studies 
Cells were cultured in treated polystyrene plates or flasks (Costar) or in chamber slides 
(Lab-Tek). CD14+ monocytes were cultured in RMPI 1640 (Thermo Scientific) with 10% 
fetal bovine serum (Atlas Biologicals) and 10ng/mL recombinant, human macrophage 
colony stimulating factor (M-CSF, Peprotech). 293T cells were maintained in DMEM 
(Cellgro) with 10%FBS. 
 
Production of SIVmac316-E767* viral stocks for in vitro PCNA studies 
High titre viral stocks were produced by transfecting 5ug of proviral plasmid into 2x106 
293T cells in a T75 flask using a calcium phosphate transfection kit (Profection, 
Promega) according to the manufacturer’s instructions. The medium was changed daily 
and virus containing medium was harvested at 72h post transfection. The amount of 
virus was quantitated by SIVp27 ELISA (ABL).  
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 siRNA knockdown assays 
Two siRNA constructs specific for human PCNA were used in this study (Qiagen). One 
construct, designated siRNA-5, had the same sequence as the Macaca mulatta PCNA 
reference sequence: sense 5’-(GGA UCU UAG GCA UUC UUA ATT)-3’; antisense 5’-
(UUA AGA AUG CCU AAG AUC CTT)-3’. The second construct, designated siRNA-6, 
had a single basepair mismatch (in bold) relative to the Macaca mulatta PCNA 
reference sequence: sense 5’-(GGA UUU AGA UGU UGA ACA ATT)-3’, antisense 5’-
(UUG UUC AAC AUC UAA AUC CAT)-3’. A proprietary nonsilencing control, 
designated siRNA-NS, was used as a control (Allstars Negative siRNA, Qiagen).  
 
CD14+ monocytes were cultured with M-CSF for 5 days to yield monocyte-derived 
macrophages (MDM) and replated at 3x105 cells/well in a 12 well plate. Oligofectamine 
(Invitrogen) was used to transfect 100 pmol PCNA-specific or control siRNA per well 
according to the manufacturer’s instructions. The procedure was repeated the next day 
to increase the transfection efficiency. The following day macrophages were infected 
(20ng SIVp27/well) with SIVmac316-E767*, a macrophage tropic variant with a high 
replicative capacity (hereafter called SIV316*)247. At 1 dpi, the medium was changed 
and the cells were washed to remove the inoculum. Protein RNA and culture 
supernatants were harvested at 3 dpi. Viral replication was quantitated by SIVp27 
ELISA. Three experiments were performed in triplicate  
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TUNEL staining 
TUNEL (Terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining to 
detect apoptotic cells was performed using the ApopTag Fluorescein kit (Millipore) 
according to the manufacturer’s instructions. Incorporation of fluorescein-conjugated 
nucleotides allows for direct detection of apoptotic nuclei by immunofluorescence. 
Nuclei were counterstained with DAPI.  
 
sCD163  and SIVp27 ELISA 
ELISA kits for soluble CD163 (Trillium Diagnostics) and SIVp27 (Advanced Bioscience 
Laboratories) were used according to the manufacturers’ protocols as previously 
described42,248,249. Briefly, plasma (sCD163) or culture supernatant (SIVp27) were 
added to the ELISA plate for 1h. Bound antigen was detected using HRP conjugated 
detection antibodies. TMB was used as the chromogenic substrate. Protein 
concentration was determined by measuring the 450nm absorbance versus a reference 
standard.   
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Table 2.1 Sequence of oligonucleotides used for qRTPCR 
 
Target Sequence (5’ – 3’) 
CD14   
Forward CCGAGATGTATGTGGTCCAG 
Reverse GATCGAGCACTCTGAGCTTG 
Probea AGCGCCCTAAACTCCCTCAATCTGT 
CD16   
Forward GCTCCGGATATCTTTGGTGA 
Reverse AGCACCCTGTACCATTGAGG 
Probea TTTCAGCTGGCATGCGGACTGAAGAT 
S100A9   
Forward GGACACAAATGCAGACAAGC 
Reverse AGACCTGGCTTATGGTGGTG 
Probea AGTTCATCATGCTGATGGCGAGGCTA 
CCR2   
Forward CTTCTTCATCATCCTCCTGA 
Reverse GAATCTTCTTCCTGGCATTT 
Probea TGGTTGGTGGCTGTGTTTGCTTCTGT 
PCNA  
Forward GCGGAGCAGAGTGGTAGTTC 
Reverse GCCTCCAACACCTTCTTCAG 
Probea ACCGGCTACACTTTCCTCCT 
GAPDH   
Forward GCACCACCAACTGCTTAGCAC 
Reverse TCTTCTGGGTGGCAGTGATG 
Probea TCGTGGAAGGACTCATGACCACAGTCC 
 
a. Probes were modified with 5’– (6-carboxyfluorescein) and 3’– (tetramethylrhodamine) 
as the fluorophore and quencher respectively.  
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Chapter 3. Monocyte subsets exhibit transcriptional plasticity and a shared 
response to interferon in SIV-infected rhesus macaques  
 
Chapter Overview 
The progression to AIDS is associated with phenotypic and functional alterations to 
monocyte biology and is influenced by the relative proportion of heterogeneous 
monocyte subsets. Classical (CD14++CD16-), intermediate (CD14++CD16+), and 
nonclassical (CD14+CD16++) monocytes are distinct populations that may represent 
progressive stages of monocyte maturation or disparate myeloid lineages with different 
turnover rates and function. To investigate the relationship between monocyte subsets 
and differences in the response to SIV infection, we conducted a microarray analysis of 
the monocyte subsets in rhesus macaques at three timepoints: 1) prior to SIV infection, 
2) at 26 days post infection, and 3) necropsy terminally with AIDS. Transcripts that 
identify classical and nonclassical monocytes in humans and mice were conserved in 
rhesus macaques. We found that the majority of markers that differentiate monocyte 
subsets in uninfected animals are not differently expressed between monocyte subsets 
in SIV-infected animals. We found that classical monocytes expressed transcripts 
associated with cell proliferation, wound repair, and responses to immune stimuli, while 
nonclassical monocytes expressed transcripts associated with macrophage phenotype, 
withdrawal from cell cycle, and immune effector functions. Intermediate monocytes were 
more similar to classical monocytes than nonclassical monocytes overall, but showed 
increased transcriptional similarity to nonclassical monocytes terminally with AIDS. 
Changes to monocyte gene expression occurred within weeks of primary infection and 
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were sustained throughout the course of infection. Transcripts associated with innate 
immune responses, particularly interferon stimulated genes, were induced in all 
monocyte subsets in SIV infected animals. These studies indicate that the set of genes 
expressed by each monocyte subset is altered with SIV infection, but each subset 
retains its putative functional characteristics. Additionally, the innate immune response 
to SIV infection, including induction of interferon stimulated genes, is conserved across 
monocyte subsets. 
 
Monocyte populations expand with SIV infection 
The absolute number and relative percentage of each monocyte subset were 
determined for each animal (n = 4): 1) prior to infection, 2) at 26 dpi when increased 
monocyte egress from the bone marrow is initially observed, and 3) at necropsy, 
terminally with AIDS (Table 3.1). At the same time points, monocytes were isolated from 
each of the four animals for gene expression analysis. Prior to infection, classical 
monocytes accounted for 196 ± 56 cells/µL (87.7 ± 4.3% of total monocytes), 
intermediate monocytes were 18 ± 4 cells/ µL (7.8 ± 1.2% of total monocytes), and 
nonclassical monocytes were 11 ± 5 cells/µL (4.4 ± 1.5% of total monocytes) (Table 3.1). 
With SIV infection, the absolute number of each of the three monocyte subpopulations 
increased as well as the percentage of both intermediate and nonclassical monocytes.  
At 26 dpi, classical, intermediate and nonclassical monocytes expanded to 332 ± 40 
cells/µL (73.9 ± 3.4%), 87 ± 16 cells/µL (19.3 ± 3.1%, p = 0.03 26 dpi vs. preinfection), 
and 34 ± 15 cells/µL  (6.8 ± 2%) respectively (Table 3.1). An increased absolute number 
of monocytes was also observed at necropsy terminally with AIDS: classical monocytes 
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329 ± 75 cells/µL (74.1 ± 10.7% ), 103 ± 60 cells/µL (16.9±6.1% ), and 79 ± 70 cells/µL 
(9.0 ± 6.1%) (Table 3.1). These data indicate that the absolute number of total 
monocytes increases with SIV infection and that intermediate and nonclassical 
monocytes account for a greater percentage of total monocytes in SIV-infected animals 
compared to uninfected animals.  
 
Isolation of monocyte populations and microarray analysis 
To collect samples for microarray analysis, peripheral blood mononuclear cells were 
isolated from EDTA anti-coagulated whole blood, and the three monocyte subsets were 
collected by fluorescence activated cell sorting (FACS) (Table 3.1, Figure 3.1A). 
Monocytes were selected based on high forward scatter and low side scatter and HLA-
DR expression. CD3 and CD20 were used to exclude T-cells and B-cells, respectively 
(Figure 3.1A). Classical, intermediate, and nonclassical monocyte populations were 
sorted based on expression of CD14 and CD16 from each animal at each timepoint 
(Table 3.1, Figure 3.1A). A minimum of 1000 cells were collected for each sample 
(Range: 24 x 103 – 1 x 106 classical monocytes, 4 x 103 – 110 x 103 intermediate 
monocytes, 1 x 103 – 100 x 103 nonclassical monocytes) (Table 3.1). RNA from each 
sample (n = 33 samples, Table 3.1) was hybridized to Affymetrix rhesus macaque 
genome arrays. Each array interrogates approximately 47,000 transcripts per sample 
using probes designed from the Baylor School of Medicine rhesus macaque whole-
genome shotgun assembly and from the Affymetrix Human Genome U133 Plus 2.0 
Array. Partek Express Genomic Suite software was used to normalize the raw 
microarray signal intensities and analyze the gene expression data. 
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The total variation in gene expression across all samples can be measured by the effect 
size (F ratio) of the three variables that define each sample: animal (F = 3.01), 
monocyte subset (F = 2.98), and infection status (F = 1.83). The differences in effect 
size indicate that, across all samples, inherent differences between individual animals 
and differences between monocyte subsets account for a greater proportion of the total 
variation in gene expression compared to differences in gene expression due to SIV 
infection.  
 
Identification of transcripts that differentiate monocyte subsets or infection 
timepoints.  
To identify differently expressed transcripts, gene expression data from each of the four 
animals were grouped and compared based on the variables of interest: monocyte 
subset and infection timepoint. 3418 probe sets were identified as significantly, 
differently expressed. This list was then filtered based on an absolute fold change (AFC) 
≥ 2.0 between monocyte subsets or infection timepoints and a p-value < 0.05. Probe 
sets were annotated with the corresponding human official gene symbol and redundant 
probe sets representing the same gene and probe sets representing hypothetical genes 
were removed. In agreement with the observed effect sizes, we found 2023 genes that 
were significantly, differently expressed between monocyte subsets at one or more 
timepoint and 424 genes that were significantly differently expressed between infection 
timepoints in at least one monocyte subset.  
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Validation of microarray data by qRTPCR and FACS 
To validate the microarray expression data, we generated cDNA from available RNA 
and performed quantitative real time PCR (qRTPCR). Gene expression as determined 
by qRTPCR correlated with gene expression as determined by microarray (r = 0.56, p = 
0.0003) (Figure 3.1B). Additionally, we compared gene expression as determined by 
microarray to protein expression as determined by flow cytometry for a panel of 
monocyte related proteins (CD14, CD16, CD68, CD163, S100A8, HLA-DR, CD44v6, 
CX3CR1, CCR2). Protein expression (MFI by FACS) correlated with gene expression 
determined by microarray for 8 of the 9 target genes investigated (Table 3.2).  
 
Intermediate monocytes are more similar to classical monocytes than 
nonclassical monocytes overall, and the number of genes differently expressed 
between intermediate and nonclassical monocytes decreases with AIDS.  
To investigate the relationship between the three monocytes subsets in uninfected and 
SIV-infected animals we compared the number of genes differently expressed in at least 
one comparison between monocyte subsets (classical vs. intermediate, classical vs. 
nonclassical, or intermediate vs. nonclassical), at each infection timepoint (Figure 3.1C). 
Of the 2023 genes identified as differently expressed between monocyte subsets, 1295 
genes were differently expressed preinfection, 1178 genes were differently expressed at 
26 dpi, and 1272 genes were different expressed at necropsy (Figure 3.1C). 
Intermediate monocytes expressed 69% (890 genes, preinfection), 68% (914 genes, 26 
dpi), and 75% (960 genes, necropsy) of differently expressed genes at levels between 
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classical and nonclassical monocytes. Based on the number of differently expressed 
genes, intermediate monocytes were more similar to classical monocytes than 
nonclassical monocytes, and classical monocytes and nonclassical monocytes were 
most dissimilar at all timepoints (Figure 3.1C). We observed that the number of genes 
differently expressed between intermediate and nonclassical monocytes decreased 
terminally with AIDS. Intermediate and nonclassical monocytes were differentiated by 
847 genes preinfection, 869 genes at 26 dpi, and 624 genes at necropsy (Figure 3.1C). 
Conversely, the number of genes differentiating intermediate and classical monocytes 
increased from 237 genes in uninfected animals and 201 genes at 26 dpi to 286 genes 
at necropsy (Figure 3.1C). The number of genes differently expressed between 
classical and nonclassical monocytes did not significantly change with SIV infection: 
1139 genes preinfection, 1179 genes at 26 dpi, and 1105 genes at necropsy (Figure 
3.1C). Increased similarity between the intermediate and nonclassical monocyte 
subsets with SIV infection may reflect increased activation or maturation of the 
intermediate subset in chronic SIV infection and suggests that the set of genes that 
differentiate monocyte subsets may exhibit plasticity in response to SIV infection and 
inflammation. Despite changes in gene expression with SIV infection, Intermediate 
monocytes were more similar to classical monocytes than nonclassical monocytes at all 
timepoints investigated. 
 
Gene signature of monocyte subsets in uninfected animals 
In order to characterize genes specific to each monocyte subset in uninfected animals, 
we selected genes that were differently expressed (≥ 2.0 AFC) in each subset 
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compared to the other two subsets (Figure 3.2, Tables 3.3-3.7). Prior to infection, we 
identified 99 genes expressed ≥ 2.0-fold by classical monocytes relative to intermediate 
monocytes (range: 2.0- 5.3 fold, median: 2.6) or nonclassical monocytes (range: 2.0- 80 
fold, Median: 4.2) (Table 3.3, Figure 3.2). Only 17 genes were expressed ≥ 2.0-fold by 
intermediate monocytes relative to classical (range: 2.1- 3.8 fold, median: 2.5) or 
nonclassical monocytes (range: 2.2- 20 fold, median: 3.4) (Table 3.4, Figure 3.2). 
Nonclassical monocytes expressed 242 genes ≥ 2.0-fold relative to classical (range: 
2.0- 82 fold; median: 4.0) or intermediate monocytes (range: 2.0- 27 fold; median: 3.1) 
(Table 3.5, Figure 3.2). The low number of genes expressed ≥ 2.0-fold uniquely by 
CD14++CD16+ intermediate monocytes is the result of an overlap in shared gene 
expression with both classical and nonclassical monocytes. There were 426 genes 
expressed ≥ 2.0-fold in both classical (range: 2.0- 148.2 fold; median: 3.6) and 
intermediate monocytes (range: 2.0- 86.7 fold; median: 3.2) compared to nonclassical 
monocytes (Table3.6, Figure 3.2). Relative to classical monocytes, 29 genes were 
expressed ≥ 2.0-fold in intermediate monocytes (range: 2.0- 22.6 fold; median: 2.9) and 
nonclassical monocytes (range: 2.1- 46.5 fold; median: 4.4) (Table 3.7, Figure 3.2). 
Because intermediate monocytes shared a greater number of expressed genes with 
classical monocytes than nonclassical monocytes, and because nonclassical 
monocytes had the greatest number of uniquely expressed genes, we conclude that 
classical and intermediate monocytes are more similar to one another than the 
nonclassical monocytes that more transcriptionally dissimilar.  
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With regard to maturation, nonclassical monocytes expressed transcripts associated 
with macrophage or DC phenotypes (e.g. CD16, CD83, SPN, ITGAL, BTLA), and 
classical and intermediate monocytes expressed transcripts associated with myeloid 
and granulocyte phenotype (e.g. CD14, TREM1, CD93, CD114, CD116). This may 
indicate that classical monocytes have a more “immature” granulocyte/monocyte 
phenotype while nonclassical monocytes have a more “mature” macrophage-like 
phenotype. Additionally, expression of genes associated with proliferation (JUN, FOSL2, 
RUNX1, RUNX2) in classical monocytes and genes associated with inhibition of cell 
cycle (CDKN1C) in nonclassical monocytes may indicate that nonclasscial monocytes 
are more differentiated than classical monocytes.  
 
The set of genes sepcifc to each subset is altered with SIV infection 
We found that of the 813 genes expressed in a subset-specific manner preinfection, 
only 172 genes were also subset-specific at 26 dpi and terminally with AIDS (Figure 3.3). 
Ten genes were consistently expressed ≥ 2.0-fold by classical monocytes including 
S100A8, S100A9, and SELL (L-selectin, CD62L) (Figure 3.3). These genes are 
expressed by classical monocytes in humans and mice. Only the complement receptor 
C3AR1 (C3a receptor 1) and MERTK tyrosine kinase were consistently expressed ≥2.0-
fold by intermediate monocytes at all timepoints (data not shown). Nonclassical 
monocytes had consistently higher expression of 22 genes involved with inflammatory 
response (CX3CR1, CCL5, TNF, BTLA, GZMB) and inhibition of cell cycle (CDKN1C) 
(Figure 3.3). Both intermediate and nonclassical monocytes were consistently 
differentiated by expression of 22 genes relative to classical monocytes including CD16 
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and integrins ITGAL, ITGAD, and ITGAX (Figure 3.3). We identified 116 genes 
expressed ≥ 2.0-fold by classical and intermediate monocytes relative to nonclassical 
monocytes, including many immune receptors (CD14, CD163, FCGR1B, FCGR2B, 
FCAR, CCR1, CCR2, C5AR1). In particular, we have identified C3AR1 and MERTK as 
potential surface markers of intermediate monocytes. These data also indicate that 
SELL/CD62L is expressed by classical monocytes and CX3CR1 is expressed by 
nonclassical monocytes in rhesus macaques, as has previously been demonstrated in 
humans and mice.  
 
In silico analysis of gene-associated functions suggests classical monocytes are 
immune sensors and nonclassical monocytes are immune effectors.  
In order to investigate whether the genes that were differently expressed between the 
monocyte subsets were associated with specific biological processes, we performed an 
in silico analysis using DAVID bioinformatics tools244,245. Human official gene symbols 
were used in order to take advantage of the relative abundance of gene annotation data 
for humans relative to macaques. With DAVID tools, gene lists were annotated with the 
gene ontology (GO) terms for biological process - a controlled vocabulary for describing 
the biological function of gene products - and statistically overrepresented GO terms 
were identified. The analysis was performed for each of the infection timepoints (Table 
3.8). Interestingly, we found that the GO terms that were enriched for each subset were 
generally the same in uninfected and SIV-infected animals suggesting that the 
functional role of each subset is maintained with SIV infection and inflammation (Table 
3.8).   
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We found that genes expressed ≥ 2.0-fold by classical monocytes or both classical and 
intermediate monocytes were enriched for biological processes including defense 
response, positive regulation of cell proliferation, regulation of protein kinase cascade, 
endocytosis, and wound healing in uninfected and SIV-infected animals (Figure 3.4, 
Table 3.8). Defense response genes expressed in classical monocytes include 
inflammatory mediators (e.g. IL-8, S100A8, and S100A9). Interestingly, S100A9 and the 
S100A8/S100A9 heterodimer comprise the epitope recognized by the antibody MAC387, 
which defines a subset of macrophages that is recruited in response to 
inflammation181,250. Both classical and intermediate monocytes express receptors 
associated with detection of immune ligands including TLR4 and CD14 (LPS receptor), 
FCGR1A, CCR1, CCR2, and IL-6R. Genes associated with regulation of protein kinase 
cascade include genes involved in MAPK and NFkB signaling, which are important 
pathways in mitogenic signaling, cell survival, and cytokine secretion. Enrichment of 
MAPK-associated genes and transcription factors involved in proliferation may indicate 
that the classical subset may be or has recently been progressing through the cell cycle. 
Thus, biological processes associated with genes enriched in classical monocytes 
include proliferation, detection of innate immune stimuli, and response to inflammation.  
 
We found that genes expressed ≥ 2.0-fold by nonclassical monocytes or by 
intermediate and nonclassical monocytes were enriched for biological processes 
including defense response, negative regulation of cell proliferation, regulation of T-cell 
activation, and cellular activation in uninfected and SIV-infected animals (Figure 3.4, 
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Table 3.8). Defense response genes in nonclassical monocytes are associated with a 
range of effector functions including initiation of complement cascades (C1QA, C1QB, 
C1QC), cell-mediated cytotoxicity (GZMA, GZMB, GZMH, LTB, GNLY), and T-cell 
activation (CD4, CD47, CD83, SPN). Nonclassical monocytes may also be able to 
contribute to proinflammatory responses and recruit monocytes and T-cells to sites of 
inflammation through production of TNFα and CCL5. We found nonclassical monocytes 
express the fractalkine receptor (CX3CR1) and integrins (ITGAD, ITGAL, ITGAX, 
ITGB2). Additionally, nonclasscial monocytes express transcripts associated with 
negative regulation of cell cycle. Thus, biological processes associated with genes 
enriched in nonclassical monocytes are consistent with this subset having exited the cell 
cycle, mediating immune effector functions, producing chemoattractant ligands, and 
being able to extravasate vessels to become tissue macrophages.  
 
Changes in monocyte gene expression occur early in SIV infection 
To investigate subset-specific changes in gene expression with SIV infection, we 
identified genes that were differently expressed (≥ 2.0 AFC) between infection 
timepoints for each monocyte subset (Figure 3.5A). Between preinfection and necropsy, 
more genes were differently expressed in the nonclassical subset (265 genes) than in 
the classical (227 genes) or intermediate subsets (202 genes) (Figure 3.5A). In all 
subsets, the majority of changes in gene expression had occurred by 26 dpi, indicating 
that changes in gene expression due to SIV infection are established early (Figure 3.5A). 
The majority of genes differently expressed at 26 dpi were upregulated relative to 
preinfection in the classical and intermediate subsets. In the nonclassical subset, 
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upregulated and downregulated genes were present in approximately equal numbers 
(Figure 3.5A). Between 26 dpi and necropsy, the majority of differently expressed genes 
were downregulated relative to 26 dpi (Figure 3.5A). Many of these downregulated 
genes were transcription factors. These data suggest that changes to monocyte gene 
expression occur early in SIV infection prior to AIDS onset. Additionally, we observed 
that the pattern of changes in gene expression with SIV infection is more similar 
between classical and intermediate monocytes compared to nonclassical monocytes. 
 
Characterization of the monocyte immune response to SIV infection 
We next sought to characterize the immune response of each monocyte subset to SIV 
infection. Genes with GO annotation for innate immune response (62 genes, GO: 
0045087), interferon stimulated genes (44 genes, GO: 0034340, 0034341, or previous 
description in the literature), and adaptive immune response (24 genes, GO:0002250) 
were selected from the set of genes differently expressed with SIV infection (Figure 
3.5B-D). Almost all immune associated genes were upregulated relative to the 
preinfection timepoint. Additionally, genes modulated with SIV infection had a similar 
pattern of expression in classical, intermediate, and nonclassical monocytes (Figure 
3.5B-D).  
 
Hierarchical clustering was used to identify patterns of expression of innate immune 
response genes across monocyte subsets (Figure 3.5B). The largest cluster (Group II) 
was comprised of genes that were upregulated in all monocyte subsets with SIV 
infection. Interferon stimulated genes (ISG) as well as cytosolic sensors of nucleic acids 
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(DDX58, DDX60, RARRES3, AIM2), restriction factors (APOBEC3A, TRIM5, SAMHD1), 
and ubiquitin associated genes (HERC6, TRIM14, UBE2L6) are representative of this 
group. The second largest cluster (Group II) consisted of genes that were upregulated 
primarily in classical and intermediate monocytes. These include genes associated with 
defense response to bacteria or viruses (CD163, APOBEC3F, S100A9, HLA-B, LY96, 
SP100). Two minor clusters consisting of genes downregulated in all monocyte subsets 
(Group I), and genes upregulated primarily in intermediate and nonclassical monocytes 
(Group IV) contained transcription factors (PIAS1, IRF4, IRF8, AKIRIN2) and genes 
associated with chemotaxis (PTAFR, CXCL16), respectively. Upregulation of defense 
response genes, restriction factors, and cytosolic sensors of nucleic acids may suggest 
a mechanism of limiting SIV infection in monocytes. Immune associated genes were 
upregulated at 26 dpi and terminally with AIDS, which indicates these changes in gene 
expression in monocytes occur early and are sustained throughout infection. 
Additionally, the pattern of gene expression was similar across the three subsets, which 
suggests that the innate response to virus is conserved in spite of subset heterogeneity.  
 
Induction of interferon-stimulated genes are part of the innate immune response to HIV 
and SIV infection and have been implicated in viral pathogenesis251. We identified 44 
ISG that were changed expression in response to SIV infection (Figure 3.5C). Most 
ISGs (38/44 genes) were upregulated in all three subsets and were associated with an 
antiviral function (OAS1-3, GBP1-2, MX1-2, ISG15, ISG20). ISGs were also associated 
with myeloid cell differentiation (IRF4, IRF8, IFI16), JAK-STAT signaling (JAK2, PIAS1, 
STAT2), and response to cytokine stimulus (SP100, CXCL16, PML, SOCS3). Sustained 
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induction of interferon signaling in monocytes may be a mechanism of monocyte 
dysregulation and chronic immune activation, which contribute to SIV pathogenesis. 
 
We identified 24 adaptive immune response genes that changed expression with SIV 
infection (Figure 3.5D). 16 of these were upregulated in all subsets or intermediate and 
nonclassical subsets. These genes were associated with Th1 polarization (GIMAP1, 
GIMAP4) and T-cell binding or regulation (IDO1, SIGLEC1, ADAMDEC1). Additional 
genes associated with modulation of T-cell function were upregulated in intermediate 
and nonclassical monocytes terminally with AIDS (CD3E, CD28, CD5, CTLA4). 
Downregulated genes include the MHC class II invariant chain (CD74) and cytokine 
associated genes (IRF4, IL-1β, ADORA2B). Induction of genes associated with a Th1 
type adaptive response and costimulatory molecules, particularly in intermediate and 
nonclassical monocytes, implies that SIV infection affects the ability of monocytes to 
regulate T-cell function.  
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Conclusions 
Identification of unique biological functions associated with genes expressed by each 
monocyte subset recapitulates the fact that functional differences exist between 
monocyte subsets. We found that classical monocytes express genes associated with 
detection of innate immune ligands, angiogenesis, and wound repair. Nonclassical 
monocytes expressed genes associated with cellular activation and immune effector 
functions including T-cell activation, initiation of complement cascade, and cell-mediated 
cytotoxicity. Interestingly, the biological processes associated with each subset were the 
same in uninfected and SIV-infected animals.  
 
We also observed an increase in the number of total monocytes and in the relative 
percentage of intermediate and nonclassical monocytes in SIV-infected macaques. 
Because monocytes are functionally heterogeneous, increased number and relative 
percentage of intermediate and nonclassical monocytes, which are activated and 
promote immune effector functions, may contribute to sustained immune activation and 
mediate injurious processes that contribute to SIV pathogenesis including disseminating 
of virus into tissues, producing proinflammatory cytokines, and initiating T-cell 
responses. Additionally intermediate and nonclassical monocytes are more susceptible 
to HIV and SIV infection, compared to classical monocytes, and are putative precursors 
of tissue macrophages. Expansion of activated monocyte populations is thought to 
contribute to increased traffic of activated/infected monocytes to the CNS and the 
development of HIV and SIV encephalitis.  
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Similarities in gene expression between classical and intermediate monocytes and 
between intermediate and nonclassical monocytes may suggest that classical 
monocytes mature into nonclassical monocytes via the intermediate subset. We 
observed that classical monocytes expressed phenotypic markers of granulocytes and 
monocytes and genes associated with proliferation while nonclassical monocytes 
expressed macrophage-like transcripts and genes associated with cell cycle inhibition. 
This observation may indicate that classical monocytes are at an earlier stage of 
maturation compared to nonclassical monocytes. Intermediate monocytes were more 
similar to classical monocytes in uninfected and SIV-infected animals. The similarity in 
gene expression profiles may indicate that classical and intermediate monocytes are 
developmentally related, with classical monocytes progressing to intermediate 
monocytes in response to activating stimuli or as part of normal monocyte maturation. 
With SIV infection and AIDS, transcriptional similarity between intermediate and 
nonclassical monocytes increased, which may suggest a developmental relationship 
between intermediate and nonclassical monocytes and increased maturation of the 
intermediate subset with AIDS. Overlap in gene expression and phenotypic plasticity of 
monocyte subsets support the hypothesis that the three subsets are developmentally 
related. 
 
We found that each subset maintained a gene expression profile that allowed 
differentiation of the three populations at each of the timepoints investigated, despite 
changes in gene expression with SIV infection. In macaques SELL/CD62L was 
expressed by classical monocytes and CX3CR1 was expressed by nonclassical 
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monocytes, as has previously been described in humans and mice. Importantly, we also 
identified C3AR1 and MERTK as potential markers of intermediate monocytes. 
 
We found the majority of changes in gene expression occurred within weeks of primary 
infection and were then sustained through end-stage disease. Importantly, this indicates 
that monocyte dysregulation begins early in the course of SIV infection. Genes 
associated with innate and adaptive immunity had a similar pattern of expression in 
each of the three monocyte subsets with SIV infection. All three subsets upregulated 
defense response genes, cytosolic sensors of nucleic acids, and restriction factors. 
Induction of genes associated with detection and restriction of viral infection may 
contribute to the low prevalence of SIV infection in monocytes. Additionally all three 
subsets upregulated a number of interferon stimulated genes. This suggests that 
interferon signaling and response to interferon is also conserved across the three 
monocyte subsets. The majority of ISG were upregulated at both 26 dpi and terminally 
with AIDS. Sustained induction of interferon signaling in monocytes may also contribute 
to monocyte dysregulation and chronic immune activation, which drive SIV 
pathogenesis. Adaptive immune response genes also showed a similar pattern of 
expression in all three subsets. Nonclassical and intermediate monocytes upregulated a 
greater number of genes associated with adaptive immunity compared to classical 
monocytes in agreement with the observed enrichment of genes associated with T-cell 
activation in these subsets. Interestingly, these observations indicate that the immune 
response to SIV infection is largely conserved in monocytes despite functional 
heterogeneity between subpopulations. Additionally monocyte activation, as indicated 
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by upregulation of ISG and innate immune response genes, is observed early in 
infection and is sustained throughout disease progression. 
 
These studies identify classical, intermediate, and nonclassical monocytes as distinct 
subpopulations with unique transcriptional signatures. Despite plasticity in gene 
expression with SIV infection, the functional phenotype associated with genes 
expressed by each subset does not change. Overlap in gene expression and a 
conserved immune response to SIV infection indicate shared biology between 
monocyte subsets. Importantly, we observe that changes in monocyte gene expression 
occur prior to AIDS onset and are sustained through end-stage disease. These studies 
also provide evidence of chronic immune activation of all monocyte subsets with SIV 
pathogenesis.
 
  
	   70	  
Table 3.1. Number and percentage of monocyte subsets and plasma viral load        
over time. 
 
Animal ID CM07 DB79 FD05 FB92 
CNS pathologya SIVE SIVE SIVE SIVnoE 
Timepoint  (dpi)b 0 26 75 0 26 91 0 26 95 0 26 118 
Viral Load  (x106, 
Copy Eq./mL) Uc 24.0 7.4 Uc 23.0 11.0 Uc 48.0 58.0 Uc 21.0 NAd 
Monocyte Count 
(Cells/µL)             
     CD14++CD16- 204 265 188 246 443 508 116 334 222 217 285 400 
     CD14++CD16+ 28 93 13 21 91 271 9 119 99 14 44 28 
     CD14+CD16++ 13 26 6 24 76 289 2 22 17 6 11 4 
Percent of Total 
Monocytes (%)             
     CD14++CD16- 83.5 69.0 90.5 84.5 72.6 47.5 91.3 70.3 65.7 91.6 83.8 92.6 
     CD14++CD16+ 11.2 24.3 6.4 7.1 14.9 25.4 7.1 25.1 29.3 5.9 12.9 6.5 
     CD14+CD16++ 5.2 6.7 3.1 8.4 12.5 27.1 1.6 4.6 5.0 2.5 3.2 0.9 
Cells per sample 
(x103)e             
     CD14++CD16- 130 1000 24 100 65 190 62 46 NAd 50 38 57 
     CD14++CD16+ 36 110 18 10 54 100 14 100 NAd 4 60 24 
     CD14+CD16++ 11 15 10f 13 35 100 1f 10 NAd 1.8f 15 16 
 
a. SIVE: SIV encephalitis, SIVnoE: SIV no encephalitis.  
b. dpi: days post infection. 
c. U: undetectable (< 100 copy equivalents/mL). 
d. NA: sample not available. 
e. Total number of FACS-sorted monocytes collected from each subset.   
f. Sample failed quality control and was excluded from analysis. 
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Table 3.2. Microarray signal intensity correlates with mean fluorescenece 
intensity (MFI) by FACS 
 
Gene/Protein Spearman’s Ra p-value 
CD14 0.75 < 0.0001 
FCGR3A/CD16b  0.80 < 0.0001 
FCGR3B/CD16b 0.48 < 0.0001 
CD68 0.68 < 0.0001 
CD163 0.67 0.003 
S100A8 0.46 0.04 
HLA-DR  0.64 0.001 
CD44/CD44v6b 0.48 0.03 
CX3CR1 0.48 < 0.0001 
CCR2 0.48 NSc 
 
a. The normalized log2 microarray signal intensity was plotted vs. the median 
fluorescence intensity (MFI) as determined by FACS for each target.  
b. For these gene/protein target pairs, the microarray probe or antibody recognize a 
specific isoform of the gene or protein, as indicated 
c. Not significant 
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Table 3.3. Top 50 genes expressed ≥ 2.0-fold by classical monocytes in 
uninfected animals 
  
Fold change classical 
versus 
Gene Gene name Intermediate Nonclassical 
THBS1 thrombospondin 1 2.6 80.0 
TREM1 triggering receptor expressed on myeloid cells 1 3.0 63.1 
SERPINB10 serpin peptidase inhibitor, clade B member 10 2.6 61.8 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing 2 2.2 41.2 
S100A8 S100 calcium binding protein A8 4.5 40.5 
SLC7A11 solute carrier family 7 member 11 3.6 40.5 
S100A9 S100 calcium binding protein A9 4.7 26.2 
SLC2A3 solute carrier family 2 member 3 2.2 21.4 
GAFA1 FGF2-associated protein GAFA1 2.3 16.6 
IL8 interleukin 8 2.4 14.5 
OSM oncostatin M precursor 2.4 12.6 
QPCT glutaminyl-peptide cyclotransferase 3.6 10.5 
KCNAB1 Potassium voltage-gated channel subunit beta 1 2.7 9.4 
AAK1 AP2 Associated Kinase 1 3.5 9.1 
BCL9L  B-cell CLL/lymphoma 9-like 2.5 8.4 
ACSL1 acyl-CoA synthetase long-chain family member 1 2.2 7.0 
SELL selectin L 4.2 7.0 
RAB3D RAB3D, member Ras oncogene family 2.7 6.9 
NRG1 neuregulin 1 2.6 6.6 
ELL3 elongation factor RNA polymerase II-like 3 3.4 6.3 
NCAM1 neural cell adhesion molecule 1 2.9 5.9 
ZCCHC11 zinc finger, CCHC domain containing 11 2.8 5.6 
FOSL2 FOS-like antigen 2 3.5 5.6 
C6orf192 chromosome 6 open reading frame 192 2.2 5.6 
NP nucleoside phosphorylase 2.1 5.5 
MGST1 microsomal glutathione S-transferase 1 3.6 5.5 
CARS cysteinyl-tRNA synthetase 2.6 5.4 
KIN KIN, antigenic determinant of recA protein homolog (mouse) 2.2 5.3 
ATP13A3 ATPase type 13A3 2.5 5.1 
JUN jun oncogene 2.3 5.1 
DCUN1D3 DCN1, defective in cullin neddylation 1, domain containing 3 3.6 5.1 
PARD3 Par-3 Partitioning Defective 3 Homolog (C. elegans) 3.9 5.0 
NUP188 nucleoporin 188kDa 3.3 5.0 
SLC16A6 solute carrier family 16, member 6 2.7 5.0 
TREML4 triggering receptor expressed on myeloid cells-like 4  3.9 4.9 
TTC19 tetratricopeptide repeat domain 19 2.6 4.8 
ERCC8 excision repair cross-complementing rodent repair deficiency, 8 3.5 4.7 
RABEPK Rab9 effector p40 3.5 4.7 
BAG2 BCL2-associated athanogene 2 2.1 4.7 
RAB23 RAB23, member Ras oncogene family 2.9 4.5 
EEPD1 endonuclease/exonuclease/phosphatase family domain containing 1 2.3 4.5 
TGFBR1 transforming growth factor, beta receptor 1 2.5 4.5 
TSPAN3 tetraspanin 3 2.3 4.4 
EML1 echinoderm microtubule associated protein like 1 isoform b 2.5 4.4 
PRKCI protein kinase C, iota 2.3 4.3 
CDC42EP3 CDC42 effector protein (Rho GTPase binding) 3 2.2 4.2 
SVIL supervillin 2.6 4.2 
LILRBC leukocyte immunoglobulin-like receptor, subfamily B, member c 2.0 4.2 
MALT1 mucosa associated lymphoid tissue lymphoma translocation gene 1 2.1 4.2 
GCA grancalcin, EF-hand calcium binding protein 4.8 4.2 
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Table 3.4. Genes expressed ≥ 2.0-fold by intermediate monocytes in uninfected 
animals 
    
Fold change intermediate 
versus 
Gene Gene name Classical Nonclassical 
CD1B CD1b molecule 2.2 20.0 
GCNT1 glucosaminyl (N-acetyl) transferase 1, core 2 2.1 8.0 
CD1C CD1c molecule 2.2 7.3 
LIPA lipase A precursor 2.1 4.8 
VSIG4 V-set and immunoglobulin domain containing 4 2.5 4.2 
A2M alpha-2-macroglobulin 2.8 4.1 
ASPHD2 aspartate beta-hydroxylase domain containing 2 3.1 3.9 
MERTK c-mer proto-oncogene tyrosine kinase 2.7 3.6 
ST3GAL5 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 2.4 3.4 
MPZL2 myelin protein zero-like 2 2.5 3.3 
CDC42BPA CDC42-binding protein kinase alpha isoform B 2.5 3.0 
FABP5 fatty acid binding protein 5 (psoriasis-associated) 2.9 2.9 
C3AR1 complement component 3a receptor 1 3.8 2.8 
ABI3 ABI family, member 3 2.1 2.6 
CLEC7A C-type lectin domain family 7, member A 2.1 2.4 
RAB11FIP4 RAB11 family interacting protein 4 (class II) 2.1 2.4 
MGLL monoglyceride lipase 2.8 2.2 
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Table 3.5. Top 50 genes expressed ≥ 2.0-fold by nonclassical monocytes in 
uninfected animals 
	  
Fold change nonclassical 
versus 
Gene Gene Title Classical Intermediate 
GNLY granulysin 82.2 27.0 
MS4A7 membrane-spanning 4-domains, subfamily A, member 7 47.2 5.5 
AHNAK2 AHNAK nucleoprotein 2 36.2 15.1 
FCGR3A Fc gamma receptor IIIa 35.6 4.1 
GZMB granzyme B  31.5 13.3 
GZMH Granzyme H precursor  30.1 14.8 
CDKN1C cyclin dependent kinase inhibitor 1C 25.2 10.8 
C1QA complement component 1, q subcomponent, A chain 23.3 3.4 
SEPP1 selenoprotein P 22.9 2.5 
LPL lipoprotein lipase 19.4 3.9 
DUSP5 dual specificity phosphatase 5 18.0 9.1 
MTSS1L metastasis suppressor 1-like 17.4 7.6 
RAMP2 receptor (G protein-coupled) activity modifying protein 2 16.4 3.7 
MT1E metallothionein 1E 16.2 7.4 
HTR7A 5-hydroxytryptamine receptor 7 isoform a 16.1 4.6 
CD300E CD300E molecule 15.8 2.7 
TCF7L2 similar to Transcription factor 7-like 2  14.9 4.1 
ADA adenosine deaminase 14.0 4.1 
GZMA granzyme A 13.4 10.3 
TOB1 transducer of Erbb2 1 12.8 5.2 
C11orf95 chromosome 11 open reading frame 95 12.3 5.5 
PSMC2 Similar to proteasome (prosome, macropain) 26S subunit, ATPase 2 12.2 4.6 
NEU1 Sialidase 1 (lysosomal sialidase) 11.5 6.7 
PAG1 phosphoprotein associated with glycosphingolipid microdomains 1 11.4 5.8 
IFT81 intraflagellarTransport81 11.2 5.6 
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit) 10.8 3.0 
GPR155 G protein-coupled receptor 155 10.4 5.3 
C1QC complement component 1, q subcomponent, C chain 9.8 3.0 
ARHGAP32 Rho GTPase-activating protein 32 9.8 10.5 
HEG1 HEG homolog 1 (zebrafish) 9.5 5.1 
HIST1H2BH similar to Histone H2B 291B 9.4 9.3 
CASP2 caspase 2, apoptosis-related cysteine peptidase 9.0 7.3 
CCL5 chemokine (C-C motif) ligand 5 8.9 7.8 
C18orf45 chromosome 18 open reading frame 45 8.8 8.8 
NR4A1 nuclear receptor subfamily 4, group A, member 1 8.6 5.8 
CSRP1 Cysteine and Glycine-Rice Protein 1 8.3 3.8 
SCAMP5 similar to secretory carrier membrane protein 5 8.2 4.4 
GUCY1A3 Guanylate Cyclase 1, Soluble, Alpha 3 8.2 5.3 
CYFIP2 similar to cytoplasmic FMR1 interacting protein 2 8.2 5.6 
SASH1 SAM and SH3 domain containing 1 8.1 2.5 
NKG7 natural killer cell group 7 sequence 8.0 4.8 
NKG2D NKG2D protein 8.0 5.7 
C1QB similar to Complement C1q subcomponent subunit B precursor 8.0 2.3 
FMNL2 formin-like 2 7.9 4.7 
CARM1 coactivator-associated arginine methyltransferase 1 7.8 3.8 
TNF tumor necrosis factor 7.5 4.7 
ITGAD similar to integrin, alpha D precursor 7.4 3.1 
CAMK2G calcium/calmodulin-dependent protein kinase II gamma 7.4 7.8 
ITGAL integrin, alpha L (antigen CD11A (p180), LFA1; alpha polypeptide) 7.3 2.4 
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Table 3.6. Top 50 genes expressed ≥ 2.0-fold by classical and intermediate 
monocytes in uninfected animals 
  
Fold change versus 
nonclassical 
Gene  Gene Title Classical Intermediate 
VCAN versican 148.2 86.7 
SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 109.3 60.3 
FN1 fibronectin 1 65.9 46.9 
CYP1B1 cytochrome P450, family 1, subfamily B, polypeptide 1 65.7 77.0 
ALOX5AP arachidonate 5-lipoxygenase-activating protein 65.0 25.1 
PTGS2 prostaglandin H snth 2 48.4 35.6 
SDC2 budding uninhibited by benzimidazoles 3 homolog 47.4 46.1 
VEGFA vascular endothelial growth factor A 46.5 22.8 
BASP1 brain abundant, membrane attached signal protein 1 42.4 34.3 
RIN2 Ras and Rab interactor 2 37.9 50.7 
IL13RA1 Interleukin-13 receptor alpha-1 chain 30.5 25.9 
ADAM19 ADAM metallopeptidase domain 19 29.1 19.1 
DEPDC1 DEP domain containing 1 26.1 15.9 
MS4A6A membrane-spanning 4-domains, subfamily A, member 6A 24.9 50.0 
FCAR Fc fragment of IgA, receptor for 24.7 12.6 
PID1 phosphotyrosine interaction domain containing 1 24.5 18.4 
DCP2 DCP2 decapping enzyme 23.9 24.4 
KIR3DL killer immunoglobulin-like receptor KIR3DL 22.4 19.2 
ADO 2-aminoethanethiol (cysteamine) dioxygenase 20.2 10.2 
CCR1 chemokine (C-C motif) receptor 1 20.1 16.1 
ACVR2A activin A receptor, type IIA 18.8 22.6 
SSH2 slingshot 2 18.2 30.4 
SLC38A2 solute carrier family 38, member 2 17.9 11.1 
F3 coagulation factor III (thromboplastin, tissue factor) 17.9 11.7 
FCGR2B Fc fragment of IgG, low affinity IIb, receptor (CD32) 17.8 19.9 
RUNX1 runt-related transcription factor 1 17.5 13.0 
GSN gelsolin 17.1 15.7 
PRDM1 PR domain containing 1, with ZNF domain 16.1 19.4 
RUNX2 runt-related transcription factor 2 15.6 13.4 
ADORA2B adenosine A2b receptor 15.4 8.0 
NEK6 NIMA (never in mitosis gene a)-related kinase 6 13.2 7.1 
GAS7 growth-arrest-specific protein 7 13.1 10.8 
RB1 retinoblastoma 1 12.3 13.4 
CD163 CD163 molecule 12.3 10.9 
THBD thrombomodulin 12.2 8.3 
ADRB1 adrenergic, beta-1-, receptor 12.0 11.4 
NUFIP1 nuclear fragile X mental retardation protein interacting protein 1 11.7 7.9 
EGR2 early growth response 2 11.0 9.2 
SERPINB6 serpin peptidase inhibitor, clade B (ovalbumin), member 6 10.7 6.5 
LGALS1 lectin, galactoside-binding, soluble, 1 10.7 11.4 
KIR3DL17 killer-cell Ig-like receptor KIR3DL17 10.5 9.0 
MSR1 macrophage scavenger receptor 1 10.4 14.1 
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 10.2 11.9 
CSDA cold shock domain protein A 9.9 8.9 
SLC2A5 solute carrier family 2 member 5 9.8 8.1 
PLP2 proteolipid protein 2 9.5 5.3 
TLR4 toll-like receptor 4 9.4 10.1 
HNRPLL heterogeneous nuclear ribonucleoprotein L-like 9.3 5.3 
SEMA4C Semaphorin 4C 9.2 12.0 
GPR183 G protein-coupled receptor 183 9.0 12.6 
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Table 3.7. Genes expressed ≥ 2.0-fold by intermediate and nonclassical 
monocytes in uninfected animals 
  Fold change versus classical 
Gene  Gene Title Intermediate Nonclassical 
FCGR3B Fc fragment of IgG, low affinity IIIb, receptor 22.6 46.5 
PLVAP plasmalemma vesicle associated protein 7.7 14.2 
RNF144B ring finger protein 144B 4.4 9.8 
CCND2 cyclin D2 6.5 9.3 
PAQR4 progestin and adipoQ receptor family member IV 4.6 8.1 
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma) 3.0 6.7 
LILRA1 leukocyte immunoglobulin-like receptor, subfamily A member 1 4.1 6.6 
SUSD3 sushi domain containing 3 3.1 5.5 
ARPC1A actin related protein 2/3 complex subunit 1A 2.7 5.0 
LY6E lymphocyte antigen 6 complex, locus E 2.5 4.8 
SPN sialophorin (CD43) 2.8 4.8 
PRR5L Rho GTPase activating protein 8 2.9 4.7 
UCP2 uncoupling protein 2 3.4 4.4 
SQLE squalene epoxidase 3.0 4.4 
VMO1 Vitelline membrane outer layer protein 1 homolog 3.3 4.4 
PALLD palladin, cytoskeletal associated protein 2.2 4.1 
LRRC25 leucine rich repeat containing 25 2.3 3.8 
HSPD1 60 kDa heat shock protein, mitochondrial precursor  3.5 3.8 
LILRB1 leukocyte immunoglobulin-like receptor, subfamily B, member 1 
(CD85) 
2.0 3.6 
CD83 CD83 molecule 2.4 3.3 
ALDH2 aldehyde dehydrogenase, mitochondrial-like 2.4 3.3 
ASCC3 activating signal cointegrator 1 complex subunit 3 2.1 3.2 
PLA1A phospholipase A1 member A 4.1 3.1 
DNM1 dynamin-1-like 2.4 3.0 
BPTF nucleosome-remodeling factor subunit BPTF-like 2.8 2.9 
CTSC cathepsin C 3.4 2.7 
CD4 CD4 molecule 2.8 2.6 
CTPS CTP synthase 2.7 2.6 
NAGA N-acetylgalactosaminidase, alpha 2.2 2.1 
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Table 3.8. GO terms for biological process enriched in the set of genes differently 
expressed across monocyte subsets 
  Preinfection 26 dpi Necropsy 
GO Term Subseta #b %c pd # % p # % p 
defense response 
GO:0006952 
C 38 7.6 **** 36 5.8 ** 41 7.7 **** 
I 40 8.8 **** 40 6.4 *** 36 8.1 **** 
N 25 9.5 **** 22 13.4 **** 9 8.0 * 
            
inflammatory response C 24 4.8 *** 27 4.3 *** 28 5.2 **** 
GO:0006954 I 24 5.3 **** 29 4.6 **** 27 6.1 **** 
 N 13 4.9 ** 13 7.9 *** 7 6.3 * 
regulation of T cell 
activation 
GO:0050863 
C NS NS NS NS NS NS NS NS NS 
I 9 2.0 * 10 1.6 * 8 1.8 * 
N 13 4.9 **** 9 5.5 **** 7 6.3 **** 
             
cell activation C NS NS NS NS NS NS NS NS NS 
GO:0001775 I NS NS NS NS NS NS NS NS NS 
 N 17 6.4 **** 8 4.9 * 11 9.8 **** 
positive regulation of 
cell proliferation 
GO:0008284 
C 27 5.4 *** 26 4.2 ** 26 4.9 ** 
I 21 4.6 * 28 4.5 ** 21 4.7 ** 
N NS NS NS NS NS NS NS NS NS 
             
negative regulation of 
cell proliferation 
GO:0008285 
C NS NS NS NS NS NS NS NS NS 
I NS NS NS NS NS NS NS NS NS 
N 15 5.7 ** 12 7.3 ** 10 8.9 *** 
             
positive regulation of 
apoptosis 
GO:0043065 
C 24 4.8 ** NS NS NS NS NS NS 
I NS NS NS 26 4.1 * NS NS NS 
N 15 5.7 ** NS NS NS 8 7.1 * 
             
negative regulation of 
apoptosis 
GO:0043066 
C 25 5.0 *** 22 3.5 * 22 4.1 ** 
I 20 4.4 ** 21 3.3 * 18 4.0 * 
N 12 4.5 * 9 5.5 * 7 6.3 * 
             
positive regulation of 
cell differentiation 
GO:0045597 
C 17 3.4 ** 16 2.6 * 17 3.2 ** 
I 15 3.3 ** 16 2.5 * 13 2.9 * 
N 10 3.8 * NS NS NS 5 4.5 * 
wound healing C 21 4.2 **** 15 2.4 ** 17 3.2 *** 
GO:0042060 I 18 4.0 **** 13 2.1 * 11 2.5 * 
 N NS NS NS NS NS NS NS NS NS 
             
angiogenesis C 11 2.2 * 13 2.1 ** 12 2.2 ** 
GO:0001525 I NS NS NS 12 1.9 * 11 2.5 ** 
 N NS NS NS NS NS NS NS NS NS 
(Table continues on next page) 
 
a. C: classical. I: intermediate. N: nonclassical. 
b. #: number of queried genes associated with the GO term 
c. % = (# GO associated genes / total genes queried ) x 100 
d. p: p-value for enrichment of the GO term. p	 ≤ 0.05, *. p < 0.01, **. p < 0.001, ***.  
        p < 0.0001, ***. 
e. NS: No significant enrichment 
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Table 3.8. continued	  
  Preinfection 26 dpi Necropsy 
GO Term Subset # % p # % p # % p 
endocytosis C 16 3.2 ** 20 3.2 *** 18 3.4 *** 
GO:0006897 I 16 3.5 ** 21 3.3 *** 16 3.6 *** 
 N NS NS NS NS NS NS NS NS NS 
             
membrane organization C 29 5.8 **** 31 5.0 **** 27 5.0 *** 
GO:0016044 I 27 6.0 **** 32 5.1 **** 24 5.4 *** 
 N NS NS NS NS NS NS NS NS NS 
             
vesicle-mediated 
transport 
GO:0016192 
C 35 7.0 *** 39 6.3 *** 33 6.2 ** 
I 30 6.6 ** 40 6.4 *** 29 6.5 ** 
N NS NS NS NS NS NS NS NS NS 
             
phagocytosis C --- --- --- 7 1.1 ** 6 1.1 * 
GO:0006909 I 6 1.3 ** 7 1.1 ** 6 1.3 ** 
 N NS NS NS NS NS NS NS NS NS 
regulation of protein 
kinase cascade C 23 4.6 **** 18 2.9 ** 19 3.6 ** 
GO:0010627 I 18 4.0 *** 18 2.9 * 13 2.9 * 
 N NS NS NS NS NS NS NS NS NS 
             
regulation of MAP 
kinase activity 
GO:0043405 
C 12 2.4 ** 12 1.9 ** --- --- --- 
I 9 2.0 * 13 2.1 ** 16 3.6 * 
N NS NS NS NS NS NS NS NS NS 
             
regulation of I-kappaB 
kinase/ NFkB cascade 
C 10 2.0 ** --- --- --- 10 1.9 ** 
I 9 2.0 ** --- --- --- --- --- --- 
GO:0043122 N NS NS NS NS NS NS NS NS NS 
             
positive regulation of 
cytokine production 
GO:0001819 
C 12 2.4 **** 10 1.6 ** NS NS NS 
I 12 2.6 **** 11 1.7 ** NS NS NS 
N NS NS NS NS NS NS NS NS NS 
cell adhesion C 31 6.2 * NS NS NS NS NS NS 
GO:0007155 I 29 6.4 * NS NS NS NS NS NS 
 N 20 7.6 * NS NS NS 10 8.9 * 
             
chemotaxis C 12 2.4 ** 12 1.9 * 12 2.2 * 
GO:0006935 I 12 2.6 ** 13 2.1 * NS NS NS 
 N NS NS NS 7 4.3 ** NS NS NS 
             
cell migration C 19 3.8 ** 18 2.9 * 18 3.4 ** 
GO:0016477 I 14 3.1 * NS NS NS 15 3.4 * 
 N NS NS NS NS NS NS NS NS NS 
             
actin cytoskeleton 
organization 
GO:0030036 
C 13 2.6 * 15 2.4 * 15 2.8 * 
I 13 2.9 * 12 1.9 * 14 3.1 ** 
N 10 3.8 ** NS NS NS NS NS NS 
posttranscriptional 
regulation of gene 
expression 
GO:0010608 
C NS NS NS 18 2.9 ** 15 2.8 ** 
I NS NS NS 17 2.7 ** 12 2.7 * 
N NS NS NS NS NS NS NS NS NS 
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Figure 3.1. Gating strategy, microarray validation, and identification of 
differerently expressed genes.  
A. Classical, intermediate, and nonclassical monocytes were isolated from total PBMCs 
from each animal at each infection timepoint. Monocytes were selected based on high 
forward scatter and intermediate side scatter. HLA-DR+ cells were positively selected 
and CD3+ T-cells and CD20+ B-cells were excluded. Non-overlapping populations of 
classical (CD14++CD16-, red gate), intermediate (CD14++CD16+, blue gate), and 
nonclassical (CD14+CD16++, green gate) monocytes were sorted based on expression 
of CD14 and CD16. B. Paired XY values for gene expression values determined by 
microarray and qRTPCR. For qRTPCR analysis, cDNA was made from the same RNA 
used in the microarray analysis. Nine samples had sufficient RNA remaining to validate 
four targets each. GAPDH was used as a housekeeping gene. Gene expression values 
determined by qRTPCR significantly correlated with the gene expression values 
determined by microarray (Spearman r = 0.56, p = 0.0003). C. The number 
comparisons with ≥ 2.0-AFC between monocyte subsets prior to infection, at 26 dpi, and 
at necropsy. The length of the line between monocyte subsets is proportional to the 
number of differently expressed genes. Intermediate monocytes are most similar to 
classical monocytes, but increase in similarity to nonclassical monocytes terminally with 
AIDS.  
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Figure 3.1 
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Figure 3.2. Expression profiles of subset-specific genes, prior to SIV infection 
 Expression variability of subset-specific genes that differentiate classical (“C”, red), 
intermediate (“I”, blue), and nonclassical (“N”, green) monocytes prior to infection. Each 
of 813 genes was assigned to one of five gene expression patterns (gray bar graphs). 
The size of each slice is proportional to the number of genes specific to the indicated 
subset(s). Classical and intermediate monocytes are most similar and nonclassical 
monocytes are more dissimilar based on the numer of differently expressed genes.  
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Figure 3.2  
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Figure 3.3. Identification of transcripts that differentiate the three monocyte 
subsets prior to and with SIV infection.  
Heat maps of the 172 genes that differentiate the three monocyte subsets prior to and 
with SIV infection. Rows are the average normalized intensity for the gene indicated. 
Green indicates lower expression, and red indicates higher expression. Columns are 
the different monocyte subsets for each of the three infection timepoints. Ten genes 
were expressed ≥ 2.0-fold by classical monocytes at all timepoints. Twenty-two genes 
were expressed ≥ 2.0-fold by both intermediate and nonclassical monocytes at all 
timepoints. Twenty-two genes were expressed ≥ 2.0-fold by nonclassical monocytes at 
all timepoints. Two genes (C3AR1, MERTK) were expressed ≥ 2.0-fold by intermediate 
monocytes (data not shown). One hundred and sixteen genes were expressed ≥ 2.0-
fold by classical and intermediate monocytes at all timepoints; for simplicity, only the top 
70 genes are shown.  
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Figure 3.3. 
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Figure 3.4. In silico analysis of gene-associated biological processes reveals the 
functional nature of monocyte subsets.  
Representative GO terms for biological processes associated with genes expressed 
≥2.0-fold by classical monocytes or both classical and intermediate monocytes (left 
panels) and nonclassical or both intermediate and nonclassical monocytes (right 
panels) prior to infection are shown. Gene expression values are the log2 transformed 
fold change in classical, intermediate or nonclassical monocytes normalized to 
expression in intermediate monocytes. Representative genes are shown for each 
cluster. Complete data for functional enrichment categories at each infection timepoint 
are in Table 3.8. Classical monocytes show enrichment for genes associated with 
defense response (38 genes), positive regulation of cell proliferation (27 genes), 
regulation of protein kinase cascade (23 genes), endocytosis (16 genes), and wound 
healing (21 genes). Nonclassical monocytes show enrichment for genes associated with 
defense response (25 genes), negative regulation of cell proliferation (15 genes), 
regulation of T-cell activation (13 genes), and cellular activation (17 genes). 
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Figure 3.4. 
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Figure 3.5. Changes in monocyte gene expression with SIV infection are present 
by 26 dpi and include induction of interferon stimulated and innate immune genes.  
A. The number comparisons with ≥ 2.0-AFC between infection timepoints in each 
monocyte subset. The length of the line between infection timepoints is proportional to 
the number of differently expressed genes. The majority of changes in gene expression 
occur between preinfection and 26 dpi in all subsets. More genes are differently 
expressed by nonclassical monocytes with SIV infection compared to classical and 
intermediate monocytes. B-D. Heat maps of immune-associated genes that are 
differently expressed with SIV infection.  Rows are the average normalized intensity for 
the gene indicated. Green indicates lower expression, and red indicates higher 
expression. Columns are the different infection timepoints (P: preinfection, 26: 26 dpi, 
Nx: Necropsy) for each of the three monocyte subsets (C: classical, I: intermediate, N: 
nonclassical). Genes were selected based on GO annotation for innate immune 
response (B), response to interferon (C), and adaptive immune response (D). B. 62 
genes associated with innate immune response are differently expressed with SIV 
infection. Hierarchical clustering reveals 4 distinct patterns of gene expression (I - IV). 
The majority of innate immune genes are induced in all three subsets at 26 dpi and 
necropsy. C. 42 interferon stimulated genes are differently expressed with SIV infection. 
The majority of ISG are upregulated in all three monocyte subsets with SIV infection. D. 
24 genes associated with adaptive immune response are differently expressed with SIV 
infection. The majority of these are upregulated in all three monocyte subsets or both 
intermediate and nonclassical monocytes. 
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Figure 3.5 
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Chapter 4. SIVE lesions are comprised of CD163+ macrophages present in the 
CNS during early SIV infection and SIV+ macrophages recruited terminally with 
AIDS  
 
Chapter Overview 
 
CNS inflammation during early SIV infection is characterized by recruitment of 
MAC387+ macrophages throughout the CNS. Overall, more BrdU macrophages were 
present in the meninges and choroid plexus compared to the perivascular space and 
lesions. BrdU+ cells in the CNS were primarily MAC387+ macrophages; but 
CD163+BrdU+ macrophages were present in the meninges and choroid plexus 
terminally with AIDS. Terminally with AIDS, macrophages accumulated in the 
perivascular space and SIVE lesions, but not in the meninges and choroid plexus. The 
ratio of CD163+ macrophages to MAC387+ macrophages in the CNS was greater in 
animals with SIVE than animals without SIVE. The majority (81.6±1.8%) of 
macrophages in SIVE lesions were present in the CNS early, by 20 days post infection 
(dpi), before lesions were present. The percentage of productively infected 
macrophages was 2.6-fold greater in macrophages that entered the CNS late, after 49 
dpi, compared to early macrophages (p<.05). The rate of CD163+ macrophage 
recruitment to the CNS was inversely correlated with time to death (p<.03) and was 
greater with SIVE. In animals with SIVE, soluble CD163 in plasma correlated with 
CD163+ macrophage recruitment to the CNS (p=.02). We conclude that the majority of 
perivascular macrophages that comprise SIVE lesions and MNGCs were present in the 
CNS early and SIV-infected macrophages traffic to the CNS terminally with AIDS. 
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Early CNS inflammation with SIV infection is characterized by recruitment of 
MAC387+ macrophages to the perivascular space, meninges, and choroid plexus. 
We and others have previously described two populations of macrophages (Mϕ) 
recruited to the CNS88,181. One is phenotypically defined as CD163+CD68+MAC387- 
perivascular macrophages, and the second is MAC387+CD163-CD68- “inflammatory” 
macrophages. Using single color IHC, we counted the number of CD163+ and 
MAC387+ macrophages in the CNS of uninfected animals (Uninfected, n = 3), SIV-
infected animals sacrificed at 22 dpi (SIV 22dpi, n = 3), and SIV infected animals that 
progressed to AIDS with SIVE (SIVE, n = 5) and without SIVE (SIVnoE, n = 4) (Figure 
4.1). MAC387+ macrophages were absent from CNS tissues of uninfected animals but 
were numerous at 22 dpi (perivascular space: 2 ± 1 Mϕ/mm2 uninfected, 13 ± 3 Mϕ/mm2  
SIV 22dpi, p = .0007; meninges: 14 ± 6 Mϕ /mm2 uninfected, 770 ± 100 Mϕ /mm2 SIV 
22dpi, p = .002; choroid plexus: 17 ± 3 Mϕ /mm2 uninfected, 180 ± 100 Mϕ /mm2 SIV 
22dpi) (Figure 4.1A-D, open circles). The number of CD163+ macrophages was not 
significantly increased in infected animals sacrificed at 22 dpi compared to uninfected 
animals (Figure 4.1A-D). No SIVE lesions were present in the CNS of animals sacrificed 
at 22 dpi. These data indicate that with SIV infection early CNS inflammation is 
characterized by recruitment of MAC387+ macrophages and the absence of SIVE 
lesions.  
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There is a greater ratio of CD163+ to MAC387+ macrophages in the perivascular 
space, meninges and choroid plexus of animals sacrificed with AIDS and SIVE.  
CNS pathology with SIV infection may be influenced not only by the absolute number of 
macrophages in the CNS, but also the relative proportion of CD163+ perivascular 
macrophages to MAC387+ inflammatory macrophages181. Because of this we 
determined the ratio of CD163+ to MAC387+ macrophages in the perivascular space, 
meninges, and choroid plexus of SIV infected animals (ratio = absolute cell count 
CD163+ Mϕ / absolute count MAC387+ Mϕ per region). Because SIVE lesions were not 
present in SIVnoE animals or animals sacrificed at 22 dpi, inter-group comparisons 
were not made with regard to SIVE lesions. A higher ratio of CD163+ to MAC387+ 
macrophages (representing increased numbers of CD163+ macrophages and 
decreased numbers of MAC387+ macrophages) was found in SIVE animals compared 
to SIVnoE animals or SIV-infected animals sacrificed at 22 dpi (Figure 1A, C, D). 
Extending our prior observation that increased severity of SIVE lesions was reflected in 
a greater ratio of CD163+ to MAC387+ macrophages in SIVE lesions,181 we now find 
that the ratio of CD163+ to MAC387+ macrophages was also higher in the perivascular 
space, meninges, and choroid plexus. This suggests that accumulation of CD163+ 
macrophages and decreased numbers of MAC387+ macrophages are associated with 
the development of AIDS and SIVE. Overall, both MAC387+ and CD163+ macrophages 
accumulated primarily in the perivascular space and SIVE lesions and not in the 
meninges or choroid plexus. 
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The phenotype of BrdU+ macrophages recruited to the CNS varies by CNS 
compartment.   
To investigate differences in macrophage traffic from the bone marrow to the CNS in 
acute infection versus AIDS, monocyte progenitors in the bone marrow were labeled by 
BrdU administered at 6 dpi and 20 dpi (“Early”, n = 7) or 49 dpi and 48h prior to 
necropsy (“Late”, n = 5) (Table 4.1).  Analysis of CNS tissue was stratified by timing of 
BrdU administration and CNS pathology, and BrdU+ cells were counted in the 
perivascular space, SIVE lesions (when present), meninges, and choroid plexus (Table 
4.2, Figure 4.2). MAC387+BrdU+ and CD163+BrdU+ macrophages together accounted 
for essentially all of the BrdU+ cells in the CNS (Figure 4.2). We did not find 
CD3+BrdU+ T-lymphocytes as previously reported (data not shown)42.  
 
Low numbers of BrdU+ macrophages were found in the perivascular space (range: 0- 6 
BrdU+ macrophages/mm2) where both MAC387+BrdU+ and CD163+BrdU+ 
macrophages were present (Table 4.2, Figure 4.2A, B). In SIVE lesions, the majority of 
BrdU+ macrophages were MAC387+BrdU+ with rare CD163+BrdU+ macrophages as 
previously reported42,181 (Table 4.2, Figure 4.2C, D). In the meninges, the majority of 
BrdU+ macrophages were MAC387+BrdU+ in animals sacrificed at 22 dpi, but equal 
numbers of MAC387+BrdU+ and CD163+BrdU+ macrophages were present in the 
meninges of animals sacrificed with AIDS, with and without SIVE (Table 4.2, Figure 
4.2E, F). In the choroid plexus, CD163+BrdU+ macrophages outnumbered 
MAC387+BrdU+ macrophages regardless of timing of BrdU administration or CNS 
pathology (Table 4.2, Figure 4.2G, H). The observation that CD163+ macrophages 
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present in the meninges at 22 dpi and in SIVE lesions terminally were not BrdU+ 
suggests these CD163+ macrophages were already present in the CNS prior to BrdU 
administration or, alternatively, they may not be recruited from the bone marrow. The 
differences we find in the relative proportion of MAC387+BrdU+ and CD163+BrdU+ 
macrophages in SIVE lesions, meninges, and choroid plexus may reflect different traffic 
patterns or mechanisms of recruitment between these CNS compartments or between 
macrophage subsets. 
 
Recruitment of BrdU+ macrophages to the CNS is greatest terminally with AIDS 
and SIVE 
A greater number of BrdU+ macrophages were present in the CNS of SIVE animals 
compared to SIVnoE animals, and in animals given BrdU late compared to animals 
given BrdU early (Table 4.2, Figure 4.2). Recruitment of MAC387+BrdU+ macrophages 
to the CNS was greatest terminally in animals with AIDS and SIVE in the perivascular 
space (p < 0.05), SIVE lesions (p < 0.01), and meninges (p < 0.05), but not choroid 
plexus (Table 4.2, Figure 4.2). The number of CD163+BrdU+ macrophages recruited to 
the CNS was greater terminally in animals with AIDS and SIVE in the meninges (p < 
0.05) and choroid plexus, but not the perivascular space or SIVE lesions (Table 4.2, 
Figure 4.2). The presence of CD163+BrdU+ macrophages in the meninges terminally 
suggests that the lack of CD163+BrdU+ macrophages in SIVE lesions is likely not due 
to differences in labeling affinity between macrophage subsets. Overall, these data 
indicate that recruitment of CNS macrophages from the bone marrow is greatest during 
end stage disease in animals with SIVE, and recruitment of MAC387+BrdU+ 
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macrophages is more widespread within the CNS compared to CD163+BrdU+ 
macrophages.   
 
Dextran dyes preferentially label CD163+ macrophages in vivo and CD163+ 
monocytes in vitro.     
Because BrdU only labels monocytes and macrophages that traffic to the CNS, we used 
dextran dyes injected into the CSF to assess macrophage turnover within the CNS of 
infected animals. Macrophages within the perivascular space, meninges, and choroid 
plexus were labeled by serial injection of fluorescently-conjugated dextran dyes into the 
cerebromedullary cistern of 12 rhesus macaques (Table 4.1, Figure 4.3). Across all 
CNS regions, post-mortem examination showed that dextran-labeled cells were 
CD163+ and MAC387+ macrophages. CD163+ macrophages accounted for 94.2 ± 
1.1% of all dextran-labeled cells, and 98.7 ± 0.4% of CD163+ macrophages were 
dextran-labeled. MAC387+ macrophages accounted for 7.0 ± 1.0% of all dextran-
labeled cells and 16.5% ± 2.4% of MAC387+ macrophages were dextran labeled 
(Figure 4.4). No other CNS cell types, including endothelial cells, astrocytes, and 
parenchymal microglia were dextran-labeled.  
 
Because of the preferential uptake of dextran dyes by CD163+ macrophages compared 
to MAC387+ macrophages, both of which are monocyte derived, we assessed dextran 
uptake in ex vivo monocytes from uninfected animals (n= 6) (Figure 4.5). Following a 15 
minute incubation of whole blood with dextran dyes in vitro, all monocyte subsets were 
dextran-labeled. Dextran uptake was greater in CD14++CD16+ intermediate monocytes 
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compared to CD14++CD16- classical monocytes (p = .03) or CD14+CD16++ 
nonclassical monocytes (p = .002) (Figure 4.5). These data could indicate that 
differences in labeling affinity between monocyte and macrophage subsets reflect 
differences in lineage, maturation, or activation  
 
The percentage of productively infected macrophages in animals with AIDS and 
SIVE is 2.6-fold greater for macrophages that enter the CNS late compared to 
macrophages present in the CNS at 20 dpi.  
SIVE lesions were evaluated to determine at which time macrophages that comprise 
SIVE lesions entered the CNS and to determine which cells are productively infected 
(n= 4 animals, 21 SIVE lesions total) (Figure 4.6). Using the dextran labeling scheme 
(Table 4.1, Figure 4.3A), macrophages labeled with Dextran:FITC (administered at 20 
dpi) were present in the CNS prior to or on day 20 pi and are termed “early 
macrophages”, and macrophages that were not Dextran:FITC labeled were recruited to 
the CNS after 20 dpi and are termed “late macrophages”. Surprisingly, we found 70.7 ± 
3% of cells in SIVE lesions were Dextran:FITC labeled, early macrophages and 29.3 ± 
3% were late macrophages (Figure 4.6A, C). This was not expected because we do not 
observe SIVE lesions in animals sacrificed at 22 dpi. Interestingly, CD163+ 
multinucleated giant cells (MNGC’s) are productively infected and are Dextran:FITC 
labeled indicating they are likely derived from macrophages that were present in the 
CNS early prior to lesion formation (Figure 4.6A, B arrow). These data suggest that 
CD163+ macrophages present in the CNS early contribute to SIVE lesion formation 
terminally with AIDS and comprise the majority of macrophages in SIVE lesions.  
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In SIVE lesions, the majority of productively infected (SIVp28+) cells were dextran-
labeled (CD163+) macrophages, which is consistent with previous observations that 
CD163+ macrophages are a primary target cell for productive infection in the CNS 
(Figure 4.6A, B).88,181 In these cells, CD163+ expression was confirmed in adjacent 
serial sections (Figure 4.6B). Using 4-color immunofluorescence, we found early and 
late macrophages were productively infected (Figure 4.6A, C). Within each population, 
11.0 ± 1% of early macrophages were SIVp28+ and 28.7 ± 8% of late macrophages 
were SIVp28+ (p < 0.05, early vs. late) (Figure 4.6C). Scattered SIVp28+ cells that were 
not dextran labeled were also present and are likely representative of parenchymal 
microglia or infected macrophages that were not present in the perivascular space at 
the time of dextran labeling. These data indicate that both early and late macrophages 
are productively infected and that the frequency of productive infection is 2.6-fold 
greater in macrophages that entered the CNS late compared to early macrophages.   
 
Early CD163+ macrophages comprise the majority of CNS macrophages 
terminally with AIDS 
Using a combination of dextran dye injections, we characterized the distribution of 
dextran-labeled CNS macrophages to determine the timing of CD163+ macrophage 
recruitment to CNS compartments in animals sacrificed with AIDS (Table 4.3). For this, 
we determined CD163+ macrophage recruitment from 20 dpi to necropsy (% late 
macrophages) in all animals with AIDS (n = 9). A subset of animals (n = 4) that received 
all three dyes, the recruitment period was divided into 20 dpi to 49 dpi and 49 dpi to 
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necropsy, which allowed us to evaluate macrophage recruitment after viremia and 
terminally with AIDS. For all animals with AIDS, the percentage of late macrophages 
was greater in the choroid plexus (73.0 ± 6.2%, range 61.9 - 92.4%) than the meninges 
(27.3 ± 4.0%, range 13.0 - 55.9%, p = .001) or perivascular space (29.0 ± 3.9%, range 
10.7 - 47.2%, p = .001) (Table 4.3). Interestingly, in SIVE animals the percentage of 
macrophages that arrive late was lower in SIVE lesions (18.4 ± 1.8%, range 14.1 – 
21.7%) than in the perivascular space (30.1 ± 4.3%, range 13.8 – 37.9%) (Table 4.3). 
Surprisingly, the percentage of late macrophages was not significantly different between 
SIVnoE and SIVE animals in the perivascular space (27.6 ± 7.6% SIVnoE, 30.1 ± 4.3% 
SIVE), meninges (25.8 ± 2.5% SIVnoE, 28.5 ± 7.3% SIVE) and choroid plexus (65.5 ± 
1.7% SIVnoE, 77.9 ± 8.8% SIVE) (Table 4.3). We only found difference between 
SIVnoE and SIVE animals in the number of late macrophages in SIVE lesions, 
underscoring the importance of these cells in pathogenesis.  
 
The rate of CD163+ macrophage recruitment to the CNS is increased with SIV 
infection and correlates with rapid death.  
The time to death of all animals in this study sacrificed with AIDS ranged from 55 to 141 
dpi and was shorter in animals with SIVE (91 ± 14 days) compared to animals without 
SIVE (111 ± 19 days). To account for differences in the time to death from 20 dpi, we 
compared rates of CD163+ macrophage recruitment by normalizing the percentage of 
dextran-labeled cells that entered the CNS in a given time period by the number of days 
in that period. For all animals sacrificed with AIDS (n = 9), the CD163+ macrophage 
recruitment rate was determined for the time period from 20 dpi to necropsy. We found 
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that a shorter time to death correlated with an increased rate of CD163+ macrophage 
recruitment in the perivascular space (r = -0.8, p = 0.03), SIVE lesions (r = -1.0, p = 
0.08), meninges (r = -0.8, p = 0.02), and choroid plexus (r = -0.9, p = 0.03) for all 
animals (Figure 4.7).  
 
For all animals with AIDS, SIV infection increased the rate of CD163+ macrophage 
recruitment from 20 dpi to necropsy in the perivascular space (range: 4.9 – 36.3 fold, 
mean: 21.0 ± 3, p < .0001), the meninges (range: 2.2 – 8.7 fold, mean: 4.6 ± 0.8, p 
< .001), and the choroid plexus (range: 8.4 – 27.9 fold, mean: 14.3 ± 3.5, p < .05) 
compared to uninfected controls (Figure 4.8A-C)179. The CD163+ macrophage 
recruitment rate in animals with SIVE was 16% greater in the perivascular space and 
26% greater in the meninges compared to animals with AIDS and SIVnoE, although the 
differences did not reach statistical significance (Figure 4.8A, B). These data indicate 
that, overall, SIV infection greatly increases the rate of CD163+ macrophage 
recruitment to the CNS and that increased macrophage recruitment to the CNS is 
associated with rapid death.  
 
For the subset of animals that received all three dyes (n = 4), the rate of CD163+ 
macrophage recruitment from 20 dpi to 49 dpi and from 49 dpi to necropsy were 
compared (Figure 4.8D-F). We found that in SIVE lesions, 21.4 ± .01% of CD163+ 
macrophages entered the CNS after 20 dpi (Table 4.3). For these cells, the rate of 
CD163+ macrophage recruitment in SIVE lesions was greater from 49dpi to necropsy 
than from 20 dpi to 49dpi (range: 2.4 – 2.8 fold, mean 2.6 ± 0.2, p = .0003) (Figure 4.8D). 
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In contrast, the rate of CD163+ macrophage recruitment in the perivascular space was 
greater between 20dpi to 49dpi than 49dpi to necropsy in all animals  (range: 2.32 – 7.1 
fold, mean: 4.7 ± 1.2, p < .001) (Figure 4.8E). The recruitment rate in the perivascular 
space was 68% greater in animals with SIVE than animals with SIVnoE during the post 
acute period 20 dpi to 49dpi (p = .002) but was not significantly different with regard to 
SIVE terminally with AIDS (Figure 4.8E). In the meninges the CD163+ macrophage 
recruitment rate was 91% greater in animals with SIVE compared to animals with 
SIVnoE terminally with AIDS (p < 0.05) (Figure 4.8F). These data may suggest that the 
rate of CD163+ macrophage recruitment in the perivascular space is greatest post 
acute infection and CD163+ macrophage recruitment in the meninges and SIVE lesions 
is greatest terminally with AIDS.  
 
The expansion of activated CD14++CD16+ monocytes is associated with greater 
CD163+ macrophage recruitment and SIVE.  
It has previously been demonstrated that increased monocyte activation is associated 
with the development of HAND and SIVE lesions39,42,68,252. Soluble CD163 (sCD163) is 
shed by activated CD14++CD16+ monocytes, and plasma levels of sCD163 serve as a 
marker of monocyte activation248,249. Higher sCD163 in plasma correlated with a greater 
percentage of late CD163+ macrophages recruited in the perivascular space and SIVE 
lesions in animals with AIDS and SIVE (perivascular space: r = 1.0, p = .02; SIVE 
lesions: r = 1.0, p = .08) (Figure 4.9A, B). This did not occur in animals with AIDS and 
SIVnoE. There was no correlation between plasma sCD163 and the percentage of late 
macrophages in the meninges and choroid plexus (Figure 4.9C, D). This suggests that 
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monocyte activation in the periphery is associated with accumulation of CD163+ 
macrophages in the perivascular space and SIVE lesions in animals with SIVE.  
 
Because CD14++CD16+ monocytes are putative precursors of CD163+ macrophages 
in the CNS, we investigated the relationship between the rate of CD163+ macrophage 
recruitment, the number of CD14++CD16+ blood monocytes, and the development of 
SIVE (Figure 4.10). We found the average CD14++CD16+ monocyte count was greater 
in animals with SIVE compared to animals with SIVnoE (SIVnoE: 36 ± 4 cells/µL, SIVE: 
104 ± 16 cells/µL, p = 0.02) (Figure 4.10). In animals with SIVE, an increased rate of 
CD163+ macrophage recruitment in the perivascular space and meninges was 
associated with a reduced number of CD14+CD16+ monocytes in the blood, though this 
trend was not statistically significant (perivascular space: r = -0.9; meninges: r = -0.8) 
(Figure 4.10). Here we demonstrate that SIVE is associated with the expansion of 
CD14++CD16+ monocytes, increased monocyte activation, and accumulation of CNS 
macrophages. These data may suggest that monocyte dysregulation leads to increased 
numbers of activated monocytes and that this population is reduced in the blood as 
monocytes traffic to the CNS, which results in macrophages accumulation in the CNS 
with SIVE.   
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Conclusions 
These studies characterize macrophage accumulation and productive SIV infection in 
the CNS with the development of SIVE. Interestingly, we found that the majority of 
CD163+ macrophages in SIVE lesions were already present in the CNS by 20 dpi. Late 
CD163+ macrophages recruited after 20 dpi and MAC387+ macrophages recruited 
terminally with AIDS were also present in SIVE lesions. Early and late CD163+ 
macrophages were productively infected and the percentage of productively infected 
macrophages was 2.6-fold greater in late CD163+ macrophages compared to early 
macrophages. This suggests that SIV may be reintroduced into the CNS by traffic of 
infected monocytes/macrophages during end stage disease. Together these data 
indicate that SIVE lesions are formed by redistribution of resident perivascular 
macrophages, traffic of productively infected CD163+ macrophages from the periphery, 
and recruitment inflammatory MAC387+ macrophages from the bone marrow terminally 
with AIDS.  
 
We found differences in CD163+ and MAC387+ macrophage accumulation between 
CNS compartments. Early infection was characterized by the recruitment of MAC387+ 
macrophages throughout the CNS during primary/acute infection. Terminally with AIDS, 
both CD163+ and MAC387+ macrophages accumulated in perivascular cuffs and SIVE 
lesions. We found that the ratio of CD163+ to MAC387+ macrophages in the 
perivascular space, meninges, and choroid plexus was greater in animals with AIDS 
and SIVE than animals with AIDS and SIVnoE or SIV without AIDS. It is possible that 
MAC387+ macrophages represent an M1 polarized subpopulation that promotes an 
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antimicrobial microenvironment that limits viral replication in the CNS and that a switch 
to an M2 polarized microenvironment is associated with the development of SIVE.  
 
Recruitment of bone marrow derived (BrdU+) cells to the CNS, the majority of which 
were MAC387+, was greatest in the meninges and choroid plexus compared to the 
perivascular space and SIVE lesions. Additionally, the meninges and choroid plexus did 
not show significant macrophage accumulation with AIDS and SIVE suggesting a higher 
rate of turnover in these compartments. Overall recruitment of monocytes/macrophages 
from the bone marrow was greatest terminally with AIDS and SIVE. Although 
CD163+BrdU+ macrophages accounted for more than half of all BrdU+ cells in the 
meninges and choroid plexus terminally with AIDS, few CD163+BrdU+ macrophages 
were present in the perivascular space or SIVE lesions. This may indicate that CD163+ 
macrophages that accumulate in SIVE lesions are derived from within the CNS or are 
recruited from outside the bone marrow. These data likely indicate that different 
mechanisms of macrophage recruitment exist between CNS compartments and 
macrophage subsets. 
 
In animals with SIVE, we observed increased monocyte activation and expansion of the 
CD14+CD16+ subset that correlated with increased accumulation of CD163+ 
macrophages in the perivascular space and in SIVE lesions. This may indicate that 
increased numbers activated monocytes in the periphery leads to greater accumulation 
of macrophages in the CNS. In all animals, SIV infection increased the rate of 
macrophage recruitment to the CNS and rapid recruitment was associated with shorter 
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time to death. Together, these data suggest that with SIV infection increased monocyte 
activation and expansion leads to more rapid traffic of monocytes/macrophages to the 
CNS, which contributes to the development of SIVE.   
 
These studies indicate that the development of SIVE is a dynamic process affected by 
systemic immune activation, macrophage heterogeneity, and productive infection of the 
CNS. SIV infection leads to CNS inflammation during primary/acute infection and 
increased recruitment of monocytes/macrophages throughout disease. Increased 
numbers of activated monocytes and increased traffic of monocytes/macrophages from 
the bone marrow in animals with SIVE suggests that CNS disease is associated with 
monocyte dysregulation and the inability to limit systemic immune activation. An 
increased frequency of productive infection in CD613+ macrophages recruited to the 
CNS terminally with AIDS may indicate that traffic of activated/infected 
monocytes/macrophages to the CNS during end stage disease contributes to SIVE. 
Importantly we have demonstrated that resident perivascular macrophages play a major 
role in SIVE lesion formation in end stage disease. 
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Table 4.1: Experimental design for dextran labeling studies.  
Treatmenta 
SIV, 22dpi AIDS AIDS AIDS AIDS 
Early BrdU Early BrdU Early BrdU Late BrdU Late BrdU 
1 dye 2 dyes 3 dyes 2 dyes 3 dyes 
n = 3 n = 2 n = 2 n = 3 n = 2 
BrdU 6 & 20 dpi 6 & 20 dpi 6 & 20 dpi 49 dpi & Nec. 49 dpi & Nec. 
Dextran:FITC 20 dpi 20 dpi 20 dpi 20 dpi 20 dpi 
Dextran:AF647 – – –  Nec.b  49 dpi Nec.b 49 dpi 
Dextran:Biotin – – – – – – Nec.b – – – Nec.b 
Sacrificed 22dpi AIDS AIDS AIDS AIDS 
 
a. All animals were infected with SIVmac251 (1ng SIVp27, iv) on day 0. Anti-CD8 
antibody was administered at 6 dpi, 8 dpi, and 12 dpi.  
b. “Nec.” indicates administration of BrdU or dextran 48 hours prior to necropsy.  
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Table 4.2: Macrophage traffic from the bone marrow to the CNS is greatest 
terminally with AIDS.  
Groupa Subset 
Perivascular 
Spaceb 
SIVE 
lesionsc Meningesb 
Choroid 
Plexusb 
SIV, 22dpi 
BrdU Early 
n = 3 
CD163+ 2 ± 0.4 – – – 45 ± 8 110 ± 30d 
MAC387+ 2 ± 0.8 – – – 260 ± 40 35 ± 30d 
SIVE, AIDS 
BrdU Early 
n = 3 
CD163+ 1 ± 0.2 2 ± 0.4 120 ± 30 160 
MAC387+ 2 ± 0.3 6 ± 2 120 ± 40 45 
SIV, AIDS 
BrdU Late 
n = 3 
CD163+ 2 ± 0.2 – – – 150 ± 30 290 
MAC387+ 1 ± 0.3 – – – 250 ± 100 100 ± 90d 
SIVE, AIDS 
BrdU Late 
n = 2 
CD163+ 1 ± 0.3 1 ± 0.2 310 ± 40 270 ± 50d 
MAC387+ 4 ± 0.5 21 ± 4 340 ± 90 70 ± 20d 
 
a. Early: BrdU administered at 6 dpi and 20 dpi. Late: BrdU administered at 49 dpi and 
48 h prior to necropsy. 
b. Counts are the mean ± SEM of the number of CD163+BrdU+ or MAC387+BrdU+ 
macrophages per mm2.  
c. Counts are the mean ± SEM of the number of CD163+BrdU+ or MAC387+BrdU+ 
macrophages per SIVE lesion. 
d. Choroid plexus tissue was available from 2 animals in this group 
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Table 4.3: Distribution of dextran-labeled CD163+ macrophages in CNS tissues. 
CNS Region 
CNS 
Pathology 
Present  
20 dpia 
Entered  
20-Nec.a 
Entered  
20-49 dpib 
Entered  
49 dpi-Nec.b 
Perivascular Space SIVE 69.9 ± 4.3  % 30.1 ± 4.3  % 27.6 ± 2.8  % 7.3 ± 0.5   % 
SIVnoE 72.4 ± 7.6  % 27.6 ± 7.6  % 16.1           % 12.7          % 
SIVE lesion SIVE 81.6 ± 1.8  % 18.4 ± 1.8  % 4.3 ± 0.1    % 17.1 ± 0.1 % 
SIVnoE – – –  – – –  – – –  – – –  
Meninges SIVE 71.5 ± 7.3  % 28.5 ± 7.3  % 14.2 ± 3.6  % 21.3 ± 6.8 % 
SIVnoE 74.2 ± 2.5  % 25.8 ± 2.5  % 12.4 20.3          % 
Choroid Plexus SIVE 22.1 ± 8.8
c % 77.9 ± 8.8c % NDd NDd 
SIVnoE 34.5 ± 1.7c % 65.5 ± 1.7c % NDd NDd 
 
Dextran labeled macrophages in the CNS were counted by sampling 3000-4000 cells 
from frontal, temporal parietal, and occipital cortices, 1000 cells from meninges, and 2 
sections of choroid plexus per animal. When present, 10 or more SIVE lesions were 
counted per animal. Values are the mean ± SEM percentage of all dextran labeled 
macrophages for n animals.  
a. SIVE (n = 5), SIV (n = 4) 
b. For animals that received the three dye regimen, the period 20 dpi-Necropsy can be 
subdivided into 20 dpi- 49 dpi and 49 dpi- Necropsy. SIVE (n = 3), SIV (n = 1) 
c. p < 0.02, choroid plexus vs. perivascular space, meninges, or SIVE lesions.  
d. ND: Not done.  
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Figure 4.1. CD163+ and MAC387+ macrophages accumulate in the perivascular 
space and SIVE lesions in SIV infected animals. A-D. Single-label IHC for CD163 
(closed squares) or MAC387 (open circles) in uninfected animals (n = 3), SIV-infected 
animals sacrificed at 22 dpi (SIV 22 dpi, n = 3), and SIV-infected animals that 
progressed to AIDS with encephalitis (SIVE, n = 5) or without (SIVnoE, n = 4). Each 
data point represents one tissue section or one SIVE lesion. A-D. MAC387+ 
macrophages are not present in the normal, uninfected CNS but are recruited to the 
CNS with SIV infection. CD163+ macrophages outnumber MAC387+ macrophages in 
uninfected and SIV-infected animals. A & B. In animals with AIDS, CD163+ and 
MAC387+ macrophages accumulate primarily in the perivascular space (A) and in SIVE 
lesions (B). B. SIVE lesions are only observed terminally in animals that progressed to 
AIDS. C & D. In the meninges (C) and choroid plexus (D), MAC387+ macrophages are 
more numerous at 22dpi than terminally with AIDS. A-D. Animals with AIDS and SIVE 
have higher ratios of CD163+ to MAC387+ macrophages than animals with AIDS and 
no SIVE or animals sacrificed at 22dpi. The numbers above each graph are the average 
ratio of CD163+ to MAC387+ macrophages for SIV infected animals. NA: Not 
Applicable. * P < .05, ** P < .01, *** P < .001, **** P < .0001. 
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Figure 4.1  
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Figure 4.2. Recruitment of MAC387+ and CD163+ macrophages from the bone 
marrow differs in timing and magnitude by CNS region. Recruitment of CNS 
macrophages from the bone marrow was determined by BrdU labeling of monocyte 
progenitors during early (6 dpi & 20 dpi) and late (49 dpi & 48h pre necropsy) SIV 
infection. Double-label IHC for BrdU (blue) and MAC387 or CD163 (brown) was used to 
determine the number of BrdU+ macrophages in SIV-infected animals stratified by 
timing of BrdU administration and CNS pathology: Early BrdU, 22 dpi (n = 3); Early 
BrdU, SIVE (n = 3); Late BrdU, SIVnoE (n = 3); Late BrdU, SIVE (n = 2). Each data 
point represents one tissue section or one SIVE lesion. A. BrdU+ macrophages in the 
perivascular space are MAC387+BrdU+ and CD163+BrdU+ in CNS tissue from all 
animals. Arrows indicate MAC387+BrdU+ or CD163+BrdU+ macrophages. Scale bars 
are 50µm. B. Few BrdU+ macrophages are present in the perivascular space, overall. 
More MAC387+BrdU+ macrophages are present in animals sacrificed with AIDS and 
SIVE that were given BrdU late. C. BrdU+ macrophages in SIVE lesions are 
MAC387+BrdU+ with rare CD163+BrdU+ macrophages. D. More MAC387+BrdU+ 
macrophages are present in SIVE lesions in animals sacrificed with AIDS and SIVE that 
were given BrdU late. E. BrdU+ macrophages in the meninges are MAC387+BrdU+ and 
CD163+BrdU+. F. In animals sacrificed at 22dpi, the majority of BrdU+ macrophages in 
the meninges are MAC387+BrdU+ with few CD163+BrdU+ macrophages present. In 
animals sacrificed with AIDS, BrdU+ meningeal macrophages are MAC387+BrdU+ and 
CD163+BrdU+. More MAC387+BrdU+ and CD163+BrdU+ macrophages are present in 
animals given BrdU late compared to animals given BrdU early and animals with SIVE 
compared to animals with SIVnoE.  G. BrdU+ macrophages in the choroid plexus are 
CD163+BrdU+ with scattered MAC387+BrdU+ macrophages present. H. CD163+BrdU+ 
are more numerous than MAC387+BrdU+ macrophages regardless of timing of BrdU 
administration or CNS pathology. More CD163+BrdU+ macrophages are present in 
animals that were given BrdU late compared to animals that were given BrdU early. NA: 
Not applicable. * P < .05, ** P < .01, *** P < .001, **** P < .0001. 
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Figure 4.2 
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Figure 4.3. Experimental design for dextran labeling of CNS macrophages.  
A. Injection of fluorescent-conjugated dextran dyes into the cisterna magna labels 
macrophages in the perivascular space, meninges, and choroid plexus at the time of 
administration. Serial injection of dextran conjugated to different fluorophores allows for 
determination of time of CNS entry: fluorescein - 20 dpi, Alexa Fluor 647- 49 dpi, biotin - 
48h pre-necropsy. Triple-labeled macrophages (fluorescein+AlexaFluor647+biotin+) 
were present at 20 dpi, double-labeled macrophages (AlexaFluor647+biotin+) entered 
the CNS 20 dpi- 49 dpi, and single-labeled macrophages (biotin+) entered the CNS 
after 49 dpi. B. Three-color immunofluorescence of a blood vessel and associated 
perivascular macrophages in the cerebral cortex of an animal sacrificed with AIDS and 
SIVE. Triple- (long arrow), double- (short arrow), and single- (arrowhead) labeled 
macrophages are present. Note that the majority of macrophages were present in the 
CNS at 20 dpi. Insets are single channel images. Scale bar is 50µm.  
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Figure 4.3 
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Figure 4.4. Dextran dyes robustly label CD163+ and not MAC387+ CNS 
macrophages. Immunofluorescent staining for CD163 (A) or MAC387 (B) in cortical 
meninges from an animal that was given two dextran dyes: fluorescein - 20 dpi, Alexa 
Fluor 647 - 48h pre-necropsy. Images are representative of all CNS regions examined 
from 12 animals. Insets are enlargements of the area indicated by a white rectangle. 
Scale bar is 50µm. A. The majority of dextran-labeled cells are CD163+ macrophages. 
Almost all CD163+ macrophages are dextran-labeled. B. Some dextran-labeled cells 
are MAC387+ macrophages. The majority of MAC387+ macrophages are not dextran-
labeled.    
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Figure 4.4 
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Figure 4.5. Dextran uptake varies between monocyte subsets ex vivo.  
Dextran uptake in normal monocytes was determined by FACS after in vitro labeling of 
whole blood with fluorescein-conjugated dextran (Dextran:FITC). A. A representative 
histogram (n =6 animals) of Dextran:FITC uptake by classical (CD14++CD16-), 
intermediate (CD14++CD16+), and nonclassical (CD14+CD16++) monocytes. B. 
Dextran:FITC is taken up by all monocyte subsets. Dextran uptake is greatest in 
CD14++CD16+ intermediate monocytes, a putative CD163+ macrophage precursor  
*P < .05, ** P < .01. 
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Figure 4.5  
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Figure 4.6. Macrophages that enter the CNS late in animals with AIDS  
and SIVE are the primary cell type that is productively infected.  
A & B. Immunofluorescent staining for SIVp28 (A, red) or CD163 (B, red) in serial 
sections (10 µm) of an SIVE lesion from an animal that received Dextran:FITC (green, 
20 dpi), Dextran:AF647 (cyan, 138 dpi), and was sacrificed at 140 dpi with AIDS and 
SIVE. DAPI was used to stain nuclei (gray). The images presented here are 
representative of more than 20 lesions from four SIVE animals sampled from multiple 
cortical regions. The majority of productively infected cells (SIVp28+) were dextran-
labeled CD163+ macrophages. SIVp28+, productively infected macrophages that are 
not dextran labeled are present. These cells may be parenchymal microglia or 
macrophages that were not present in the perivascular space at the time of dextran 
administration. A SIVp28+CD163+ multinucleated giant cell (MNGC, white arrows) is 
Dextran:FITC+ indicating that the macrophages that compose the MNGC were present 
in the CNS by 20 dpi. Boxes inset on the left are single channel control images. The 
scale bar is 25µm. C. Four color IF was used as above to determine the frequency of 
productive infection in “Early” (Dextran:FITC+, present at 20 dpi) and “Late” 
(Dextran:FITC-, entered after 20 dpi) macrophages in SIVE lesions for each SIVE 
animal. The majority of macrophages in SIVE lesions were uninfected macrophages 
present in the CNS prior to 20 dpi. SIVp28+ early macrophages and SIVp28+ late 
macrophages (black bars) were present in approximately equal numbers. In SIVE 
lesions 11.0 ± 1% of early macrophages and 28.7 ± 8% of late macrophages were 
SIVp28+.  
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Figure 4.6 
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Figure 4.7. The recruitment rate of CD163+ macrophages to the CNS is inversely 
proportional to time to death.  Paired XY values for time to death and CD163+ 
macrophage recruitment rate are plotted for animals sacrificed with AIDS (n = 9). Time 
to death is inversely correlated with the rate of CD163+ macrophage recruitment to the 
perivascular space (A), SIVE lesions (B), meninges (C), and choroid plexus (D) in SIVE 
and SIVnoE animals. A Spearman rank test is used for correlation statistics. * P < .05. 
 
	   120	  
Figure 4.7 
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Figure 4.8. The rate of CD163+ macrophage recruitment to the CNS is increased 
with SIV infection and is greater in animals with SIVE. The rate of CD163+ 
macrophage recruitment was derived by normalizing the percentage of dextran-labeled 
cells that entered the CNS in a given period (Table 4.3) by the number of days in that 
period. Each data point represents one lesion or one tissue section (11-14 cortical 
sections, 3-4 sections of meninges, and 1 choroid plexus section per animal). A-C. The 
recruitment rate was determined 20 dpi- necropsy for all animals that progressed to 
AIDS (n = 9). Basal turnover of perivascular, meningeal, and choroid plexus 
macrophages was determined in uninfected animals reconstituted with EGFP-
expressing CD34+ stem cells (n = 3). Compared to uninfected animals, the recruitment 
rate of CD163+ macrophages 20 dpi- necropsy in animals sacrificed with AIDS is 
increased 20-fold in the perivascular space (A), 5-fold in the meninges (B), and 15-fold 
in the choroid plexus (C). The CD163+ macrophage recruitment rate is greater in 
animals with SIVE (n = 5) than animals with SIVnoE (n = 4) although this did not reach 
statistical significance (A & B). D-F. In a subset of animals that progressed to AIDS and 
received all three dyes (n = 4), the recruitment rate was determined 20 dpi- 49 dpi and 
49 dpi- necropsy to compare differences in recruitment post acute infection and 
terminally with AIDS, respectively. D. In SIVE lesions, the rate of CD163+ macrophage 
recruitment is greater terminally, 49 dpi- necropsy, compared to 20 dpi- 49 dpi. E. In the 
perivascular space, the CD163+ macrophage recruitment rate is greater 20 dpi- 49 dpi 
compared to 49 dpi-necropsy in both SIVE and SIVnoE animals. The CD163+ 
macrophage recruitment rate is 68% greater in animals with SIVE than animals with 
SIVnoE post acute infection, 20 dpi- 49 dpi, but was not significantly different terminally 
with AIDS, 49 dpi-necropsy. F. In the meninges the CD163+ macrophage recruitment 
rate is 91% greater in SIVE animals than SIVnoE animals terminally with AIDS.  
* P < .05, ** P < .01, *** P < .001, **** P < .0001. 
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Figure 4.8 
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Figure 4.9. Increased CD163+ macrophage recruitment in the perivascular space 
and SIVE lesions correlates with higher concentration of sCD163 in plasma in 
SIVE animals. Paired XY values for plasma concentration of sCD163, an activation 
marker shed by CD14++CD16+ monocytes, and percentage of dextran-labeled CD163+ 
macrophages that entered the CNS after 20 dpi are plotted. Values for sCD163 are the 
average of weekly measurements from 20 dpi- necropsy. A & B. Higher plasma levels 
of sCD163 are associated with increased CD163+ macrophage recruitment to the 
perivascular space (A) and SIVE lesions (B) in SIVE but not SIVnoE animals. C & D. 
Plasma levels of sCD163 are not correlated with CD163+ macrophage recruitment to 
the meninges (C) or choroid plexus (D) in SIVE and SIVnoE animals. * P < .05. 
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Figure 4.9 
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Figure 4.10. CD163+ macrophage recruitment to the perivascular space and 
meninges is associated with lower numbers of CD14++CD16+ monocytes in the 
blood. Paired XY values for average number of CD14++CD16+ monocytes and 
CD163+ macrophage recruitment rate are plotted. Activated CD14++CD16+ monocytes 
are more numerous in SIVE animals than SIVnoE animals (104 ± 16 cells/µL vs. 36 ± 4 
cells/µL, p = 0.02). A, C. Higher rates of CD163+ macrophage recruitment to the 
perivascular space (A) and meninges (C) are associated with lower numbers of 
CD14++CD16+ monocytes in the blood in SIVE but not SIVnoE animals. B, D. The was 
no correlation between CD14++CD16+ monocyte number and macrophage recruitment 
rate in SIVE lesions (B) or choroid plexus (D). A Spearman rank test is used for 
correlation statistics.  
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Figure 4.10 
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Chapter 5: PCNA is expressed by CD163+ CNS macrophages in SIV-infected 
macaques and is associated with decreased macrophage apoptosis with SIV 
infection in vitro.  
 
Chapter Overview 
A subset of CNS macrophages express PCNA in the context of SIV or HIV infection. 
PCNA expression occurs absent standard markers of cell proliferation (Ki-67, BrdU, 
Topoisomerase II) and correlates with both SIV and HIV infection in the same cell. The 
biological function of PCNA in SIV or HIV infected macrophages in the CNS is not 
known. In these studies, we characterized the pattern of PCNA expression in 
monocytes and macrophages in SIV-infected rhesus macaques and performed siRNA 
knockdown in primary monocyte-derived macrophages in vitro to investigate the role of 
PCNA in SIV infection. We found that PCNA is expressed by CD163+ macrophages, 
but not MAC387+ macrophages in SIVE lesions. PCNA was not detected in CD14+ 
monocytes from uninfected or chronically SIV-infected animals. We also found that few 
PCNA+ macrophages in the CNS are BrdU-labeled, which suggests that PCNA 
expression is independent of recent proliferation in the bone marrow. In vitro siRNA-
mediated knockdown of PCNA in primary monocyte-derived macrophages prior to SIV 
infection was associated with an increase in SIVp27 production. We also observed that 
PCNA knockdown is associated with increased apoptosis following SIV infection 
compared to nonsilencing controls. These data suggest that PCNA expression is 
restricted to CD163+ macrophages in the CNS, which may be productively infected, and 
	   128	  
is independent of proliferation. Additionally, PCNA mediated inhibition of apoptosis may 
be a mechanism by which SIV-infected macrophages are long-lived in the CNS.  
 
PCNA is expressed by CD163+ macrophages and is rarely present in MAC387+ or 
BrdU+ macrophages in SIVE lesions. 
Previous studies have shown that PCNA is expressed by CNS macrophages in SIV 
infected macaques and that a high percentage of PCNA+ macrophages are productively 
infected (SIVp28+ and SIV RNA+)216,217. We characterized PCNA expression in two 
subpopulations of CNS macrophages: 1) CD163+ perivascular macrophages, which are 
the primary cell type infected in the CNS,88,185 and 2) MAC387+ inflammatory 
macrophages, which are not productively infected in the CNS (Table 5.1, Figure 5.1)181. 
In SIVE lesions, 70.7 ± 2.8% of PCNA+ cells were PCNA+CD163+ macrophages and 
4.8 ± 1.2% of PCNA+ cells were PCNA+MAC387+ macrophages (Table 5.1, Figure 5.1 
A, B). Because PCNA has been associated with cell proliferation, we investigated 
whether PCNA+ macrophages were labeled with BrdU, a marker of recent proliferation 
in the bone marrow. We found 14.4 ± 5.8% of PCNA+ cells were BrdU+, which 
suggests that the majority of PCNA+ cells were not proliferating (Table 5.1, Figure 5.1C). 
Thus in the CNS, PCNA is expressed primarily in CD163+ perivascular macrophages, 
but not in inflammatory MAC387+ macrophages. These data suggest that PCNA 
expression is not due to recent cell division in the periphery and is restricted to CD163+ 
macrophages that may be productively infected. 
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PCNA is not expressed by circulating monocytes in normal and chronically SIV-
infected animals.  
We next investigated whether PCNA is expressed by monocytes, which are the 
precursors of CNS macrophages. CD14+ monocytes were isolated from both uninfected 
(n = 4) and chronically SIV-infected (n = 4, 120 dpi) animals (Figure 5.2). PCNA mRNA 
was not detected in CD14+ monocytes from uninfected or SIV infected animals by 
qRTPCR (Figure 5.2A). As a control, GAPDH mRNA was detected in all samples. 
Additionally, PCNA protein was not detected in CD14+ monocytes from uninfected or 
SIV infected animals (Figure 5.2B). As a control PCNA was detected in an equivalent 
amount of lysate from THP-1 cells, a myelomonocytic cell line. These data further 
support the hypothesis that expression of PCNA in CNS macrophages is not carried 
over from expression in the periphery.  
 
SIV infection induces PCNA expression in MDM in vitro 
Because PCNA expression in CNS macrophages is associated with productive infection 
in the same cell, we sought to investigate whether PCNA expression was induced by 
SIV infection in vitro. Monocytes from uninfected animals were cultured in vitro with fetal 
bovine serum and macrophage colony stimulating factor (M-CSF) to generate 
monocyte-derived macrophages (MDM). After 5 days in culture, 22.1 ± 7% of MDM 
were PCNA+ by immunofluorescence (Figure 5.3). The PCNA promoter is serum 
responsive, and PCNA expression by MDM in vitro may be due to mitogenic factors in 
the culture medium253,254. PCNA expression may also be associated with the maturation 
of MDM in vitro. To assess whether PCNA was induced by SIV infection, MDM were 
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infected with SIV316* and PCNA expression was assessed by qRTPCR at 0 dpi, 1 dpi 
and 3 dpi. PCNA mRNA was increased 1.6-fold at 1 dpi and 2-fold at 3 dpi relative to 
uninfected controls (Figure 5.4). These data indicate that PCNA is induced in MDM in 
response to SIV infection.   
 
PCNA knockdown in primary MDM increases SIVp27 production and increases 
the percentage of apoptotic macrophages.  
To determine whether PCNA has a specific effect on viral replication, we treated MDM 
with PCNA-specific siRNA (siRNA-5 or siRNA-6) or a nonsilencing control (siRNA-NS) 
prior to SIV infection. The commercially available PCNA-specific siRNAs were designed 
from the human PCNA reference sequence. The sequence of siRNA-5 was a perfect 
match to the M. mulatta PCNA reference sequence, and the sequence of siRNA-6 
contained a single base pair mismatch relative to the M. mulatta PCNA reference 
sequence. siRNA treatment of MDM decreased PCNA mRNA by 52 ± 4% for siRNA-5 
and 30 ± 5% for siRNA-6 relative to a nonsilencing siRNA, measured at 3 dpi (Figure 
5.5A).  The decrease in PCNA protein was commensurate to the reduction in PCNA 
mRNA (Figure 5.5B). SIVp27 production, measured at 3 dpi, was 2.0 ± 0.3 fold greater 
(p = 0.03) in samples treated with PCNA-specific siRNA relative to nonsilencing controls 
(Figure 5.5C). Because lower levels of PCNA were associated with increased SIVp27 
production, PCNA may have an antiviral effect in primary MDM.  
 
Conducting the siRNA knockdown experiments, we noted that PCNA knockdown 
frequently lead to the death of primary MDM cultures and that numerous small cells that 
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appeared apoptotic were present in samples treated with PCNA-specific RNA compared 
to controls. To confirm this observation, we performed TUNEL staining on SIV-infected, 
siRNA-treated primary MDM. As noted previously, siRNA-5 decreased PCNA 
expression more efficiently than siRNA-6. Lower PCNA expression was associated with 
an increase in the percentage of apoptotic (TUNEL+) macrophages with SIV infection 
(25.2 ± 3.6% siRNA-5, p = 0.004 vs. control; 15.3 ± 2.5% siRNA-6, p = 0.008 vs. 
control; 5.2 ± 2.5% siRNA-NS) (Figure 5.5D). These data suggest that PCNA 
expression prevents apoptosis in SIV-infected macrophages.  
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Conclusions 
These studies investigate the role of PCNA expression in CNS macrophages in the 
context of SIV infection. PCNA expression has classically been associated with DNA 
replication in cycling cells; however, human and monkey monocytes and macrophages 
are thought to be terminally differentiated cells that do not divide outside of the bone 
marrow57,74,75. Consistent with this, we found that PCNA is not expressed by circulating 
monocytes and few PCNA+ macrophages in the CNS were BrdU labeled following an 
intravenous BrdU pulse. These observations support the hypothesis that PCNA 
expression in CNS macrophages is not associated with recent proliferation in the bone 
marrow.  
 
In SIVE lesions, PCNA was expressed in CD163+ perivascular macrophages, which are 
a primary target of SIV infection, and was not expressed in MAC387+ inflammatory 
macrophages, which are rarely productively infected88,181,185. We also found that SIV 
infection increased PCNA expression in macrophage cultures in vitro. These data 
suggest that PCNA is expressed in CD163+ macrophages with SIV infection.  
 
PCNA knockdown was associated with increased SIVp27 production in vitro, which may 
indicate a direct role for PCNA in inhibiting viral replication. Moreover, we show that 
PCNA knockdown was associated with increased macrophage apoptosis with SIV 
infection. Thus PCNA expression may limit viral replication and inhibit apoptosis in SIV 
infected macrophages.  
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Taken together, these data suggest that PCNA is expressed by CD163+ macrophages 
in the CNS in response to SIV infection independent of cell proliferation. PCNA-
mediated inhibition of apoptosis may be a mechanism by which CNS macrophages are 
more long-lived and thus contribute to the formation and maintenance of a viral 
reservoir in the CNS.   
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Table 5.1: Phenotype of PCNA+ macrophages in SIVE lesions. 
 
Population   Percentagea 
PCNA+CD163+ vs. total PCNA+   70.7 ± 2.8%;   nb = 42 
PCNA+MAC387+ vs. total PCNA+   4.8 ± 1.2%;     nb = 25 
PCNA+BrdU+ vs. total PCNA+   14.4 ± 5.8%;   nb = 38 
PCNA+CD163+ vs. total CD163+   65.4 ± 7.5%;   nb = 42 
PCNA+MAC387+ vs. total MAC387+   16.7 ± 8.4%;   nb = 25 
PCNA+BrdU+ vs. total BrdU+   59.0 ± 21%;    nb = 38 
 
a. Data are the Mean ± SEM, for 4 SIVE animals. Three or more CNS regions were 
examined per animal for each stain.  
b. n is the total number of lesions evaluated for each stain.  
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Figure 5.1. PCNA is expressed by CD163+ CNS macrophages but is rarely present 
in MAC387+ or BrdU+ macrophages. Double label IHC for PCNA (brown) and CD163 
(blue, A), MAC387 (blue, B), or BrdU (red, C). Images are representative of multiple 
cortical regions (n ≥ 3 regions) examined from each of four animals with SIVE. Scale 
bar is 50µm. A. The majority of PCNA+ cells (brown) in SIVE lesions are CD163+ 
macrophages (blue). PCNA+CD163- and CD163+PCNA- cells are present. The arrow 
indicates a multinucleated giant cell that is CD163+ and has several PCNA+ nuclei. B. 
Few PCNA+ cells (brown) in SIVE lesions are inflammatory MAC387+ macrophages 
(blue). Many PCNA+MAC387- and MAC387+PCNA- cells are present. C. Few PCNA+ 
cells (brown) are BrdU+ macrophages (red) recently recruited from the bone marrow. 
Many PCNA+BrdU- cells are present. Few BrdU+PCNA- cells are present.  
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FIGURE 5.1 
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Figure 5.2. PCNA is not expressed by CD14+ monocytes in uninfected or 
chronically SIV-infected animals. RNA and protein were isolated from CD14+ 
monocytes from uninfected (n = 4) and chronically SIV-infected (n = 4, 120 dpi) animals. 
A. qRTPCR for PCNA transcripts was performed on cDNA (3 ng) made from total 
CD14+ monocyte RNA. PCNA mRNA was not detected in CD14+ monocytes from 
uninfected or SIV-infected animals. GAPDH served as an internal control. B. Western 
blot for PCNA was performed on soluble protein (20 µg) from whole cells lysates. PCNA 
protein was not detected in CD14+ monocytes from uninfected or SIV-infected animals. 
PCNA was detected in 20 µg lysate from cycling THP-1 cells. Actin was used as the 
loading control.  
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FIGURE 5.2 
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FIGURE 5.3. Monocyte-derived macrophages express PCNA in vitro.  
Immunofluorescence for PCNA (red) in primary monocyte-derived macrophages (MDM) 
after 5 days of culture in RPMI1640 with 10% FBS and 10ng/mL M-CSF. DAPI (blue) 
was used as a nuclear counterstain. Arrows indicate PCNA+ macrophages. Insets are 
single channel images. Scale bar is 50um. After 5 days in culture, 22.1 ± 7% of MDM 
were PCNA+ (n = 3 animals).   
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FIGURE 5.3 
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Figure 5.4. SIV infection increases PCNA expression in primary MDM. 
PCNA expression in uninfected and SIV-infected MDM as determined by qRTPCR. 
Total RNA was harvested from uninfected MDM, and MDM infected with SIV316* at 1 
dpi and 3 dpi (n = 4 animals). PCNA expression was normalized to GAPDH and fold-
change was calculated using the ΔΔCT method. For each animal, the fold-change in 
SIV-infected MDM was calculated relative to the uninfected timepoint. Each symbol 
represents one animal. Dashed line and error bars are the mean ± SEM of all animals. 
SIV infection increased PCNA mRNA 1.6±0.4 -fold at 1 dpi and 2.0±0.3 -fold at 3 dpi 
relative to the uninfected timepoint. 
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Figure 5.4 
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Figure 5.5. PCNA knockdown in primary MDM increases SIVp27 production and 
increases the frequency of macrophage apoptosis.  
Data presented here are representative of three experiments in triplicate. CD14+ 
monocytes were cultured with M-CSF for 5 days, transfected with siRNA, and then 
infected with SIV316*. At 3 dpi, protein, RNA, and culture supernatants were harvested 
and TUNEL staining was performed. A. Treatment of MDM with PCNA-specific siRNA 
decreased PCNA mRNA by 49% for siRNA-5 and 22% for siRNA-6, relative to a 
nonsilencing control (siRNA-NS). PCNA expression was normalized to GAPDH and 
fold-change was calculated using the ΔΔCT method. B. Treatment of MDM with PCNA-
specific siRNA decreased PCNA protein by 55% for siRNA5 and 17% for siRNA6, 
relative to a nonsilencing control as determined by western blot. The numbers above 
each lane indicate relative band density as determined using ImageJ densitometry tools. 
C. Treatment of MDM with PCNA-specific siRNA increased viral replication to 1547 ± 
250 pg/mL for siRNA-5 and 1684 ± 280 pg/mL for siRNA-6, compared to 921 ± 120 
pg/mL for the nonsilencing control, as determined by ELISA for SIVp27. D. In samples 
treated with nonsilencing siRNA, 5.2 ± 2.5% of MDM were TUNEL+. PCNA knockdown 
increased the frequency of apoptotic macrophages to 15.3 ± 2.5% for siRNA-6 (p = 
0.008 vs. nonsilencing) and 25.2 ± 3.6% for siRNA-5 (p = 0.004 vs. nonsilencing). 
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FIGURE 5.5 
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DISCUSSION: 
Discussion Overview 
This thesis provides new data regarding: 1) differences in gene expression between 
monocyte subsets and changes in gene expression with SIV infection (manuscript 
submitted to Blood), 2) recruitment and turnover of CNS macrophages, the timing of 
viral neuroinvasion, and the development of SIVE (manuscript submitted to Am J 
Pathol), and 3) PCNA expression and function with regard to macrophage retention in 
the CNS (manuscript in preparation). Here we will discuss the specific implications of 
each set of studies with regard to the current understanding of monocyte/macrophage 
biology in SIV infection and the development of SIVE and HIVE.   
  
I. Differences in gene expression between monocyte subsets and changes in 
gene expression with SIV infection (Chapter 3) 
 
With HIV infection, the progression to AIDS and the development of HIVE are 
associated with expansion of blood monocytes and increased monocyte activation. We 
performed a microarray analysis to characterize changes in gene expression that occur 
at acute infection and terminally with AIDS in classical (CD14++CD16-), intermediate 
(CD14++CD16+), and nonclassical (CD14+CD16++) monocytes. We find that the 
majority of changes in gene expression occur early in infection and persist through end 
stage disease. With SIV infection we observe expansion of the CD16+ monocyte 
subsets and increased similarity between intermediate and nonclassical monocytes 
terminally with AIDS. Although the set of genes expressed by each subset changes 
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over time, we define a panel of 172 genes that differentiate the three monocyte subsets 
in uninfected and SIV infected animals. Overall, we find that classical monocyte have an 
immature myeloid phenotype and express genes associated with cell proliferation and 
detection of immune ligands; whereas nonclassical monocytes have a macrophage-like 
phenotype and express genes associated with inhibition of cell cycle and immune 
effector functions. Despite apparent functional differences between monocyte subsets, 
innate immune genes, including interferon-stimulated genes, are upregulated in all three 
subsets with SIV infection. We conclude that SIV infection is associated with changes in 
gene expression indicative of monocyte dysregulation early in SIV infection, induction of 
a shared innate immune response dominated by induction of interferon-stimulated 
genes, and increased maturation of intermediate monocytes terminally with AIDS.  
 
Identification of unique markers of classical, intermediate, and nonclassical 
monocytes in macaques with and without SIV infection 
We found that only 172 of 813 genes differently expressed between monocyte subsets 
prior to infection were also differently expressed in SIV-infected animals. In this study 
we show that in uninfected and SIV-infected macaques classical monocytes express 
CD62L/SELL, S100A8, and S100A9, while nonclassical monocytes express CX3CR1. 
These markers are also differently expressed between classical and nonclassical 
monocytes in humans and mice58,61. The chemokine and Fc receptors FcγRIa, CCR1, 
and CCR2, which are expressed on classical monocytes and not intermediate 
monocytes in humans and mice, were expressed on both classical and intermediate 
monocytes in rhesus macaques61,64.	  Few markers uniquely differentiate the intermediate 
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subset as they share markers with classical and nonclassical monocytes. We identified 
two genes in macaques specific to intermediate monocytes whose proteins are known 
to be expressed on the cell surface: MERTK and C3AR1. In humans, the receptor 
tyrosine kinase MERTK is a marker of intermediate monocytes, and C3AR1 was 
reported to be more highly expressed in CD16+ monocytes56,61. MERTK is involved in 
leukocyte migration, clearance of apoptotic cells, inhibition of lymphocyte activation, and 
has been linked to susceptibility to multiple sclerosis255. The subset-specific genes 
identified herein may provide useful markers of the individual monocyte subsets in 
uninfected and SIV- infected animals.    
 
Transcripts expressed by classical and nonclassical monocytes suggest 
differences in the biological function of monocyte subsets 
Genes expressed by classical monocytes were associated with defense response, 
proliferation, and wound healing. Expression of CCR1, CCR2, and CD62L suggests that 
classical monocytes can be mobilized in response to CCR1 and CCR2 ligands 
(CCL2/MCP-1, CCL7/MCP-3, CCL5/RANTES), home to lymphoid organs or sites of 
inflammation (via CD62L/SELL), and mediate inflammation or wound healing. Classical 
monocytes also express transcripts for S100A8 and S100A9 whose proteins comprise 
the antigen (calprotectin, S100A8/S100A9) recognized by the antibody MAC387250,256. 
MAC387 has been used to identify a population of inflammatory macrophages that is 
recruited to the CNS in response to acute inflammation181,250,256. Notably, MAC387+ 
macrophages present in SIVE lesions were found to have recently emigrated from the 
bone marrow, as indicated by BrdU labeling of proliferating monocyte precursors42,181. 
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Expression of genes associated with cell proliferation in classical monocytes also may 
suggest their recent proliferation in the bone marrow. Thus, the classical monocyte pool 
may represent precursors of inflammatory MAC387+ macrophages found in tissues. 
Though we did not perform functional studies in macaques, the biological functions 
suggested by genes enriched in the classical monocyte subset appear to recapitulate 
the known biology of mouse classical (Ly6C+) monocytes, which are mobilized from the 
bone marrow in a CCR2 dependent manner, are recruited to sites of inflammation, and 
differentiate into classically activated (M1 polarized) macrophages in inflamed tissue66. 
 
Nonclassical monocytes express transcripts associated with defense response, cell 
cycle inhibition, cellular activation, and macrophage phenotype. The withdrawal from the 
cell cycle and similarities to tissue macrophages may suggest that nonclassical 
monocytes are at a later stage of maturation than classical monocytes75. Genes 
expressed by nonclassical monocytes, or both intermediate and nonclassical 
monocytes, suggest the ability to mediate a range of immune effector functions 
including cell mediated cytotoxicity and T-cell activation. Notably, intermediate and 
nonclassical monocytes were more transcriptionally similar terminally with AIDS 
compared to early infection or preinfection timepoints. This may indicate increased 
activation or maturation of the intermediate subset with fulminant disease and reflect a 
phenotypic plasticity in response to the pathogenic microenvironment. Expression of 
CX3CR1 on nonclassical monocytes suggests that they are able to migrate in response 
to fractalkine, which is upregulated in the CNS with AIDS and HIVE204. Additionally, 
expression of integrins on nonclassical monocytes likely indicates the ability to bind 
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activated endothelial cells and migrate into tissues. Recruited nonclassical monocytes 
could contribute to neurodegeneration by elaborating proinflammatory mediators and 
recruiting additional leukocytes through production of TNFα and CCL5. The expansion 
of both nonclassical and intermediate monocytes may negatively contribute to AIDS 
progression and SIVE through increased traffic of activated and infected monocytes into 
the CNS and elaboration of chemoattractant and proinflammatory cytokines. 
 
Changes in monocyte gene expression begin early in SIV infection and indicate a 
role for nonclassical monocytes in AIDS pathogenesis 
 Comparing early and end-stage disease, we observed that the majority of changes in 
gene expression were present by 26 dpi and were then sustained throughout infection. 
We have previously shown that increased monocyte egress from the bone marrow is 
detectable within weeks of primary infection, and the magnitude of the expansion of 
blood monocytes is predictive of how rapidly the animals progress to AIDS and the 
severity of macrophage mediated AIDS related pathogenesis42. This suggests that 
monocyte dysregulation with SIV infection is present early after infection and prior to 
AIDS onset. Although, intermediate monocytes have been the primary focus of previous 
research, we observed that the nonclassical subset had the greatest number of genes 
that were differently expressed with SIV infection. Moreover, expansion of these cells 
correlates with AIDS related pathologies including CNS and cardiac disease42,93. This 
suggests that nonclassical monocytes merit additional focus going forward. Because 
nonclassical monocytes are innate effector cells, likely precursors to tissue 
macrophages, and regulators of adaptive immunity, changes to nonclassical monocyte 
	   150	  
biology may have varied effects. It is likely that these cells expand in response to 
macrophage turnover in the lymph nodes with AIDS and as a general innate immune 
response to tissue damage42,52. Further studies to elucidate the mechanisms and 
consequences of monocyte dysregulation in early SIV infection are needed.    
 
SIV infection is associated with the induction of interferon-stimulated genes in all 
monocyte subsets 
We found that interferon-stimulated genes (ISG) were upregulated in all three monocyte 
subsets by 26 dpi and terminally with AIDS indicating a sustained interferon response 
that likely indicates ongoing immune activation that may contribute to exhaustion of the 
immune system with chronic SIV infection. IFNα, which is produced primarily by 
plasmacytoid dendritic cells in response to TLR signaling, has been implicated as a 
major mediator of chronic immune activation in HIV and SIV infection257-261. Whereas 
the direct effect of HIV or SIV on monocytes is likely limited by the low frequency of 
infected monocytes, the effects of IFN-α signaling on monocytes may be more 
widespread. Gene array studies of CD14+ monocytes from HIV-infected patients and 
whole blood from SIV-infected rhesus macaques have demonstrated a robust and 
sustained induction of ISG208,258-260. In humans, greater monocyte ISG induction is 
associated with higher viral load and increased neuronal damage, suggesting a link 
between type-I interferon responses and HIVE208,258. Importantly, comparisons between 
pathogenic infection of humans and rhesus macaques, and nonpathogenic infection of 
sooty mangabees or African green monkeys have demonstrated that increased IFN-α 
production and failure to downregulate ISG induction after acute viremia are associated 
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with pathogenic infection259-261. We also observed upregulation of genes associated with 
detection of cytosolic nucleic acids and host restriction factors (APOBEC3A, TRIM5, 
SAMHD1), which may contribute to limited infection of monocytes in vivo. Despite 
heterogeneity of monocyte subsets, the pattern of induction of ISG and genes 
associated with innate immunity was similar between the three monocyte subsets, 
indicating a conserved immune response to SIV infection.  
 
Caveats of the rapid macaque model of SIV infection 
We found that intermediate monocytes and classical monocytes share more expressed 
in macaques, whereas intermediate monocytes and nonclassical monocytes share 
more expressed genes in humans61. This suggests that the biology of monocyte 
subsets may vary between humans and nonhuman primates. Addditionally, the genes 
identified in these studies may by be affected by the depletion of CD8+ lymphocytes. 
Studies of SIV infection without CD8+ depletion and in HIV-infected humans are 
necessary to validate the findings herein. We found high inter-animal variability in gene 
expression, which indicates that the genes identified as differently expressed in a given 
study will be greatly affected by the subject pool. Studies that evaluate the effect of 
antiretroviral therapy on gene expression in monocyte subsets and associated changes 
in disease progression are also needed.  
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II. Recruitment and turnover of CNS macrophages, timing of viral neuroinvasion, 
and the development of SIVE (Chapter 4) 
 
The development of SIVE is influenced by SIV infection and macrophage accumulation 
in the CNS. In these studies we characterized recruitment of CD163+ perivascular 
macrophages and inflammatory MAC387+ macrophages to the CNS with SIV infection. 
We find that early CNS inflammation is characterized by recruitment of MAC387+ 
macrophages through the CNS. The meninges and choroid plexus show greater 
recruitment of BrdU+ macrophages from the blood with a high rate of turnover. In 
contrast, CD163+ and MAC387+ macrophages accumulate in the perivascular space 
and SIVE lesion with the development of AIDS and SIVE. We observed that throughout 
the CNS, higher ratios of CD163+ to MAC387+ macrophages are associated with AIDS 
and SIVE. These studies indicate that the basal rate of macrophage recruitment is 
increased with SIV infection and the higher rates are associated with shorter time to 
death. Additionally, increased macrophage activation in the periphery is associated with 
the development of SIVE in these animals. Importantly, we find that SIVE lesions are 
composed primarily of CD163+ macrophages present in the CNS early, at 20 dpi, in 
addition to productively infected macrophages recruited to the CNS terminally with AIDS.  
 
SIVE lesions are formed by redistribution of resident CD163+ macrophages and 
recruitment of hematogenous macrophages 
A major and surprising observation of this study was that 81.6% of CD163+ 
macrophages in SIVE lesions were present in the CNS early in infection prior to the 
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development of SIVE lesions. After 20 dpi approximately 4.3% of CD163+ macrophages 
in SIVE lesions entered the CNS from 20 dpi to 49 dpi and 17.1% entered the CNS after 
49 dpi. These data fit the hypothesis that SIVE lesions arise more so from the focal 
redistribution of perivascular macrophages already present in the CNS than from the 
recruitment of monocytes from the periphery. It has been previously demonstrated that 
perivascular macrophages and juxtavascular microglia are able to migrate along the 
CNS vasculature in response to activation262. Low macrophage recruitment in SIVE 
lesions from 20 dpi to 49 dpi could also be explained by occlusion of CNS blood vessels, 
which would prevent extravasation until recanalization of the blood vessel263,264. 
 
Formation of CNS lesions by redistribution of resident macrophages and recruitment of 
hematogenous macrophages has been previously described in multiple sclerosis 
(MS)265-267. In MS aggregation of parenchymal CD68+HLA-DR+ macrophages is 
thought to represent the earliest stage of lesion formation265. These preactive lesions 
progress to early active MS lesions that contain CD68+ microglia and hematogenous 
CD68+ perivascular macrophages and MRP14+ macrophages266,267. These are likely 
the same three populations of CNS macrophages we describe with HIVE and 
SIVE42,181,266,267. In contrast to early active lesions, late active or inactive MS lesions 
consist primarily of CD68+ macrophages and few MRP14+ macrophages are present267. 
These observations parallel ours in that an increased ratio of CD163+ to MAC387+ 
macrophages is associated with disease progression. In active lesion formation, the 
transition from early active MS lesions to late/inactive MS lesions is thought to be 
mediated by macrophage activation and redistribution of CNS macrophages rather than 
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accumulation of recruited hematogenous macrophages266,267.  A redistribution of 
macrophages to CNS lesions was also reported in a mouse model of spinal cord 
injury268. Blood-derived monocytes and macrophages were present diffusely throughout 
the spinal cord at 1 and 3 days post injury but coalesced into a lesion 7- 14 days post 
injury prior to resolution of the lesion268. These similarities between HIVE and SIVE, MS, 
and spinal cord suggest recruitment of hematogenous macrophages and redistribution 
of local macrophages are involved in CNS lesion formation.  
 
Timing of SIV infection of the CNS and the development AIDS and SIVE  
Data from this study suggest that there is a 2.6-fold higher percentage of productive 
infection in macrophages that enter the CNS late, but we also find cells that entered the 
CNS early that are productively infected. Additionally, MNGCs, many of which are 
SIVp28+, were also comprised of CD163+ macrophages that were present in the CNS 
at 20 dpi. This is consistent with two hypotheses: 1) SIV is introduced into the CNS 
early but is controlled by the immune response until it recrudesces with AIDS, and/or 2) 
Acute virus is cleared from the CNS and reintroduction of infectious virus by traffic on 
infected monocytes/macrophages at the onset of AIDS is necessary to reestablish and 
maintain CNS infection12-16,186,189,193,269. Previous analysis of viral sequences from 
peripheral and CNS tissue from two of the animals sacrificed at 22 dpi indicate 
compartmentalization of SIV in the CNS as early as 20 dpi37. Additionally, using 
molecular clocks, phylogenetic analysis of peripheral and CNS viral sequences from 
four of the animals sacrificed with AIDS we found multiple instances of late SIV 
neuroinvasion beginning at approximately 50 dpi in animals sacrificed with AIDS (Marco 
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Salemi, unpublished data). Together the phylogenetic data discussed above and our 
observation that late macrophages have a higher frequency of productive infection 
support a hypothesis of late SIV neuroinvasion by traffic of infected CD163+ 
macrophages into the perivascular space. It is important to note that these studies 
utilized CD8+ lymphocyte depletion which compresses the window of disease from 1- 3 
years to 2- 4months such that early and end stage events are not as temporally distant 
as in a natural history.   
 
Resident CD163+ perivascular macrophages are important in the development of 
AIDS and SIVE 
Perivascular macrophages are considered important in the development of HIV and SIV 
encephalitis and neuronal dysfunction, as they are the primary cell type productively 
infected26,85,185,270. A significant role for perivascular macrophages in the development of 
CNS pathology is supported by the observation that rate of turnover of perivascular 
macrophages increased from <0.2%/week in uninfected macaques to ~3%/week in SIV-
infected animals and that 71% of perivascular macrophages were present in the CNS at 
20 dpi suggesting there is an accumulation of perivascular macrophages with little or no 
turnover.  Previous studies on the rate of perivascular macrophage turnover in rodents 
(~8%/week as determined in mouse bone marrow chimeras and ~2%/week as 
determined by serial dextran labeling in rats) indicate that the total population of 
perivascular macrophages is replaced over several months although individual 
macrophages may reside in the CNS for years176,171,177,271. The slow turnover rate of 
perivascular macrophages in the CNS, some of which may be infected, likely contribute 
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to the maintenance of a viral reservoir in the CNS with HIV or SIV infection. Previous 
research has indicated that the number of activated macrophages in the CNS is a better 
correlate of HIV dementia than viral replication in the CNS198. 
 
Peripheral monocyte activation predicts CD163+ macrophage recruitment in SIVE 
animals  
Perivascular macrophages are monocyte derived, and activation and expansion of the 
CD16+ monocyte compartment with AIDS leads to increased trafficking of monocytes to 
the CNS42,48,88,93. Peripheral correlates of SIVE underscore the important concept that 
the mechanism(s) that drive neuropathogenesis are not only limited to factors within the 
CNS compartment. Notably, the range of values for plasma sCD163 and CD14+CD16+ 
monocyte count is greater between SIVE animals than between SIVnoE animals. This 
suggests that animals that develop SIVE have lost the ability to regulate monocyte 
homeostasis. We found that peripheral monocytes in SIVE animals show increased 
activation relative to SIVnoE animals and concomitantly develop a more severe CNS 
pathology with increased CD163+ macrophage recruitment and presence of SIVE 
lesions. This relationship between increased monocyte activation, increased 
macrophage recruitment to the CNS, and SIVE support the hypothesis that lack of 
immune regulation in the periphery contributes to the development of SIVE. 
 
Macrophage turnover via cell death or traffic out of the CNS 
A major assumption of our dextran labeling model is that once macrophages are 
present in the CNS they remain. Thus we do not account for cell death or macrophages 
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that exit the CNS. Apoptosis of perivascular macrophages and microglia is considered 
to be low to negligible in the normal CNS, and HIV-1 infection has been shown to 
reduce the frequency of apoptotic CD68+ macrophages in vivo165,272. Overall, studies of 
macrophage death in the normal CNS and in response to activation and infection have 
not been done. CNS macrophages are able to actively migrate from the brain to the 
cervical lymph nodes along olfactory nerves that penetrate the cribiform plate, but the 
factors that drive this process are not known273-275. Recirculation of macrophages from 
the CNS to the blood is thought to be impaired with HIV or SIV infection, which may be 
a mechanism of macrophage retention and SIVE lesion formation205,276,277. Osteopontin, 
a cytokine that is elevated in the CNS with HIVE and SIVE, inhibits macrophage 
apoptosis and promotes macrophage retention in the CNS205. All of these factors 
contribute to macrophage retention in the CNS and accumulation of macrophages over 
time.   
 
A higher ratio of CD163+ to MAC387+ macrophages is associated with the 
development of AIDS and SIVE  
We have previously observed that the severity of SIV encephalitis was related to an 
increased ratio of CD68+ to MAC387+ macrophages in HIVE and SIVE lesions181. In 
this study we extend this observation and found that the CD163:MAC387 ratio is greater 
in animals with AIDS compared to SIV-infected animals without AIDS, and in animals 
with SIVE compared to animals with SIVnoE. We have previously suggested that 
resident perivascular macrophages are M2 polarized and inflammatory MAC387+ 
macrophages are M1 polarized181,209,278. M1 polarized macrophages are considered to 
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be proinflammatory, classically activated macrophages that mediate antiviral Th1 type 
immune responses. Conversely, M2 alternatively activated macrophages mediate Th2 
type immune response and have been associated with tissue repair and resolution of 
inflammation. We observed an increased influx of MAC387+ macrophages at 22 dpi 
throughout the CNS prior to significant accumulation of CD163+ macrophages. This 
may suggest that during the early stages of CNS infection a M1 polarized, antiviral 
immune response predominates and is a response to CNS infection. In animals 
sacrificed with AIDS, particularly with SIVE, the number of MAC387+ macrophages had 
decreased relative to 22 dpi and many more CD163+ macrophages were present which 
may indicate a switch to a M2 microenvironment. This suggests that a shift from M1 to 
M2 polarization is associated with the progression of neuroAIDS and the development 
of SIVE. 
 
MAC387+ macrophage do not differentiate into CD163+CD68+ resident 
macrophages in the CNS 
We have previously demonstrated that MAC387 is marker of recently recruited 
macrophages in the CNS42,181. It is not known whether MAC387+ macrophages are able 
to differentiate into CD163+CD68+ macrophages or CD68+CD163- microglia. Our BrdU 
data show that MAC387+ macrophages found at necropsy had entered the CNS prior to 
20 dpi. This indicates that with long-term residence in the CNS (35-121 days in this 
study), these particular cells did not differentiate into a CD163+CD68+ macrophage 
phenotype. 
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CD163+BrdU- macrophages in the CNS may represent proliferation of resident 
macrophages or recruitment from a site other than the bone marrow. 
Very few CD163+BrdU+ macrophages were present in the perivascular space and SIVE 
lesions of animals sacrificed with AIDS and SIVE in spite of the higher number of total 
CD163+ macrophages in SIVE animals. The lack of CD163+BrdU+ macrophages in 
SIVE lesions is consistent with the notion that SIVE lesions are made up of local 
perivascular macrophages recruited from within the CNS, and may also represent 
macrophage proliferation in situ. In mice, tissue macrophages have been shown to 
proliferate in response to IL-4 produced in Th2 immune responses279. Although, 
macrophages are not thought to divide in humans and nonhuman primates, the local 
microenvironment in SIVE or HIVE may support proliferation of CD163+ macrophages. 
Another possibility is that CD163+ macrophages are recruited to the perivascular space 
and SIVE lesions from sites other than the bone marrow. In HIV-infected humans and 
SIV-infected macaques virus isolated from the CNS was shown to have sequences 
similar to virus isolated from the spleen, which could indicate traffic of splenic 
monocytes to the CNS188,280,281. A splenic reservoir of monocytes has been identified in 
mice, which is mobilized in response to myocardial infarction and lung 
adenocarcinoma83,282. 
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The presence of CD163+BrdU+ macrophages in the meninges and choroid plexus 
underscores differences between CNS compartments and a possible route of 
viral entry into the CNS  
Given that we did not find CD163+BrdU+ macrophages in the perivascular space and 
SIVE lesions, it is interesting that we did find CD163+BrdU+ macrophages in the 
meninges and choroid plexus in numbers equal to or greater than MAC387+BrdU+ 
macrophages. This observation suggests that these two compartments are more similar 
to each other, and possibly the blood, than to the perivascular space and CNS 
parenchyma. As the vascular compartment of the CNS, the meninges are a direct link 
between the blood and the brain. Importantly, cell associated HIV has been shown to 
traffic to the brain through the meninges120. Thus, it is possible that virus may be 
continually reintroduced into the brain in end stage disease due to traffic of infected 
CD163+ macrophages through the meninges. 
 
Overall, these studies identify differences in recruitment of inflammatory and 
perivascular macrophage subsets across different CNS compartments. Differences in 
macrophage recruitment and turnover suggest that the meninges and choroid plexus 
are routes of monocyte traffic, and that macrophages associated with pathogenesis 
accumulate in the perivascular space and SIVE lesions. These studies identify late 
infiltrating CD163+ macrophages as a primary target of SIV infection with AIDS and 
SIVE. Importantly, our observations indicate that formation of SIVE lesions is a dynamic 
process involving multiple populations of resident and recruited CNS macrophages that 
is likely dependent on viral replication in the CNS during end stage disease.  
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III. PCNA expression and macrophage retention in the CNS (Chapter 5) 
 
PCNA is not expressed by macrophages in the normal CNS, but PCNA+ macrophages, 
most of which are productively infected, are present in the CNS with HIVE and SIVE. In 
these studies we characterized PCNA expression in monocyte and macrophage 
subpopulations with and without SIV infection, and investigated the function of PCNA in 
these cells. We find that PCNA is expressed by CD163+ macrophages but not 
MAC387+ macrophages in SIVE lesions. PCNA+ macrophages in the CNS are not 
BrdU+ macrophages that have recently undergone division in the bone marrow. 
Additionally, PCNA is not detected in CD14+ blood monocytes in uninfected or 
chronically SIV infected animals. We find that SIV infection increases PCNA expression 
in primary monocyte-derived macrophages (MDM) in vitro. Furthermore, PCNA 
knockdown in MDM is associated with increased viral replication and increased 
macrophage apoptosis. We conclude that PCNA expression in CD163+ macrophages is 
due to induction in response to SIV infection rather than cell proliferation and is 
associated with decreased apoptosis in infected macrophages.  
 
PCNA expression by CNS macrophages is not associated with cell proliferation in 
vivo 
Historically, PCNA has been used as a marker of cell proliferation in cancer studies. But 
in humans and monkeys, monocytes and macrophages are considered to be terminally 
differentiated cells that do not divide after the promonocyte stage in the bone 
marrow57,74,75. Our data suggest that PCNA expression in CNS macrophages is 
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independent of proliferation in the periphery as the majority of PCNA+ macrophages in 
the CNS are not BrdU+ and PCNA is not detected in CD14+ monocytes in the blood. It 
is possible that PCNA expression exists in monocytes, but is below the limit of detection 
of our assays. Similarly, PCNA expression may be restricted to a subset of monocytes 
that give rise to PCNA+ macrophages in tissues49. Although proliferation of CNS 
macrophages is thought to be negligible in healthy animals, alternatively activated, M2 
polarized macrophages have been shown to proliferate in mice57,74,75. Whether a 
corresponding population of proliferating macrophages exists in human and nonhuman 
primates in Th2 immune responses is not known.  
 
PCNA is induced by SIV infection and is expressed by CD163+ perivascular 
macrophages and not MAC387+ inflammatory macrophages in the CNS 
In the CNS, the majority of productively SIV infected cells express PCNA, and the 
majority of PCNA+ cells are productively infected (SIVp28+, SIV RNA+)216,217. We find 
PCNA is expressed by CD163+ macrophages, which are targets of HIV and SIV 
infection, but not inflammatory MAC387+ macrophages even though these cells are 
found to be BrdU+ in situ. These observations support the hypothesis that PCNA 
expression in CNS macrophages is associated with SIV infection and not cell 
proliferation. Further evidence for this hypothesis is the induction PCNA in cultured 
macrophages following SIV infection. That we did not observe PCNA induction in 
CD14+ monocytes from chronically SIV infected animals may be explained by the low 
frequency of infected monocytes in the blood.  
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Because PCNA expression is associated with productive HIV and SIV infection, it is 
likely that HIV and SIV induce PCNA via direct mechanisms. Previous studies indicate 
that DNA damage repair pathways are directly induced by viral replication and viral 
proteins 203,229 and PCNA is induced by viral proteins including HTLV-I Tax 
(transactivator) and adenovirus E1A transforming protein283,284. PCNA+ cells that do not 
appear to be productively infected, may be latently infected. Additionally, because we 
observed PCNA expression in monocyte-derived macrophage cultures without SIV 
infection, PCNA may also be induced indirectly in uninfected bystander cells via soluble 
viral proteins or production of mitogenic factors216,217. 
 
PCNA expression inhibits viral replication and macrophage apoptosis in vitro 
The role of PCNA expression in HIV and SIV infection is not known. Our studies 
suggest that PCNA inhibits viral replication in SIV-infected macrophages. This agrees 
with previous reports that other DNA damage repair and cell cycle proteins (p21, Rad18, 
Rad52), which bind to both HIV and PCNA, inhibit HIV infection or replication147,230-232. 
HIV and SIV infection of macrophages is non-lytic and is characterized by resistance to 
cytopathic effects of viral replication and lower viral replication compared to infection in 
CD4+ T-lymphocytes86,98. Thus PCNA expression may be a mechanism of inhibition of 
viral replication that limits the cytopathic effects of productive HIV or SIV infection in 
macrophages.  
 
We observed that PCNA knockdown with siRNA was associated with increased 
apoptosis in SIV-infected culture compared to nonsilencing controls. This may suggest 
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that PCNA-mediated inhibition of apoptosis provides a mechanism for the observed 
longevity of HIV and SIV infected macrophages in vivo and in vitro235. This hypothesis is 
supported by our observation that long-term culture of MDM in vitro is associated with 
expression of PCNA. With HIV and SIV infection, the formation and maintenance of a 
viral reservoir in the CNS is dependent on infection of a long-lived cell type135.  Our data 
suggest a scenario where PCNA induction in infected macrophages results in such a 
reservoir.  
 
These studies suggest that PCNA is induced in CD163+ macrophages by SIV infection, 
independent of proliferation and that PCNA-mediated inhibition of apoptosis may be 
associated with limited viral replication in infected macrophages.  
 
IV. Discussion Summary  
HIV and SIV infection are associated with changes in monocyte biology that contribute 
to AIDS pathogenesis. We find altered gene expression in all monocyte subsets as 
early as 26 dpi, when monocyte expansion is first observed, suggesting that monocyte 
dysregulation begins early in infection and persists through end stage disease. Overall, 
the studies in this thesis support the observation that increased monocyte activation and 
traffic are associated with the development of SIVE. We find SIV infection results in 
increased numbers of total monocytes, higher rates of monocyte/macrophage 
recruitment to the CNS, and macrophage accumulation in the CNS. With monocyte 
expansion from the bone marrow, there is an increase in monocyte activation evidenced 
by: increased numbers of CD16+ monocytes, transcriptional maturation of the 
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intermediate monocyte subset (which has not been previously described), and higher 
levels of sCD163 in plasma. Importantly, sCD163 in plasma predicts traffic of CD163+ 
macrophages to perivascular cuffs and SIVE lesions, which are the primary sites where 
macrophages accumulate with SIVE. We also find evidence of chronic monocyte 
activation as interferon stimulated genes were upregulated in all monocyte subsets with 
SIV infection.  
 
These studies provide further evidence for the hypothesis that continued recruitment of 
activated macrophages and reintroduction of virus into the CNS during end stage 
disease contribute to the development of neuroAIDS and SIVE. We find macrophage 
recruitment from the bone marrow to the CNS is greatest terminally with AIDS and SIVE. 
Importantly, in SIVE lesions productive SIV infection is more frequent in CD163+ 
macrophages recruited terminally with AIDS. We conclude that SIVE lesion formation 
occurs late in disease and represents a redistribution of resident CD163+ macrophages 
and recruitment of inflammatory MAC387+ macrophages from the bone marrow, which 
likely occurs in response to traffic of activated and infected monocyte/macrophage from 
the periphery.    
 
Our findings underscore the importance of macrophage heterogeneity in SIV infection 
and neuroAIDS. We extend our previous observation that a higher ratio of CD163+ to 
MAC387+ macrophages in SIVE lesions is associated with more fulminant disease 181. 
In this thesis we find that a higher CD163+:MAC387+ ratio is associated with SIVE 
across CNS compartments. Dextran and BrdU labeling studies indicate that MAC387+ 
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macrophages have a high turnover compared to CD163+ macrophages. Accumulation 
of CD163+ macrophages with high turnover of MAC387+ macrophages may contribute 
to a higher CD163+:MAC387+ ratio. The differences in turnover may be explained by 
selective retention of long-lived CD163+PCNA+ macrophages in the CNS compared to 
MAC387+ macrophages that do not express PCNA. Additionally, a high 
CD163+:MAC387+ ratio may reflect accumulation of  CD163+PCNA+ macrophages, 
which are infected and activated and may constitute a viral reservoir, thus contributing 
to the development of SIVE. 
 
The observed pattern of recruitment of CD163+ and MAC387+ macrophages to the 
CNS appears similar to the classical model of wound healing in which proinflammatory 
(M1) macrophages are recruited in response to infection/injury followed by recruitment 
of reparative (M2) macrophages that attenuate inflammation and promote tissue repair. 
In the first weeks of SIV infection, there is a rapid influx of MAC387+ macrophages into 
the CNS, which is likely occurring as part of an antiviral (M1) response to the initial 
seeding of SIV in the CNS during acute viremia. Subsequently, CD163+ macrophages 
(M2) are recruited to the CNS and the number of MAC387+ macrophages decreases. 
Therefore, it is possible that early in the course of infection, the immune system is 
competent to remove infectious virus from the CNS. However, we do not ultimately 
observe continued resolution of inflammation, but rather viral replication and recruitment 
of both CD163+ and MAC387+ macrophages terminally with AIDS. Thus SIVE may 
reflect the inability of the immune system to properly resolve CNS infection via the 
standard innate immune response.  
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It is important to note that although we emphasize end stage events, early events may 
also contribute to the development of AIDS and SIVE. Notably, we observe that 
increases in monocyte number, expansion of CD16+ monocytes, changes in monocyte 
transcription in all subsets, and CNS inflammation all begin early in disease. All together, 
the studies in this thesis underscore the importance of monocyte dysregulation, chronic 
immune activation, and changes in the biology of subpopulations of monocytes and 
macrophages in the pathogenesis of SIV infection and the development of SIVE.  
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